前往化源商城

75-75-2 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CYP273
Protocol: Tox21 Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a BioRaptr Flying Reagent Dispenser (FRD, Beckman Coulter, Brea, CA). Compounds dissolved in DMSO and positive control (furafyllline) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000075213 uM-Replicate_1Activity at 0.0000171744 uM-Replicate_1Activity at 0.0000689059 uM-Replicate_1Activity at 0.0001619730 uM-Replicate_1Activity at 0.0003751800 uM-Replicate_1Activity at 0.0007781017 uM-Replicate_1Activity at 0.00212 uM-Replicate_1Activity at 0.00657 uM-Replicate_1Activity at 0.017 uM-Replicate_1Activity at 0.038 uM-Replicate_1Activity at 0.085 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.435 uM-Replicate_1Activity at 1.330 uM-Replicate_1Activity at 4.074 uM-Replicate_1Activity at 10.46 uM-Replicate_1Activity at 23.64 uM-Replicate_1Activity at 52.95 uM-Replicate_1Activity at 115.2 uM-Replicate_1Activity at 299.6 uM-Replicate_1Activity at 1087.9 uM-Replicate_1Activity at 2306.0 uM-Replicate_1Activity at 5157.0 uM-Replicate_1Activity at 11530.0 uM-Replicate_1Activity at 25780.0 uM-Replicate_1Activity at 57660.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-3.5643-2.3504-2.9312-2.3657-2.8224-2.60180.03942.8539-0.9099-0.8614-3.0049-2.5808-0.7-3.5643QC'd by SIGMAInactive0
Inactive0004-4.9449-1.1401-4.88281.72781.7167-2.1117-5.69640.39330.89390.1314-2.73353.195-4.9521-4.9449QC'd by SIGMAInactive0
Inactive00042.7107-2.18841.39851.45820.7693-2.47871.522.89860.9702-0.02532.12932.77661.5392.7107QC'd by EnamineInactive0
Inactive0004-2.1522-2.3143-3.894-2.36983.0635-2.9724-0.6981.807-0.3874-2.23870.0851-4.19653.0171-2.1522QC'd by SIGMAInactive0
Inactive0-4.34892.25260.8543-15.2749-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.3957-1.8486-1.8251-1.3415-0.2999-5.8043-1.46250.1520.0394-2.6869-2.4228-2.2664-9.6519-14.3957QC'd by SIGMAInactive0-4.09892.18760.881
Inactive0-4.39891.34430.8661-18.2112-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.0093-2.34660.81450.3878-0.5249-2.2045-0.0596-0.3675-2.1137-2.5302-0.6582-8.8446-8.7305-16.0093QC'd by AcrosInactive0-4.19891.62660.9372
Inactive0-4.37131.3310.7782-33.4439-3.50340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.5366-4.0189-0.7745-2.4487-0.7353-13.4714-1.9963-2.0808-1.5803-2.9931-5.0804-13.0346-7.2628-16.8143-29.5366QC'd by LightBiologicalsInactive0-4.37131.22210.9463
Inactive0-4.14891.62660.9461-28.1716-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-20.143-1.7608-0.23880.22480.5264-2.4986-0.1313-2.2365-0.2423-3.4362-3.0971-3.2181-11.2156-20.143QC'd by EnamineInhibitor79.640731.491610Partial curve; partial efficacy; poor fit-4.09892.58840.988
Inhibitor79.640737.878410Partial curve; partial efficacy; poor fit-4.09892.33320.6037-41.3784-3.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.14860.0477-0.2424-0.1109-17.1482-2.60430.09871.3021-8.8121-0.6811-2.6079-6.0005-11.8578-31.1486QC'd by LightBiologicalsInhibitor70.979933.811310Partial curve; partial efficacy; poor fit-4.14891.47870.9532
Inactive0-4.14891.3310.6595-35.6335-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-26.36121.8269-1.26512.0528-1.3342-1.1508-1.3078-0.329-8.12350.9213-0.3901-8.3475-13.4823-26.3612QC'd by LightBiologicalsInhibitor63.260940.716221Partial curve; partial efficacy-4.19891.55790.9889
Inhibitor31.7055100.219240Partial curve; high efficacy-4.49891.41630.9793-102.2947-2.0755-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.79751.59931.9578-0.4182-5.9156-12.3257-6.81250.6301-0.9357-7.8675-21.9718-39.1747-68.2733-88.7975QC'd by SIGMAInhibitor28.2576108.402740Partial curve; high efficacy-4.54891.24750.9984
Inactive0-4.44891.53860.9285-23.7863140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.48852.58192.144-0.92281.57780.3813-0.7273-0.01780.48032.4385-0.728-9.9293-11.8247-21.4885QC'd by SIGMAInactive0-4.39891.62590.9598
Inhibitor9.333739.896721Complete curve; partial efficacy-5.02992.04370.9899-39.89670-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-36.3129-0.2423-0.4463-0.29990.64780.36361.006-0.49871.2825-1.1546-7.8589-17.895-35.8398-36.3129QC'd by LightBiologicalsInhibitor11.750456.388421Partial curve; partial efficacy-4.92991.1110.9845
Inhibitor31.7055101.457340Partial curve; high efficacy-4.49891.1110.9982-102.7597-1.3024-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-82.349-1.7206-3.1014-1.0307-0.462-0.0614-0.5481-3.1286-4.6801-13.1432-23.5612-42.1146-67.192-82.349QC'd by SIGMAInhibitor25.184689.509140Partial curve; high efficacy-4.59891.37230.9943
Inactive0-4.39891.37230.9408-30.7143-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-27.2619-3.9038-4.25970.95220.2767-0.086-3.7725-0.0863-0.3476-4.4856-5.6587-11.4378-17.5999-27.2619QC'd by EnamineInactive0-4.39891.37230.9104
Inhibitor0.0291.537495Complete curve; high efficacy-7.69891.210.9985-95.5053-3.9679-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.9758-10.1145-26.2532-42.3865-67.4835-79.9456-90.8539-91.593-94.2489-95.4721-96.0956-96.1267-97.0582-96.9758QC'd by SIGMAInhibitor0.141694.840291Complete curve; high efficacy-6.84891.210.9987
Inhibitor70.979957.401421Partial curve; partial efficacy-4.14891.46410.9678-60.4859-3.0846-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-45.8227-1.5241-1.1304-2.119-3.4583-2.7138-4.9163-1.3699-5.0741-7.7268-8.2608-10.3758-24.1789-45.8227QC'd by TCIInhibitor63.260959.370621Partial curve; partial efficacy-4.19891.82650.9826
Inhibitor31.705588.458340Partial curve; high efficacy-4.49891.24750.9907-90.0614-1.6031-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-73.0646-2.1792-0.7242-0.9217-2.0267-1.1711-1.4022-1.5555-4.0648-12.1704-19.1709-32.2561-64.0802-73.0646QC'd by SIGMAInhibitor31.705586.838540Partial curve; high efficacy-4.49891.1110.9934
Inhibitor7.09899.944883Complete curve; high efficacy-5.14891.34430.9949-102.6257-2.681-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-98.8687-2.2636-1.9377-0.2674-0.3864-3.2139-8.5636-4.0834-14.5383-36.543-60.2337-91.3595-96.848-98.8687QC'd by TCIInhibitor5.638199.072784Complete curve; high efficacy-5.24891.62660.998
Inhibitor14.162399.52242Partial curve; high efficacy-4.84890.70.9894-100.6417-1.1197-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.2822-1.4919-2.9847-0.2649-1.6478-3.8502-2.8959-7.6423-18.6375-36.1235-44.1844-53.91-71.7844-88.2822QC'd by SIGMAInhibitor17.829395.774281Complete curve; high efficacy-4.74891.210.9995
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: PPARGV841
Protocol: Tox21 Assay Protocol Summary:

PPARg-bla cells were dispensed at 3000 cells/5uL/well in 1536-well black wall/clear bottom plates using a Multidrop Combi (Thermo Fisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C and 5% CO2 for 5 h, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA), followed by addition of 1ul Rosiglitazone (50 nM, final concentration in the wells). The assay plates were incubated at 37 C for 17 h, and then 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA). The assay plates were incubated at room temperature for 1 h and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT). For cell viability readout that measures cytotoxicity, 4 ul/well of CellTiter-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader (PerkinElmer).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000056507 uM-Replicate_1Activity at 0.0000126354 uM-Replicate_1Activity at 0.0000282534 uM-Replicate_1Activity at 0.0000545573 uM-Replicate_1Activity at 0.0001216490 uM-Replicate_1Activity at 0.0002748434 uM-Replicate_1Activity at 0.0005839002 uM-Replicate_1Activity at 0.00107 uM-Replicate_1Activity at 0.00238 uM-Replicate_1Activity at 0.00531 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.026 uM-Replicate_1Activity at 0.059 uM-Replicate_1Activity at 0.132 uM-Replicate_1Activity at 0.275 uM-Replicate_1Activity at 0.550 uM-Replicate_1Activity at 1.225 uM-Replicate_1Activity at 2.701 uM-Replicate_1Activity at 5.947 uM-Replicate_1Activity at 13.22 uM-Replicate_1Activity at 29.14 uM-Replicate_1Activity at 62.57 uM-Replicate_1Activity at 81.11 uM-Replicate_1Activity at 231.6 uM-Replicate_1Activity at 765.1 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Cytotoxic26.601171.216320Partial curve; partial efficacy-4.57512.18760.8672-65.21636-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-49.97752.49711.48773.03828.079717.45510.04225.22866.55741.99683.698911.506414.0341-10.5752-14.8614-49.9775QC'd by GVKCytotoxic29.84784.287440Partial curve; high efficacy-4.52514.0950.968-84.5512
Inactive04.95490.575614-5.611540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-9.314-6.8558-1.1004-0.8255-0.6797-8.1548-15.9262-1.6069-7.7597-0.501-12.1814-1.7242-6.95863.929613.7565-9.314QC'd by GVKInactive0
Inactive00.30.633311.5-23.844940 0 0 0 0 0 0 0 0 0 0 0 0 0 08.4281-16.5374-12.93487.0323-3.6789-2.8836-2.76545.7014-0.19730.549410.0739-0.12317.9813.130110.7938.4281QC'd by TocrisInactive0
Inactive04.95490.69980.537814.540 0 0 0 0 0 0 0 0 0 0 0 0 0 118.360911.485814.849619.667810.648413.8553-1.35933.7867-10.38522.94886.3689-0.02621.05442.29492.535818.3609QC'd by VitasInactive0
Inactive04-1.0011-1.16233.5977-0.847-1.0312-1.94480.4407-24.0494-4.5331-0.608-4.366-1.017-0.3251-13.08767.2429-1.0011QC'd by SpecsInactive04.0950.4654-14.7396
Inactive04-5.1553-2.0255-5.16044.0448-4.49031.1397-0.6423-2.2296-7.4487-10.4834-2.9971-3.5049-1.42950.363-18.3724-5.1553QC'd by TocrisInactive0
Inactive04-8.1269-5.9139-1.10460.0757-3.25890.7602-2.88260.24281.6263-2.86441.36551.62729.678-0.2226-5.5614-8.1269QC'd by MicrosourceInactive00.40.8323-16.1701
Inactive041.149-2.8036-0.2684-4.2203-3.428-2.2774-7.4382-0.4482-1.30493.0007-6.8573-2.7623-9.1964-7.0127-2.02121.149QC'd by BoscheInactive0
Inactive0416.2985-2.502921.1078-6.460323.3879-0.022618.4521-0.54180.860311.9010.054-3.62941.818-2.85361.526516.2985QC'd by PrestwickInactive0
Inactive00.20.3987-37.38220.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-25.0206-3.1976-8.2211-14.0768-12.0416-13.00814.1029-17.2276-21.2599-26.145-0.6783-21.0808-22.9927-27.8185-21.1893-25.0206QC'd by SpecsCytotoxic0.133317.032320Partial curve; partial efficacy; poor fit-6.87510.90.711-21.0323
Inactive0413.52950.8494-6.26896.40051.462-4.46314.914815.14597.0837-16.72781.8242-0.8270.51092.2813-18.313713.5295QC'd by GVKInactive0
Inactive041.07494.85385.42516.80140.176619.74910.54476.45555.75095.58095.4366-2.35289.5672-5.38677.06381.0749QC'd by GVKInactive0
Inactive01.71370.40575.5-2.109640 0 0 0 0 0 0 0 0 0 0 0 0 0 03.5511-0.7312-1.8884-3.42474.5912-0.43598.7993.04363.671610.04288.079212.3883-0.43084.5233.61033.5511QC'd by GVKInactive0
Cytotoxic1.299293.821487Complete curve; high efficacy-5.88634.95490.9595-94.9238-1.1023-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-93.96736.412110.1246-14.3191-0.84260.2686-5.6544-14.949813.767-9.2782-0.8353-8.3994-93.3842-96.4673-87.8619-93.9673QC'd by TocrisCytotoxic0.580392.766388Complete curve; high efficacy-6.23632.40640.9824-91.233
Inactive04.95490.43776.5-0.663340 0 0 0 0 0 0 0 0 0 0 0 0 0 010.6054-3.0840.5555-2.91033.7169-4.30284.3823-0.87557.713310.09695.25755.7342-3.17235.009211.113710.6054QC'd by EnamineInactive0
Inactive03.51170.3178-8.1843040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.20311.15650.2974-0.1370.4540.8656-3.38190.5286-2.9143-2.9365-18.9036-9.38325.2371-18.8441-3.0228-6.2031QC'd by SIGMAInactive04.95490.4136-12.4925
Inactive0418.7861-1.809110.467610.40441.65325.57118.61174.53798.29258.4417-0.35010.39197.78056.20791.768218.7861QC'd by VitasInactive0
Inactive04-15.03330.0338-1.2236-0.3378-0.7385-1.6326-3.58-27.84245.7451-20.6107-0.7640.56088.7778-15.2377-14.6033-15.0333QC'd by SpecsInactive0
Inactive03.06540.50610-25.57240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-5.881-21.7267-8.98661.3878-5.0881-10.29820.5358-0.5916-1.478112.63597.6015-6.99780.18490.41334.8547-5.881QC'd by SIGMAInactive0
Inactive04-24.0209-2.5533-2.6619.022-24.2481-14.3537-2.092430.2354-0.9087-0.9914-11.4549-0.0186-3.1651-12.56592.6133-24.0209QC'd by TocrisCytotoxic33.488977.294120Single point of activity-4.47514.95490.8719-79.2763
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: TGF788
Protocol: Tox21 Assay Protocol Summary:

SBE-bla HEK 293T cells were dispensed at 4,000/well in 6 uL of assay medium into black wall/clear-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C and 5% CO2 for an overnight, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA). The assay plates were incubated at 37 C and 5% CO2 for 5 hr. One uL of LiveBLAzer B/G FRET substrate (Life Technologies) was added using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA) and the plates were incubated at room temperature for 2 hr. Fluorescence intensity (405 nm excitation, 460 nm and 530 nm emissions) was measured using an Envision plate reader (PerkinElmer, Shelton, CT). For cytotoxicity read, 4 uL of CellTiter-Glo reagent (Promega Corporation, Madison, WI) was added to each well of the assay plates using FRD. After 30min incubation at room temperature, the luminescence intensity was measured using ViewLux plate reader (PerkinElmer).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000115944 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001076943 uM-Replicate_1Activity at 0.0002499208 uM-Replicate_1Activity at 0.0005150359 uM-Replicate_1Activity at 0.00142 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.877 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive00042.1534-7.6354-9.5776-5.6143-1.012111.30590.3687-11.0158-1.1805-1.4643-13.2683-8.404711.77132.1534QC'd by ACCInactive0
Inactive00040.3853-2.34471.6915-3.8832-12.234-6.063910.4031-0.10763.0444-17.8434-9.0523-0.63646.16940.3853QC'd by ACCInactive0
Inactive0004-4.04217.28871.1321-1.0076-0.4257-17.815-1.9458-2.8324-0.26711.5412-6.3086-16.0498-1.234-4.0421QC'd by ACCInactive0
Inactive00042.2262-0.27841.1596-5.39745.13174.5477-1.56778.2001-2.3624-0.74210.3122-9.13862.05512.2262QC'd by ACCInactive0
Inactive0004-7.0334-9.58-0.28810.49541.5448-2.6274-5.451-10.57076.8461-12.23223.36080.0777-10.594-7.0334QC'd by RTIInactive0
Inactive00040.5577-6.92164.08684.81427.0784-12.4576-9.757-0.17037.57714.0781-2.79689.74059.81750.5577QC'd by RTIInactive0
Inactive0004-9.59890.1876-3.80886.11587.2443-9.1093-0.73231.2719-1.27595.66738.78383.38780.0903-9.5989QC'd by RTIInactive0
Inactive00044.351-5.72861.4678-2.1564-14.60168.34676.6356-0.760210.7032-11.9786-6.40967.79392.8074.351QC'd by RTIInactive0
Inactive00040.5045-3.7529-1.7626-8.850714.2694-9.98430.0505-9.8421-1.91.78692.24271.7842-8.44340.5045QC'd by RTIInactive0
Inactive0-5.65134.95490.5844-10.1340.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-4.82153.5787-2.24930.3702-1.35587.5103-2.2408-2.10150.0327-5.0605-8.2738-14.2783-5.3299-4.8215QC'd by RTIInactive0
Inactive0-7.3254.95490.4788-2.754110.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.417614.9854-0.321512.242812.8638-7.8629-2.609614.4642-7.0084-3.0391-3.4978-8.9617-4.4531-1.4176QC'd by RTIInactive0
Inactive00040.26-0.762716.0941-0.699314.358614.84582.28110.1025-0.21150.6563-1.03243.6094-4.03590.26QC'd by RTIInactive0-5.23974.95490.3552
Inactive0-6.75654.95490.3325-3.11255.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.722210.09291.46324.36381.165514.80424.4674-8.09957.7835-8.22510.42724.0697-1.7864-11.7222QC'd by RTIInactive0-4.15654.95490.5825
Inactive0-8.48820.40.4872-11.87911840 0 0 0 0 0 0 0 0 0 0 0 0 0 12.539612.5472-0.71070.8605-10.70591.0837-11.80228.1488-10.492-13.9866-11.0593-10.6589-8.91962.5396QC'd by RTIInactive0
Inactive0004-16.4655-1.01182.37924.2934-13.9101-0.655-0.0372-12.7646-1.3391-4.99346.1809-15.64490.1065-16.4655QC'd by RTIInactive0-4.19991.3310.6533
Inactive0004-15.12790.8718-5.70941.3373-4.1706-10.7425-0.4827-6.8534-4.311-5.94720.3002-4.3387-5.5218-15.1279QC'd by RTIInactive0-4.2071.10.6324
Inactive0-8.39894.95490.39841-15.510440 0 0 0 0 0 0 0 0 0 0 0 0 0 03.2263-11.0633-8.0336-1.45620.8124-6.810510.32120.1049-8.2487-6.59317.18083.677413.793.2263QC'd by RTIInactive0
Inactive00042.7249-5.44857.2482-0.56370.9545-5.3267-5.53923.12183.20911.32840.045-4.3055-6.82312.7249QC'd by RTIInactive0
Inactive0004-10.928-3.0077-3.118-2.9977-8.1818-4.913-2.4687-8.7243-4.03920.46591.2575-8.5593-9.3013-10.928QC'd by RTIInactive0-5.34144.95490.4847
Inactive0-8.36044.95490.59011-10.626540 0 0 0 0 0 0 0 0 0 0 0 0 0 01.1574-7.1662-7.371-0.1699-1.2819-2.6537-0.86892.15273.9489-0.44732.1474-0.889910.26721.1574QC'd by RTIInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: TGF602
Protocol: Tox21 Assay Protocol Summary:

SBE-bla HEK 293T cells were dispensed at 4,000/well in 5 uL of assay medium into black wall/clear-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C and 5% CO2 for an overnight, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA). Compound transfer was followed by the addition of 1 uL of 0.25 ng/mL TGF-beta1 or assay buffer using two separate tips of Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). The assay plates were incubated at 37 C and 5% CO2 for 5 hr. One uL of LiveBLAzer B/G FRET substrate (Life Technologies) was added using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA) and the plates were incubated at room temperature for 2 hr. Fluorescence intensity (405 nm excitation, 460 nm and 530 nm emissions) was measured using an Envision plate reader (PerkinElmer, Shelton, CT). For cytotoxicity read, 4 uL of CellTiter-Glo reagent (Promega Corporation, Madison, WI) was added to each well of the assay plates using FRD. After 30 min incubation at room temperature, the luminescence intensity was measured using ViewLux plate reader (PerkinElmer).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152025 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive00046.3658-2.60391.44354.05925.1651.5102-2.10565.56941.89612.346-4.64773.2753.08096.3658QC'd by VitasInactive0
Inactive0004-9.1232-2.0779-7.2059-6.51591.88635.3085-6.6134-1.7254-6.0177-3.3289-0.59720.0597-3.9679-9.1232QC'd by VitasInactive0
Inactive0004-14.6818-7.381320.16795.2078-9.80888.5495-2.93110.32990.2627-2.9852-0.46775.9958-7.8291-14.6818QC'd by VitasInactive0-7.97132.33320.3462
Inactive0-5.47133.92950.49668.5-1.252540 0 0 0 0 0 0 0 0 0 0 0 0 0 11.07970.0681-8.5437-0.30444.31163.9143-5.1188-3.4351.9874-2.03211.031410.54466.43281.0797QC'd by EnzoInactive0-7.07134.95490.5615
Inactive00042.2672-3.51267.52698.31222.744-0.57573.1093-0.029311.067916.0548.29036.47982.8462.2672QC'd by MicrosourceInactive0
Inactive00041.15580.33993.3299-0.092-7.5073-0.3577-8.3319-10.4863-2.41117.30391.4618-0.16762.62321.1558QC'd by VitasInactive0
Inactive00042.38522.9608-0.180512-1.30482.0019-0.0637-3.707-2.1689-0.0132-1.6392-0.1802-4.9692.385QC'd by MicrosourceInactive0-7.67134.95490.4055
Inactive0-5.72134.95490.542411-1.126140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.80521.32884.0595-4.21330.09360.00891.8704-2.1286-8.02172.98916.6742.851417.2213-2.8052QC'd by MicrosourceInactive0
Inactive0004-6.9975-21.5549-1.7139-11.1167.3205-15.0277-9.9118-10.7417-5.8795.0736-0.6498-8.2048-18.5531-6.9975QC'd by MicrosourceInactive0
Inactive0004-2.6286-1.0414-9.22751.67330.72290.357-0.6243-0.7725-9.54890.1376-3.2384-0.9664-7.7543-2.6286QC'd by VitasInactive0
Inactive00041.48930.60671.47462.70132.3731-0.48691.4237-6.3250.2843-0.1355-6.63581.48270.1211.4893QC'd by Prestwick Chemical; Inc.Inactive0
Inactive00047.6340.08773.034612.5867-17.70837.34379.2840.28641.555113.69274.523118.55914.637.634QC'd by MicrosourceInactive0-8.07131.1110.4375
Inactive0-4.97133.990.6591-16.2645.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-4.52787.61125.25697.85098.909813.50341.78571.81494.4803-1.71623.85622.872-16.8866-4.5278QC'd by SIGMAInactive0-4.77133.1320.3667
Inactive00040.171-1.53623.69791.224901.11573.99470.113-6.284-4.8884-3.60180.32042.90880.171QC'd by Prestwick Chemical; Inc.Inactive0
Inactive0-6.42133.06540.79-18.2130.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.1261-5.52083.18081.589-0.9417-0.8591.82581.0372-3.0226-22.6775-19.6966-22.219-6.7412-1.1261QC'd by SelleckInactive0-7.42132.72020.7639
Inactive00042.8502-9.313811.4561-6.908611.19517.78194.2316-1.51561.28360.275812.5861-1.362612.53392.8502QC'd by PrestwickInactive0
Cytotoxic26.832591.942820Single point of activity-4.57134.95490.9639-92.6815-0.7388-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-81.29966.0879-4.98851.72915.5077-2.3-2.0889-9.03090.0586-0.3597-1.6828-0.3346-8.2933-81.2996QC'd by MicrosourceCytotoxic26.8325100.309820Single point of activity-4.57134.95490.9433
Inactive00043.80165.117611.05366.35-1.95917.95854.8337-3.903414.1856.9862-10.64953.9475-3.363.8016QC'd by PrestwickInactive0
Inactive0-6.67130.80.5283-10.3174340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-13.44116.27583.00181.25774.3703-4.0792-0.63050.1011-6.0601-0.5984-15.2828-8.51721.0014-13.4411QC'd by PrestwickInactive0-5.87131.10.7925
Inactive0-5.47134.95490.5805100.049640 0 0 0 0 0 0 0 0 0 0 0 0 0 10.12882.1046-1.20021.64694.3816-2.8696.1445-2.4997-3.1762-3.70871.929712.16337.81960.1288QC'd by MicrosourceInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3223705
Protocol: N/A
Comment: Journal: MedChemComm
Year: 2012
Volume: 3
Issue: 7
First Page: 735
Last Page: 751
DOI: 10.1039/C2MD20079A
Standard TypeStandard RelationStandard Value
pKa=2.39
pKa=1.54
pKa=15.6
pKa=-1.9
pKa=-3.4
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167MG
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (DMEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive040.10310.1406-0.03150.12620.060.1031QC'd by "NCI"0
Inactive040.02-0.0462-0.0096-0.0036-0.06880.02QC'd by "NCI"0
Inactive040.0352-0.02430.01330.08820.02270.0352QC'd by "NCI"0
Inactive04-0.0032-0.14120.03560.0067-0.0827-0.0032QC'd by "SigmaAldrich"0
Inactive04-0.0421-6.0E-4-0.01160.00418.0E-4-0.0421QC'd by "NCI"0
Inactive04-0.08870.05490.011900.0103-0.0887QC'd by "NCI"0
Inactive040.05490.14040.09660.0264-0.00150.0549QC'd by "NCI"0
Inactive04-0.0674-0.0024-0.1251-0.0771-0.0044-0.0674QC'd by "NCI"0
Inactive040.07660.11210.11820.1033-0.02320.0766QC'd by "NCI"0
Inactive040.02350.0289-0.01920.0237-0.01010.0235QC'd by "Labotest"0
Inactive04-1.0E-40.04880.0010.01740.0628-1.0E-4QC'd by "NCI"0
Inactive04-0.00820.10220.09650.07640.0317-0.0082QC'd by "NCI"0
Inactive040.04070.1229-0.00830.10480.07010.0407QC'd by "NCI"0
Inactive04-0.0682-0.10260.0427-0.0797-0.01-0.0682QC'd by "NCI"0
Inactive04-0.01790.0067-0.06430.0889-0.0161-0.0179QC'd by "NCI"0
Inactive04-0.0027-0.0933-0.0538-0.0212-0.0192-0.0027QC'd by "NCI"0
Inactive04-0.0156-0.0199-0.013-0.0358-0.0233-0.0156QC'd by "NCI"0
Inactive040.03220.01980.0576-0.00580.03020.0322QC'd by "Chembridge"0
Inactive040.10750.08580.07490.0633-0.01660.1075QC'd by "NCI"0
Inactive04-0.186-0.0569-0.018-0.0052-0.0633-0.186QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: P53600
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000 cells/5 ul/well in 1536-well black wall/clear bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 16 hours. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Flying Reagent Dispenser, the plates were incubated at room temperature for 2 hours, and fluorescence intensity was measured by an Envision plate reader. For cell viability readout that measures cytotoxicity, 4 ul/well of CellTiter-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).
Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000043054 uM-Replicate_1Activity at 0.0000099513 uM-Replicate_1Activity at 0.0000394398 uM-Replicate_1Activity at 0.0000922287 uM-Replicate_1Activity at 0.0002147056 uM-Replicate_1Activity at 0.0004452702 uM-Replicate_1Activity at 0.00122 uM-Replicate_1Activity at 0.00376 uM-Replicate_1Activity at 0.00955 uM-Replicate_1Activity at 0.022 uM-Replicate_1Activity at 0.049 uM-Replicate_1Activity at 0.109 uM-Replicate_1Activity at 0.249 uM-Replicate_1Activity at 0.761 uM-Replicate_1Activity at 2.332 uM-Replicate_1Activity at 5.986 uM-Replicate_1Activity at 13.53 uM-Replicate_1Activity at 30.31 uM-Replicate_1Activity at 65.96 uM-Replicate_1Activity at 171.5 uM-Replicate_1Activity at 622.7 uM-Replicate_1Activity at 1320.0 uM-Replicate_1Activity at 2952.0 uM-Replicate_1Activity at 6600.0 uM-Replicate_1Activity at 14760.0 uM-Replicate_1Activity at 33000.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive000411.68960.1156-13.79419.96613.16310.7283-0.13048.42250.8152-0.10070.800321.2177-5.098911.6896QC'd by GVKInconclusive22.349231.210810Partial curve; partial efficacy; poor fit-4.65074.95490.8311
Inactive00044.1278-1.2132-0.531.1724-13.6008-15.8488-1.6086-19.5261-1.84034.6782.76125.28040.28044.1278QC'd by SequoiaInactive0
Inactive0004-9.80083.31944.9321-4.8812-12.78760.30429.0414-8.94990.223314.08858.8057-15.4411-4.9694-9.8008QC'd by TocrisInactive0
Inactive0004-1.97565.0865-1.7855-7.44442.244-1.822215.634118.165121.11031.735-10.98693.971310.803-1.9756QC'd by MicrosourceInactive0
Inactive00046.85951.21214.5834-1.147427.33062.48186.32539.01910.214520.70491.9499-9.1091-8.70446.8595QC'd by SIGMAInactive0
Inactive0-4.80072.09370.639333.4297-12.96840 0 0 0 0 0 0 0 0 0 0 1 0 0 025.4284-14.8066-9.0853-13.581-7.588-35.7992-8.9477-21.4634-0.5226-3.92488.5216-5.58437.506325.4284QC'd by MicrosourceInactive0
Inactive0004-15.007-3.1282-9.3591-0.59167.66516.92395.64735.12210.15582.5991-1.3526-6.47-0.785-15.007QC'd by MicrosourceInactive0
Inactive000424.0896-0.8446-9.61-6.08550.45112.491311.00488.98224.16252.593115.94870.8545-5.437324.0896QC'd by VitasInactive0
Inactive0004-17.67891.269819.24249.9274-7.42686.6741.6608-11.9547-6.5433-0.12947.7321-0.9298-3.0587-17.6789QC'd by SequoiaInactive0
Inactive0004-14.1816-14.82752.70742.3606-2.2355-4.2683-14.785-4.9866-14.55780.587-5.4301-8.78443.5884-14.1816QC'd by MicrosourceInactive0-9.20073.19250.6375
Inactive0004-1.2316-19.54044.6965-1.2942-1.67070.2407-15.5972-0.1313-8.4723-7.3738-1.20892.41540.8864-1.2316QC'd by SequoiaInactive0
Inactive00041.5567-5.753613.963810.2956-0.5580-1.68249.770620.988-2.01438.1577-7.9909-2.67841.5567QC'd by VitasInactive0
Inactive0-5.00071.96730.395926.0362-2.459340 0 0 0 0 0 0 0 0 1 0 0 0 0 10.23290.7504-0.0238-13.01490.91413.2757.6-0.817-14.514333.15894.5704-6.010126.66430.2329QC'd by VitasInactive0-7.85074.95490.3764
Inactive00040.4996-11.00798.4449-5.51661.0437-5.31884.2154-11.5318-0.68280.560410.3541-10.0764-3.39490.4996QC'd by SequoiaInactive0
Inactive0004-11.29821.6112-9.15080.0988-19.993-7.174916.2891-28.8965-0.2185-13.4455-15.182-7.4087.9797-11.2982QC'd by SIGMAInactive0
Cytotoxic0.001329.371420Complete curve; partial efficacy; poor fit-8.90074.95490.6762-1.930827.4406-1.40 0 0 0 0 0 0 0 0 0 0 0 0 0 02.084327.380322.2956-1.7991-14.5009-13.0557-1.27961.8292-4.68462.1858-2.80191.152812.67842.0843QC'd by MicrosourceInactive0
Cytotoxic22.349237.143520Single point of activity-4.65074.95490.6826-37.6249-0.4814-30 0 0 0 0 0 1 0 0 0 0 0 0 0 0-35.0886-10.0183-3.78480.92698.32995.971651.8329-7.9197-7.10119.7258-3.0119-1.82540.4137-35.0886QC'd by MicrosourceCytotoxic19.918841.056720Single point of activity-4.70074.50450.7845
Inactive0004-8.20534.878-0.8843.033-7.545116.823-9.3197.52683.3384-2.1505-2.9445-18.3014-0.1048-8.2053QC'd by SpecsInconclusive25.076243.037610Single point of activity-4.60074.95490.5622
Inactive000420.76650.814812.61279.9828-12.22150.44040.7956-15.56271.1625-6.82596.0669-0.0505-1.196720.7665QC'd by Prestwick Chemical; Inc.Inconclusive22.349234.562510Single point of activity-4.65074.0950.9286
Inconclusive8.897437.738210Single point of activity-5.05073.1320.718338.15130.413130 0 0 0 0 0 0 0 0 0 0 0 0 0 1-5.95941.40094.89037.6788-4.8095-4.8507-6.912-0.4163-7.58221.59434.88844.768442.6535-5.9594QC'd by MicrosourceInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: PPARDV813
Protocol: Tox21 Assay Protocol Summary:

PPARd-bla cells were dispensed at 3000 cells/6uL/well in 1536-well black wall/clear bottom plates using a Multidrop Combi (Thermo Fisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C and 5% CO2 for 5 h, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA). The assay plates were incubated at 37C for 17 h. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA), the plates were incubated at room temperature for 2 h, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT). For cell viability readout that measures cytotoxicity, 3 ul/well of CellTiter-Glo reagent was added into the assay plates using a Bioraptr FRD. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader (PerkinElmer).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000056507 uM-Replicate_1Activity at 0.0000126354 uM-Replicate_1Activity at 0.0000282534 uM-Replicate_1Activity at 0.0000545573 uM-Replicate_1Activity at 0.0001216490 uM-Replicate_1Activity at 0.0002748434 uM-Replicate_1Activity at 0.0005839002 uM-Replicate_1Activity at 0.00107 uM-Replicate_1Activity at 0.00238 uM-Replicate_1Activity at 0.00531 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.026 uM-Replicate_1Activity at 0.059 uM-Replicate_1Activity at 0.132 uM-Replicate_1Activity at 0.275 uM-Replicate_1Activity at 0.550 uM-Replicate_1Activity at 1.225 uM-Replicate_1Activity at 2.701 uM-Replicate_1Activity at 5.947 uM-Replicate_1Activity at 13.22 uM-Replicate_1Activity at 29.14 uM-Replicate_1Activity at 62.57 uM-Replicate_1Activity at 81.11 uM-Replicate_1Activity at 231.6 uM-Replicate_1Activity at 765.1 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive045.0580.58783.96498.27420.65169.52473.12011.507713.407917.11790.7965-0.1972-0.2713.53349.47835.058QC'd by ACCInactive04.95490.3417-19.3831
Inactive040.57897.8746-4.33412.29310.97451.7903-1.31545.43053.1718-0.71742.00676.20794.374810.092913.29840.5789QC'd by ACCInactive04.95490.4949-26.437
Inactive04.95490.6963-10.2105740 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.7472-0.91931.9147.14814.911510.4394.50156.54532.65299.46148.43257.11826.6631-15.5921-4.8591-9.7472QC'd by ACCInactive04.95490.6194-25.9724
Inactive04-1.38632.22032.1256-0.83431.85181.9311-0.1926-3.6983-1.38221.64112.95822.0078-0.18210.35611.8491-1.3863QC'd by ACCInactive04.95490.368-5.6607
Inactive042.16212.4047.04135.890510.57542.26199.52187.9118-3.6632.21993.94575.2295-0.3069-10.36667.24912.1621QC'd by RTIInactive0
Inactive03.51170.6241-0.882811.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.15239.670619.58416.96296.91510.254614.38550.6844-2.184-2.15540.44819.7065-0.265-3.3054-0.562-6.1523QC'd by RTIInactive03.1320.6987-3.3136
Inactive043.0005-1.3829-7.57010.6794-1.7299-3.3259-2.0593-0.0319-6.2265-19.4168-32.7868-0.4794-6.3149-0.8204-4.713.0005QC'd by RTIInactive02.40640.57093.5
Inactive04-0.9041-3.89125.19785.9821-0.3373-0.62371.0742-0.0925-1.671-1.52034.9743-4.8118-2.06562.0438-0.2223-0.9041QC'd by RTICytotoxic83.211253.059320Single point of activity-4.07984.95490.7813-54.5977
Inactive04-6.92411.113-22.2956-13.8951-6.52040.657-0.4317-1.31558.7492-0.70054.3984-9.5369-3.3388-4.4874-21.7918-6.924QC'd by RTIInactive0
Inactive01.3310.6539-22.2754-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.22950.27350.5035-1.2924-3.8998-1.7196-0.39576.12350.6329-4.1209-6.5931-1.7946-1.2827-3.4116-7.4745-15.2295QC'd by RTIInactive0
Inactive04.44950.5887-18.1062-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.33850.5610.5633-1.3892-11.17654.7920.4685-0.7439-1.05073.55120.3819-1.5905-0.41731.3302-3.581-16.3385QC'd by RTIInactive03.92950.3698-9.7368
Cytotoxic64.058474.143141Partial curve; partial efficacy-4.19341.75290.8438-74.6592-0.5161-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-56.56-2.62-0.5421-1.2794-4.5179-0.28550.2007-2.45628.6014-2.5747.0279-0.9199-3.9874-21.7796-13.0189-56.56QC'd by RTIInactive0
Cytotoxic15.481784.418681Complete curve; high efficacy-4.81022.25260.9577-84.19960.219-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-86.62511.0724-0.4756-1.65681.185400.5656-0.9223-0.03520.9563-6.4759-1.249-4.9719-68.6593-67.8943-86.6251QC'd by RTICytotoxic34.659276.250220Partial curve; high efficacy; poor fit-4.46020.70.6618-83.5567
Inactive04-1.97220.2807-0.9509-0.14650.54840.2814-2.3584.4949-0.9592-0.7169-0.1151-1.2590.75847.8741-2.5295-1.9722QC'd by RTIInactive0
Cytotoxic70.241234.72320Single point of activity-4.15344.44950.9733-35.723-1-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-30.6025-0.8503-2.4108-3.40260.0361-1.8716-1.587-1.54080.2175-1.9559-1.20791.73770.0124-2.1498-5.579-30.6025QC'd by RTIInactive04.95490.4531-12.1425
Inactive04.95490.3679-24.8496.058940 0 0 0 0 0 0 0 0 0 0 0 0 0 0-18.99170.24884.1486-2.933216.0524-0.65890.309411.66522.186-1.91066.154712.31919.2652-5.009715.7714-18.9917QC'd by RTIInactive010.5224-16.699
Inactive04-0.6116-1.26834.1431-1.04687.01522.24789.1749-5.97242.43479.1987-0.031414.7940.1315-0.453512.3931-0.6116QC'd by RTIInactive0
Inactive02.35310.6768-25.3893240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-17.82448.906-3.31022.048-1.22355.25761.82452.96895.00977.30253.1246-1.5559-3.9808-0.7939-3.8933-17.8244QC'd by RTIInactive04.95490.4398-13.5448
Inactive044.3139-3.3381-0.0437-3.784-3.4733-1.0961-4.52432.70552.52170.37448.5773-0.4554-3.5979-5.7737-0.88864.3139QC'd by RTIInactive0
Inactive04-9.5087-15.805319.0012-0.6736-1.300421.99571.600810.539-16.8838-1.05661.95121.67870.9763-1.6046-2.3734-9.5087QC'd by RTIInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167MR
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (DMEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive040.06820.17150.15520.2805-0.08310.0682QC'd by "APAC"0
Inactive040.0073-0.03930.005-0.09740.03070.0073QC'd by "APAC"0
Inactive04-0.4123-0.248-0.1541-0.1037-0.0973-0.4123QC'd by "APAC"0
Inactive040.19330.41050.28830.44640.38910.1933QC'd by "APAC"0
Inactive040.44160.65360.7260.63220.73960.4416QC'd by "APAC"0
Inactive040.2127-0.00470.08240.2587-0.01090.2127QC'd by "APAC"0
Inactive040.13480.40170.15030.02750.21030.1348QC'd by "APAC"0
Inactive040.16380.07840.19640.35280.10370.1638QC'd by "APAC"0
Inactive04-0.0775-0.1328-0.144-0.2205-0.105-0.0775QC'd by "APAC"0
Inactive040.12810.06390.0321-0.01010.04060.1281QC'd by "APAC"0
Inactive04-0.4235-0.3306-0.3534-0.2876-0.4525-0.4235QC'd by "APAC"0
Inactive040.1880.24950.21320.11330.30530.188QC'd by "APAC"0
Inactive040.26490.13370.33710.1823-0.01240.2649QC'd by "APAC"0
Inactive040.14720.44310.35470.41120.45620.1472QC'd by "APAC"0
Inactive040.18370.1140.0230.16450.38450.1837QC'd by "APAC"0
Inactive04-0.5082-0.4883-0.5711-0.5038-0.4992-0.5082QC'd by "APAC"0
Inactive04-0.2494-0.1585-0.0187-0.265-0.2494-0.2494QC'd by "APAC"0
Inactive04-0.489-0.6545-0.2063-0.2875-0.5573-0.489QC'd by "APAC"0
Inactive04-0.1512-0.1725-0.2697-0.1595-0.2932-0.1512QC'd by "APAC"0
Inactive040.1730.29550.30070.26150.34070.173QC'd by "APAC"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: P53MS958
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000cells/3ul/well in 1536-well black-clear bottom plates. After the assay plates were incubated at 37 C, 5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate. Following compound addition, 3 uL of rat liver microsomes (Molecular Toxicology, Boone, NC) at final concentration of 0.5 mg/mL and 1uL of B-Nicotinamide adenine dinucleotide 2'-phosphate (NADPH) at final concentration of 0.5 mg/mL were transferred to the assay plate. The plates were incubated at 37 C for 16 hours. 1 uL of LiveBLAzer detection mixture was added to each well and the plates were incubated at room temperature in the dark for 2 h. Fluorescence intensity at 460 and 530 nm emission and 405 nm excitation were measured by an Envision plate reader. For cell viability readout that measures cytotoxicity, 4 ul/well of CellTiter-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000043235 uM-Replicate_1Activity at 0.0000098296 uM-Replicate_1Activity at 0.0000380988 uM-Replicate_1Activity at 0.0000933477 uM-Replicate_1Activity at 0.0002146311 uM-Replicate_1Activity at 0.0004426192 uM-Replicate_1Activity at 0.00122 uM-Replicate_1Activity at 0.00372 uM-Replicate_1Activity at 0.00957 uM-Replicate_1Activity at 0.022 uM-Replicate_1Activity at 0.049 uM-Replicate_1Activity at 0.109 uM-Replicate_1Activity at 0.249 uM-Replicate_1Activity at 0.768 uM-Replicate_1Activity at 2.332 uM-Replicate_1Activity at 5.986 uM-Replicate_1Activity at 13.53 uM-Replicate_1Activity at 30.31 uM-Replicate_1Activity at 65.96 uM-Replicate_1Activity at 171.5 uM-Replicate_1Activity at 622.7 uM-Replicate_1Activity at 1320.0 uM-Replicate_1Activity at 2952.0 uM-Replicate_1Activity at 6600.0 uM-Replicate_1Activity at 14760.0 uM-Replicate_1Activity at 33000.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive000415.4129-0.3878-0.18645.37348.8557-0.29272.5035-10.205-0.2227.988-2.2891.52765.497915.4129QC'd by ACCInactive0
Inactive0-9.30074.95490.81131-17.707840 0 0 0 0 0 0 0 0 0 0 0 0 0 01.0149-13.08993.2756-1.32141.18321.8535-0.3978-0.4282.5506-0.24571.49181.68870.55861.0149QC'd by ACCInactive0
Inactive00040.0279-7.8342-1.89942.16960.5638-6.7392.6266-0.50970.73195.3764-7.7238-0.06747.02780.0279QC'd by ACCInactive0
Inactive00041.38786.287211.3346-1.35856.9465-2.58585.0519-2.5689.0021.6411-1.72927.00831.07741.3878QC'd by ACCInactive0-5.45072.40640.4602
Inactive0004-6.0549-14.8117-16.0755-3.9155-14.9771-10.937-32.5334-11.9531.4447-12.5843-18.1191-11.5121-10.2319-6.0549QC'd by RTIInactive0
Inactive0004-22.5649-3.3758-16.2168-4.5428-4.51510.1292-2.6754-23.201-8.3262-3.0518-1.1305-3.6383-2.6115-22.5649QC'd by RTIInactive0-8.59910.80.691
Inactive0004-0.2302-3.0733-11.95531.9394-0.062-0.7676-9.0695-1.09531.199-3.6509-10.3544-18.6262-9.6473-0.2302QC'd by RTIInactive0-4.20294.95490.345
Inactive0004-31.97-9.3562-1.8629-4.3936-8.3595-10.443-39.3827-2.50720.54372.3156-5.5145-4.9746-4.5578-31.97QC'd by RTIInactive0
Cytotoxic48.936540.016120Single point of activity-4.31044.95490.9076-41.0161-1-30 0 0 0 0 0 0 0 0 0 0 0 0 0 10.8752-0.1555-0.1471-0.86110.5088-1.62211.8567-5.5667-4.26740.6449-1.1659-1.471-37.97790.8752QC'd by RTIInactive0
Inactive0-4.4812.25260.6231-17.4881-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.1568-8.0428-0.62356.2346-0.9991-1.44871.2877-1.82882.3924-2.4336-0.4068-0.0819-10.8685-14.1568QC'd by RTIInactive0
Inactive0-4.15464.95490.3365-27.53820.41540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.24640.0979-1.09382.89261.68642.0417-11.5049-1.00074.87532.0771-10.214919.6036-0.4282-21.2464QC'd by RTIInactive0-4.35463.92950.4572
Cytotoxic1.909462.99420Single point of activity-5.71914.95490.8427-65.284-2.29-30 0 0 0 0 0 0 0 0 0 0 1 1 1 121.2448-4.4527-11.9693-0.7569-1.67770.0603-12.88981.4183.8556-64.004-3.125819.149730.660221.2448QC'd by RTIInconclusive26.970339.101610Partial curve; partial efficacy-4.56912.40640.8048
Inactive0-5.73594.95490.4398-11.70950.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-18.5079-13.1487-1.13453.01137.6647-1.76074.95091.42740.7821-7.5706-10.5531-11.2568-1.1121-18.5079QC'd by RTIInactive0-5.13593.990.4729
Inactive0-4.91744.95490.4007150.513840 0 0 0 0 0 0 0 0 0 0 0 0 0 1-8.2124-6.4957-1.34376.24526.8209-1.5109-0.187612.48363.7645-4.0819-5.983812.929113.901-8.2124QC'd by RTIInactive0
Inactive0004-4.309910.7843-0.2327-5.32226.8375-6.64633.82231.011417.173-2.68034.8346-1.5527-1.3315-4.3099QC'd by RTIInactive0
Inactive0-4.78644.95490.4643-0.5-6.943640 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.3412-9.0513-3.5748-2.3634-8.2237-8.0106-6.3527-9.1377-10.7863-6.9009-9.556-4.63561.3663-2.3412QC'd by RTIInactive0
Inactive00043.8948-9.18-4.528-7.8262-5.28180.1213-2.8514-5.27810.14171.4481-10.28080.21445.40843.8948QC'd by RTIInactive0-4.27824.0450.5133
Inactive00040.9309-0.3627-0.7959-0.29194.6133-6.45136.07670.37295.22822.4365-0.3736-6.44071.19840.9309QC'd by RTIInactive0
Inactive00044.6175-2.446-2.97794.96498.591-3.7225-1.29327.6265.56985.46650.618212.56510.39614.6175QC'd by RTIInactive0
Inactive00041.16141.11370.8635-2.0253-1.3109-1.0103-7.7297-0.07730.3904-0.9231-0.2649-8.99091.4551.1614QC'd by RTIInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167CG
Protocol: Tox21 Assay Protocol Summary:

2,000 HEK293 cells in 5 uL of culture medium containing 10% dialyzed FBS per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (Thermo Scientific). The assay plates were incubated for 4-5 hr at 37C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys, San Diego, CA). After the assay plates were incubated overnight at 37C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.0303-0.04260.0285-0.09190.0085-0.0303QC'd by "NCI"0
Inactive040.0853-0.06580.02019.0E-40.06280.0853QC'd by "NCI"0
Inactive040.16730.04180.01560.0204-0.00980.1673QC'd by "NCI"0
Inactive04-0.1980.02190.0160.02350.0689-0.198QC'd by "SigmaAldrich"0
Inactive040.0038-0.0014-0.00825.0E-4-0.1170.0038QC'd by "NCI"0
Inactive040.0026-0.0041-0.01760.0697-0.01480.0026QC'd by "NCI"0
Inactive040.1333-0.0845-0.0206-0.01310.12030.1333QC'd by "NCI"0
Inactive040.03690.00440.0618-0.01070.01570.0369QC'd by "NCI"0
Inactive04-0.02150.02550.01530.1030.0492-0.0215QC'd by "NCI"0
Inactive04-0.00280.08780.0034-0.01623.0E-4-0.0028QC'd by "Labotest"0
Inactive040.02210.0083-0.0285-0.04060.10790.0221QC'd by "NCI"0
Inactive040.02430.10020.08470.0514-0.00220.0243QC'd by "NCI"0
Inactive040.00680.024-0.00130.0328-0.11050.0068QC'd by "NCI"0
Inactive040.03090.0251-0.2255-0.1044-0.07930.0309QC'd by "NCI"0
Inactive04-0.0428-0.0779-0.07410.0110.0229-0.0428QC'd by "NCI"0
Inactive040.07660.0357-0.02130.0861-0.01260.0766QC'd by "NCI"0
Inactive04-0.0349-0.0548-0.0746-0.0452-0.1742-0.0349QC'd by "NCI"0
Inactive040.15650.01040.0178-0.0320.02410.1565QC'd by "Chembridge"0
Inactive04-0.05070.0691-0.01840.01950.0897-0.0507QC'd by "NCI"0
Inactive04-0.0232-0.1816-0.1161-0.2126-0.2187-0.0232QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: P53MS482
Protocol: Please refer to other AIDs 1963578, 1963580, 720687, 720685, 720678 and 720681 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the p53 with rat microsomes agonist mode assay (AID 1963578), cell viability counter screen (AID 1963580), and auto fluorescence counter screens (AID 720687, 720685, 720678, and 720681). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).
Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Blue (460 nm) auto fluorescence outcomeSample Source
inactiveinactive0inactive0inactive0active antagonist37.95478669-56.89862383inactiveRohm and Haas
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactivePfaltz-Bauer
inactiveinactive0inactive0inactive0inactive0inactiveRadian International
inactiveinactive0inactive0inactive0inconclusive antagonistinactiveSpectrum Chemical
inactiveinactive0inconclusive agonistinactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactive0inactiveBattelle Northwest
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inconclusive agonistinactive0inactiveSIGMA
inactiveinactive0inactive0inactive0active antagonist11.47389904-137.559426inactiveTCI
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inconclusiveinactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveShanghai Xingling
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167MB
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (DMEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.060.0769-0.0561-0.05340.0765-0.06QC'd by "NCI"0
Inactive04-0.02860.01850.15430.03970.0134-0.0286QC'd by "NCI"0
Inactive041.25510.11730.01450.07070.51551.2551QC'd by "NCI"0
Inactive040.0380.0229-0.1395-0.01880.42040.038QC'd by "SigmaAldrich"0
Inactive041.3250.07660.1836-0.10240.07711.325QC'd by "NCI"0
Inactive040.1088-0.12430.0941-0.0246-0.04550.1088QC'd by "NCI"0
Inactive040.00260.0529-0.1116-0.1678-0.11720.0026QC'd by "NCI"0
Inactive040.17340.0511-0.06420.11-0.13760.1734QC'd by "NCI"0
Inactive040.0031-0.0257-0.0731-0.021-0.01490.0031QC'd by "NCI"0
Inactive04.0950.98722.5040 0 0 0 02.51080.00570.26280.01340.77542.5108QC'd by "Labotest"0
Inactive04-0.05950.0115-0.03130.04540.0652-0.0595QC'd by "NCI"0
Inactive040.7551-0.0030.0690.14220.06940.7551QC'd by "NCI"0
Inactive04-0.0762-0.099-0.14750.0756-0.1338-0.0762QC'd by "NCI"0
Inactive040.0533-0.1182-0.00850.0808-0.08810.0533QC'd by "NCI"0
Inactive041.4117-0.0519-0.0295-0.05670.23241.4117QC'd by "NCI"0
Inactive040.15250.02280.10290.03280.11910.1525QC'd by "NCI"0
Inactive040.97520.1286-0.0289-0.0041-0.01590.9752QC'd by "NCI"0
Inactive040.090.11160.0522-0.0224-0.17680.09QC'd by "Chembridge"0
Inactive040.12760.09120.04220.0790.08710.1276QC'd by "NCI"0
Inactive04-0.05040.00170.0374-0.2014-0.0226-0.0504QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: P53344
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000 cells/5 ul/well in 1536-well black wall/clear bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 16 hours. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Flying Reagent Dispenser, the plates were incubated at room temperature for 2 hours, and fluorescence intensity was measured by an Envision plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000043054 uM-Replicate_1W530-Activity at 0.0000099513 uM-Replicate_1W530-Activity at 0.0000394398 uM-Replicate_1W530-Activity at 0.0000922287 uM-Replicate_1W530-Activity at 0.0002147056 uM-Replicate_1W530-Activity at 0.0004452702 uM-Replicate_1W530-Activity at 0.00122 uM-Replicate_1W530-Activity at 0.00376 uM-Replicate_1W530-Activity at 0.00955 uM-Replicate_1W530-Activity at 0.022 uM-Replicate_1W530-Activity at 0.049 uM-Replicate_1W530-Activity at 0.109 uM-Replicate_1W530-Activity at 0.249 uM-Replicate_1W530-Activity at 0.761 uM-Replicate_1W530-Activity at 2.332 uM-Replicate_1W530-Activity at 5.986 uM-Replicate_1W530-Activity at 13.53 uM-Replicate_1W530-Activity at 30.31 uM-Replicate_1W530-Activity at 65.96 uM-Replicate_1W530-Activity at 171.5 uM-Replicate_1W530-Activity at 622.7 uM-Replicate_1W530-Activity at 1320.0 uM-Replicate_1W530-Activity at 2952.0 uM-Replicate_1W530-Activity at 6600.0 uM-Replicate_1W530-Activity at 14760.0 uM-Replicate_1W530-Activity at 33000.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10004-2.7054-0.742917.6324-5.7098-2.4442-8.8689-8.44923.85664.8951.316-4.2342-2.2173-1.3067-2.705410004-0.008
Inactive10004-9.2163-14.98060.5352-3.1889-1.87493.657-6.40320.83436.099515.97381.8503-6.6623-7.3549-9.2163100040.5551
Inconclusive15.82281.873510Partial curve; high efficacy-4.80071.46410.942883.86851.9952.11 0 0 0 0 0 0 0 0 0 0 0 0 0 063.7671-25.2350.72594.9823.8964-6.011-7.50423.0243-0.36318.58029.552814.338143.879163.767110-5.15071.41630.6697-11.5276040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.41
Inactive10004-7.60360.157-0.8011-9.9636-13.0521-10.3016-8.2965-19.3101-11.1767-1.8658-10.3506-0.2558-4.7484-7.6036100040.7786
Inactive10004-1.25980.187213.2885.11046.52950.1337-12.0409-9.16955.1910.756-5.7729-4.064311.1384-1.2598100040.0274
Inactive10-4.79910.60.5308-18.20022.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.66682.13790.73361.997911.88191.0068-5.4624-1.91134.135-9.1428-3.5388-7.7512-8.3149-12.6668100042.1474
Inactive100040.120.6216.73751.29862.96138.4418-20.9196-8.36372.5119-0.9643-3.05170.98720.45280.12100040.1505
Inactive10004-3.34154.8601-0.05933.13132.492711.5913-1.4902-13.7451.9094-3.61140.17755.8982-1.925-3.3415100040.1916
Inactive100044.68764.03720.43261.7117-5.36330.01244.09393.29011.8675-5.35829.301-3.3996-6.65394.687610004-0.8649
Inactive1000414.45021.1662-13.4728-0.06892.7591-5.585-15.2304-11.60378.2866-5.55088.036-4.6022-4.845814.450210004-3.7942
Inactive10-4.60461.1110.576731.0459-6.10640 0 0 0 0 0 0 0 0 0 0 0 0 0 026.6548-7.6451-2.6127-0.4371-10.6818-11.93260.5693-21.22510.609-17.09791.011613.89869.803426.654810004-1.0538
Inconclusive15.166545.683610Partial curve; partial efficacy-4.81910.60.775941.0698-4.61382.20 0 0 0 0 0 0 0 0 0 0 0 0 0 032.1055-2.8274-2.73911.8943-2.4675-16.4634-3.3416-2.31647.09830.338415.525617.156218.43332.1055100040.1046
Inactive10-4.68594.50450.56518-4.235840 0 0 0 0 0 0 0 0 0 0 0 0 0 15.1259-0.5226-4.0178-6.8476-0.1323-11.918-14.7798-1.343-0.6951-0.0477-3.8234-0.157915.36455.125910004-0.8015
Inactive10004-2.57192.1271-15.6379-9.9458-0.0566-1.3009-10.3345-4.73090.7930.4322-6.21176.0155-0.1149-2.571910004-0.2737
Inactive10-4.429110.3508160.584740 0 0 0 0 0 0 0 0 0 0 0 0 0 014.03072.8758-1.4333-4.09618.1324-0.1788-1.8365-3.40460.96875.33925.74960.63436.788614.030710004-0.3011
Inactive10-5.88644.95490.460410-0.303340 0 0 0 0 0 0 0 0 0 0 0 0 0 014.81111.65651.78890.1435-7.595-1.069210.26810.1065-11.50277.37014.69215.95186.487814.811110004-6.6938
Inactive1000412.70575.94743.12190.9114-1.934610.27262.0269-12.6992-5.01885.3788-5.1369-2.868815.767612.705710004-1.5792
Inactive100048.0685-3.4653-4.85211.49384.676215.0539-6.5066-14.57680.9838-2.93245.02795.50265.54988.068510004-2.3647
Inactive100040.21273.5618-0.86484.668510.12697.869-0.11867.88796.91763.71724.3769.7145-1.76850.212710004-0.1916
Inactive1000415.68179.5665-3.95061.963.0139-1.30215.9929-15.24591.98272.56765.42287.37042.786215.681710004-3.34
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478MG
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (MEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.0468-1.0E-4-0.0634-0.0128-0.1309-0.0468QC'd by "NCI"0
Inactive04-0.02170.0466-0.04120.00330.0551-0.0217QC'd by "NCI"0
Inactive04-0.0248-0.00450.0622-0.03730.0284-0.0248QC'd by "NCI"0
Inactive040.01860.0540.055-7.0E-40.08120.0186QC'd by "SigmaAldrich"0
Inactive040.02420.07270.1578-0.01480.02860.0242QC'd by "NCI"0
Inactive040.08870.03620.13790.04160.03120.0887QC'd by "NCI"0
Inactive040.10310.0424-0.0028-0.06470.0120.1031QC'd by "NCI"0
Inactive040.022-0.01990.0104-0.01420.03070.022QC'd by "NCI"0
Inactive040.58190.1190.05910.03290.05860.5819QC'd by "NCI"0
Inactive04-0.01230.04580.0457-0.03880.0399-0.0123QC'd by "Labotest"0
Inactive04-0.0094-0.02560.0289-0.00760-0.0094QC'd by "NCI"0
Inactive040.11950.07450.00670.004-0.05970.1195QC'd by "NCI"0
Inactive04-0.0059-0.05640.01470.0049-0.0156-0.0059QC'd by "NCI"0
Inactive04-0.05470.0295-0.0247-0.0665-0.0356-0.0547QC'd by "NCI"0
Inactive04-0.0413-0.0059-0.1195-0.0027-0.0175-0.0413QC'd by "NCI"0
Inactive040.175-0.00450.11290.06590.06270.175QC'd by "NCI"0
Inactive04-0.0317-0.0316-0.01050.0141-0.0074-0.0317QC'd by "NCI"0
Inactive040.06210.0243-0.0520.16910.01120.0621QC'd by "Chembridge"0
Inactive040.0158-0.02480.0493-0.0242-0.02880.0158QC'd by "NCI"0
Inactive04-0.0654-0.1331-0.0734-0.03930.0109-0.0654QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:tumor suppressor p53 [Homo sapiens]
External ID: P53MS233
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000cells/3ul/well in 1536-well black-clear bottom plates. After the assay plates were incubated at 37 C, 5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate. Following compound addition, 3 uL of human liver microsomes (XenoTech, Kansas City, KS) at final concentration of 0.5 mg/mL and 1uL of Beta-Nicotinamide adenine dinucleotide 2-phosphate (NADPH) at final concentration of 0.5 mg/mL were transferred to the assay plate. The plates were incubated at 37 C for 16 hours. 1 uL of LiveBLAzer detection mixture was added to each well and the plates were incubated at room temperature in the dark for 2 h. Fluorescence intensity at 460 and 530 nm emission and 405 nm excitation were measured by an Envision plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000042859 uM-Replicate_1W530-Activity at 0.0000098296 uM-Replicate_1W530-Activity at 0.0000389118 uM-Replicate_1W530-Activity at 0.0000921325 uM-Replicate_1W530-Activity at 0.0002143310 uM-Replicate_1W530-Activity at 0.0004423865 uM-Replicate_1W530-Activity at 0.00121 uM-Replicate_1W530-Activity at 0.00372 uM-Replicate_1W530-Activity at 0.00955 uM-Replicate_1W530-Activity at 0.022 uM-Replicate_1W530-Activity at 0.049 uM-Replicate_1W530-Activity at 0.109 uM-Replicate_1W530-Activity at 0.249 uM-Replicate_1W530-Activity at 0.761 uM-Replicate_1W530-Activity at 2.332 uM-Replicate_1W530-Activity at 5.986 uM-Replicate_1W530-Activity at 13.53 uM-Replicate_1W530-Activity at 30.31 uM-Replicate_1W530-Activity at 65.96 uM-Replicate_1W530-Activity at 171.5 uM-Replicate_1W530-Activity at 622.7 uM-Replicate_1W530-Activity at 1320.0 uM-Replicate_1W530-Activity at 2952.0 uM-Replicate_1W530-Activity at 6600.0 uM-Replicate_1W530-Activity at 14760.0 uM-Replicate_1W530-Activity at 33000.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10-5.20073.990.3607-2.5677740 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.945810.030110.74434.3442-5.05659.97422.951914.24288.764610.73796.49832.3813-4.5519-0.945810004.0000-0.4661
Inactive10-5.65074.95490.5456-1.9439840 0 0 0 0 0 0 0 0 0 0 0 0 0 15.08469.49733.81968.4513-0.619110.36259.433713.778210.27034.69635.4408-1.6199-1.45995.084610004.00001.5918
Inactive10-5.55070.20.470118-0.201840 0 0 0 0 0 0 0 0 0 0 0 0 0 011.2543-1.00153.75646.89974.79742.8342.87626.5347.24690.758412.16298.90029.7511.254310004.0000-5.5377
Inactive100041.163-3.51611.707-1.8835-3.46991.9890.10351.2453-2.9592-3.6379-2.9446-1.8761-0.93791.16310004.00000.1358
Inconclusive1000416.859332.73635.020523.23553.332115.0249-2.90566.9949.49478.34391.2576-2.0333-2.290216.859310004.00009.1878
Inconclusive10004-2.1455-0.55639.41727.7352.03946.42493.62662.90958.6089-4.7033-4.009520.11873.2965-2.145510004.00007.8923
Inactive10004-3.66575.64289.1238-0.71545.00783.34610.6894.02219.965210.092117.6894-0.24811.5526-3.665710004.000014.7162
Inconclusive100044.2675-5.79323.71026.399110.69910.51886.8431-0.265818.58843.903414.16020.41198.98754.267510004.00006.5135
Inactive100049.866218.26245.804817.49314.15489.82548.16059.947216.279414.177417.85510.539517.09199.866210004.0000-5.4950
Inactive10004-5.329712.331.7312-5.499611.4558-3.72499.28072.31575.44163.66498.36633.099311.8517-5.329710004.0000-5.3240
Inconclusive70.04772.348410Partial curve; high efficacy; poor fit-4.15460.80.6385105.628933.28052.30 0 0 0 0 0 0 0 0 0 0 0 0 0 080.211934.473140.812939.568732.405624.682727.567430.391541.000332.340943.744858.28146.303280.211910004.0000-2.1350
Inconclusive19.093534.34910Partial curve; partial efficacy; poor fit-4.71914.95490.7411-28.10156.2475-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 11.53110.97148.54297.49310.6748-2.691-2.1743-2.26359.19559.26333.86910.8178-29.03671.53110-5.01914.95490.734118.5000-1.04734.00000 0 0 0 0 0 0 0 0 0 0 0 0 0 11.7941
Inactive10-5.33594.95490.4604141.095140 0 0 0 0 0 0 0 0 0 0 0 0 0 024.7756-3.87228.9743-3.24331.4147-5.33746.5468-1.04071.0629-0.639615.012312.85582.944224.775610004.00004.5021
Inactive100047.41038.87323.5826-6.8276-3.40045.10857.125.99217.88590.76615.2069-2.5857-2.38937.410310004.0000-2.5566
Inactive10004-1.2866-1.8663.79256.244.97715.953813.60749.92898.28548.214414.36688.1213-0.9202-1.286610004.0000-3.9577
Inconclusive1000423.99170.9944-3.96381.687221.14372.265812.972312.03323.94191.4937-3.1913.4-3.920623.991710004.00006.2522
Inactive10004-4.56660.7965-6.9681-2.20180.034-1.99810.8299-0.3127-3.4977-3.3230.25471.8446-8.8778-4.566610004.00002.4663
Inactive10-7.02153.51170.347180.303440 0 0 0 0 0 0 0 0 0 0 0 0 0 010.5722-4.18564.19643.9575-4.3305-3.43177.7017.906311.39089.358710.9552-1.394.103110.572210004.00001.0750
Inactive10004-3.64221.972216.7669-4.364-3.7771-2.02811.2212-1.9042-4.0395-1.3596-5.395-2.4515-3.7855-3.642210004.00004.9536
Inactive1000416.4401-5.27783.8363-0.299718.8033-3.88715.63613.536316.4656.73621.28493.68095.811416.440110004.00004.3898
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PPARDN875
Protocol: Tox21 Assay Protocol Summary:

PPARd-bla cells were dispensed at 3000 cells/5uL/well in 1536-well black wall/clear bottom plates using a Multidrop Combi (Thermo Fisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C and 5% CO2 for 5 h, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA), followed by addition of 1ul L165041 (300 nM, final concentration in the wells). The assay plates were incubated at 37 C for 17 h, and then 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA). The assay plates were incubated at room temperature for 2 h and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W460-Activity_Score-Replicate_1W460-Curve_Description-Replicate_1W460-Fit_LogAC50-Replicate_1W460-Fit_HillSlope-Replicate_1W460-Fit_R2-Replicate_1W460-Fit_InfiniteActivity-Replicate_1W460-Fit_ZeroActivity-Replicate_1W460-Fit_CurveClass-Replicate_1W460-Excluded_Points-Replicate_1W460-Max_Response-Replicate_1W460-Activity at 0.0000053432 uM-Replicate_1W460-Activity at 0.0000119492 uM-Replicate_1W460-Activity at 0.0000267158 uM-Replicate_1W460-Activity at 0.0000535491 uM-Replicate_1W460-Activity at 0.0001190864 uM-Replicate_1W460-Activity at 0.0002671241 uM-Replicate_1W460-Activity at 0.0005539826 uM-Replicate_1W460-Activity at 0.00105 uM-Replicate_1W460-Activity at 0.00234 uM-Replicate_1W460-Activity at 0.00523 uM-Replicate_1W460-Activity at 0.012 uM-Replicate_1W460-Activity at 0.026 uM-Replicate_1W460-Activity at 0.058 uM-Replicate_1W460-Activity at 0.130 uM-Replicate_1W460-Activity at 0.278 uM-Replicate_1W460-Activity at 0.575 uM-Replicate_1W460-Activity at 1.281 uM-Replicate_1W460-Activity at 2.834 uM-Replicate_1W460-Activity at 6.264 uM-Replicate_1W460-Activity at 13.72 uM-Replicate_1W460-Activity at 28.94 uM-Replicate_1W460-Activity at 62.03 uM-Replicate_1W460-Activity at 80.41 uM-Replicate_1W460-Activity at 226.4 uM-Replicate_1W460-Activity at 765.1 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1Ratio-Activity at 0.0000053432 uM-Replicate_1
Inactive041.3544-3.6025-11.10060.5079-2.7918-5.4215-1.58862.2484-2.91440.7394-2.26880.3914-5.63870-12.58721.3544104-2.018
Inactive04-15.2184-1.4345-14.9372-18.6702-7.55018.1374-18.6064-0.29050.5064-7.295-17.03550-7.841-15.68438.4392-15.2184104-13.1097
Inactive04.95490.3793-1.0787-22.927240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.3674-18.5894-26.91270.2375-0.09914.5459-4.31493.4543-1.702818.8745-7.8375-12.2259-13.8844-14.325411.7018-3.36741045.6564
Inconclusive04-32.139717.8789-0.2879-15.70071.95673.093211.023833.098914.5287-5.31117.895551.912723.4419016.9506-32.13970Partial curve; partial efficacy-4.37023.990.7571-50.40182.3239-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-45.0413
Inactive043.9896-4.09871.8412-3.12045.8712-0.8697-6.31117.549534.12018.50554.2248-4.4739-2.26482.6498-2.97083.9896103.1320.455313.5-0.026340 0 0 0 0 0 0 0 0 0 0 0 0 0 011.773
Inactive0422.2927.1028-5.0E-4-4.225838.800921.2981-1.3214-2.778235.0579.76275.85846.737831.77784.56448.852822.292101.46410.35767.50.867840 0 0 0 0 0 0 0 0 0 0 0 0 0 13.8741
Inactive04-0.34120.65961.825-1.04852.247814.530410.6713-8.56260.1274-13.1937-1.46446.5415-11.0314-0.4327.7594-0.341210410.183
Inactive04.44950.4269-2.139925.457140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.803523.57984.9724-7.9717-5.88080.80958.426-8.47886.71128.8114-3.7722-0.9662-22.33443.1343-2.5141-2.8035104-4.3815
Inactive04.95490.3465-2.89037.540 0 0 0 1 0 0 0 0 0 0 0 0 0 13.46972.300819.34961.474214.485745.1812.5811-2.194413.4751-1.2729-9.90865.9678-9.7845-2.98351.58293.4697104.95490.5159-5.2355540 0 0 0 0 0 0 0 0 0 0 0 0 0 10.7651
Inactive04-10.05992.6383-10.1183-2.0962.0492-1.856319.6461-0.2383-0.5044-12.9293-3.2135-13.239502.1029-12.9235-10.05991041.0034
Inactive04-8.67383.025-43.065-11.6254-3.1101-17.8757-6.1834-29.624-14.871-10.16210.298-8.212-16.59721.7604-35.9333-8.6738104-4.9729
Inactive048.13773.6209-20.611-8.03894.7368-4.03762.49851.7894-18.8422-0.9202-5.65030-5.8402-12.5403-20.15318.1377104-0.2231
Inhibitor19.672874.88130Complete curve; partial efficacy-4.85613.92950.8198-64.1155-6.7127-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-62.1796-4.634-13.3459-11.26234.9472-15.6331.1398-2.929-32.4658-13.6891-11.2074-2.76290-46.4376-62.0692-62.17960Partial curve; high efficacy-4.70610.60.9192-79.3531-4.4718-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-60.116
Inactive04-7.3579-4.2465-0.277-34.2126-13.015903.3755-22.2633-4.0875-19.7798-30.348-38.7367-8.1047-4.4191-0.5527-7.3579101.98870.36944-14.597340 0 0 0 0 0 0 0 0 0 0 0 0 0 03.814
Inactive02.25260.4074-0.4319-21.349840 0 0 0 0 0 0 0 0 0 1 1 0 0 00.4031-23.7612-43.91630-3.2633-22.403-26.6311-21.9955-31.7449-10.6738-7.562563.0101-33.08450-1.48860.4031103.29750.329-14.75990.562240 0 0 0 0 0 0 0 0 0 1 0 0 0 1-5.1882
Inactive04-10.5391-4.7618-18.6148-19.4523-16.0885-4.47450.7523-0.3342.7418-25.1761-1.5247-0.4497-12.7657-17.638-23.3008-10.5391103.92950.63292.5-11.54140 0 0 0 0 0 0 0 0 0 0 0 0 0 04.2405
Inactive04-0.76390.859-8.3531-13.6545-8.9473-24.0844-6.4411-6.37119.5466-11.1896-3.8512-2.6502-2.3564-12.7689-9.3668-0.76391049.4113
Inactive04.95490.4703-9.6511-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-4.61692.15531.2609-3.4492-4.43153.2748-2.319-4.59562.8479-11.2565-6.4049-16.7926-1.9053-15.7107-4.3338-4.6169100.20.3877-7.47191640 0 0 0 0 0 0 0 0 0 0 0 0 0 00.0081
Inactive043.92437.3478-11.7242.588920.88697.561116.737624.842540.877603.641525.466511.133-5.2481.32653.924310411.0982
Inactive04.95490.674141.08472.146840 0 0 0 0 0 0 1 0 0 0 0 0 0 1-5.437415.7508-8.9275.63585.5958-0.153910.7187-6.405626.322-6.34051.79848.8376-0.68967.11839.6649-5.43741047.3629
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478CB
Protocol: Tox21 Assay Protocol Summary:

2,000 HepG2 cells in 5 uL of culture medium (MEM containing 10% FBS) per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). The assay plates were incubated overnight at 37 C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys , San Diego, CA). After the assay plates were incubated for 1 hr at 37 C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590 nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive040.2003-0.01150.00710.23730.09540.2003QC'd by "NCI"0
Inactive040.1113-0.03910.08984.0E-4-0.03890.1113QC'd by "NCI"0
Inactive04-0.09730.0277-0.0084-0.00980.0055-0.0973QC'd by "NCI"0
Inactive04-0.1827-0.0289-0.0224-0.1537-0.0181-0.1827QC'd by "SigmaAldrich"0
Inactive040.5452-0.03350.0032-0.01370.01630.5452QC'd by "NCI"0
Inactive04-0.05130.011-0.0106-0.0503-0.0065-0.0513QC'd by "NCI"0
Inactive04-0.0252-0.1196-0.0502-0.05650.0376-0.0252QC'd by "NCI"0
Inactive040.10450.0373-0.01590.03940.00210.1045QC'd by "NCI"0
Inactive04-0.24220.0063-0.0071-0.0119-0.0133-0.2422QC'd by "NCI"0
Inactive04.50450.98673040 0 0 0 03.1340.15520.13580.19860.6053.134QC'd by "Labotest"0
Inactive04-0.0090.01850.03930.2310.0436-0.009QC'd by "NCI"0
Inactive040.07510.02710.22620.17550.01740.0751QC'd by "NCI"0
Inactive040.0132-0.0598-0.0350.09430.07230.0132QC'd by "NCI"0
Inactive049.0E-4-0.0911-0.05740.15930.17099.0E-4QC'd by "NCI"0
Inactive040.6834-0.1194-0.00280.3720.19860.6834QC'd by "NCI"0
Inactive040.1104-0.08290.06180.16230.0230.1104QC'd by "NCI"0
Inactive040.5456-0.0786-0.0186-0.0058-0.00230.5456QC'd by "NCI"0
Inactive04-0.1424-0.0976-0.10020.027-0.1146-0.1424QC'd by "Chembridge"0
Inactive040.0252-0.0593-0.08240.12910.04990.0252QC'd by "NCI"0
Inactive040.0384-0.2038-0.1551-0.007-0.01920.0384QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478MR
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (MEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.12420.2628-0.1782-0.4447-0.2156-0.1242QC'd by "NCI"0
Inactive040.52820.2696-0.353-0.2319-0.17610.5282QC'd by "NCI"0
Inactive040.36990.109-0.00360.2172-0.0050.3699QC'd by "NCI"0
Inactive040.003-0.1398-0.2166-0.05930.03410.003QC'd by "SigmaAldrich"0
Inactive040.0037-0.18840.15210.18170.12320.0037QC'd by "NCI"0
Inactive040.42260.0606-0.0267-0.1598-0.03750.4226QC'd by "NCI"0
Inactive04-0.1083-0.0289-0.054-0.2945-0.072-0.1083QC'd by "NCI"0
Inactive04-0.0618-0.03660.04-0.2576-0.1156-0.0618QC'd by "NCI"0
Inactive040.0450.2884-0.027-0.166-0.30740.045QC'd by "NCI"0
Inactive04-0.2251-0.37-0.4364-0.0983-0.1209-0.2251QC'd by "Labotest"0
Inactive04-0.32420.23140.0134-0.2318-0.0596-0.3242QC'd by "NCI"0
Inactive04-0.01610.01530.03390.01490.0696-0.0161QC'd by "NCI"0
Inactive04-0.00830.0949-0.2516-0.1363-0.3201-0.0083QC'd by "NCI"0
Inactive040.1281-0.3790.11360.0866-0.02890.1281QC'd by "NCI"0
Inactive04-0.0989-0.0902-0.1041-0.2289-0.1987-0.0989QC'd by "NCI"0
Inactive040.0739-0.0110.01860.02430.02880.0739QC'd by "NCI"0
Inactive04-0.20280.08760.015-0.0122-0.012-0.2028QC'd by "NCI"0
Inactive04-0.152-0.0722-0.03940.08260.0334-0.152QC'd by "Chembridge"0
Inactive04-0.0720.1489-0.00810.015-0.0036-0.072QC'd by "NCI"0
Inactive04-0.1159-0.19220.11950.16620.2987-0.1159QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: P53MS837
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000cells/3ul/well in 1536-well black-clear bottom plates. After the assay plates were incubated at 37 C, 5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate. Following compound addition, 3 uL of human liver microsomes (XenoTech, Kansas City, KS) at final concentration of 0.5 mg/mL and 1uL of B-Nicotinamide adenine dinucleotide 2'-phosphate (NADPH) at final concentration of 0.5 mg/mL were transferred to the assay plate. The plates were incubated at 37 C for 16 hours. 1 uL of LiveBLAzer detection mixture was added to each well and the plates were incubated at room temperature in the dark for 2 h. Fluorescence intensity at 460 and 530 nm emission and 405 nm excitation were measured by an Envision plate reader. For cell viability readout that measures cytotoxicity, 4 ul/well of CellTiter-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).
Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000042859 uM-Replicate_1Activity at 0.0000098296 uM-Replicate_1Activity at 0.0000389118 uM-Replicate_1Activity at 0.0000921325 uM-Replicate_1Activity at 0.0002143310 uM-Replicate_1Activity at 0.0004423865 uM-Replicate_1Activity at 0.00121 uM-Replicate_1Activity at 0.00372 uM-Replicate_1Activity at 0.00955 uM-Replicate_1Activity at 0.022 uM-Replicate_1Activity at 0.049 uM-Replicate_1Activity at 0.109 uM-Replicate_1Activity at 0.249 uM-Replicate_1Activity at 0.761 uM-Replicate_1Activity at 2.332 uM-Replicate_1Activity at 5.986 uM-Replicate_1Activity at 13.53 uM-Replicate_1Activity at 30.31 uM-Replicate_1Activity at 65.96 uM-Replicate_1Activity at 171.5 uM-Replicate_1Activity at 622.7 uM-Replicate_1Activity at 1320.0 uM-Replicate_1Activity at 2952.0 uM-Replicate_1Activity at 6600.0 uM-Replicate_1Activity at 14760.0 uM-Replicate_1Activity at 33000.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-0.81153.24171.7036-3.88633.70051.90923.46112.62383.42171.96184.5532-2.1817-2.0587-0.8115QC'd by SIGMAInactive0
Inactive00042.02641.27780.40633.132-0.96178.39740.80260.38625.08541.03870.96490.31392.19092.0264QC'd by Sigma DiscoveryCPRInactive0-6.03963.990.6227
Inactive0004-0.07830.8602-0.43130.77533.3389-7.07430.1475-4.9244-5.6061.28811.431-5.9165-1.58613.3747-0.0783QC'd by SIGMAInactive0-4.85182.12110.4048
Inactive0-8.53960.90.4382.5-17.2540 0 0 0 0 0 0 0 0 0 0 0 0 0 00.4242-11.5665-3.6679-0.6129-7.17834.78830.4184-0.157710.703511.6402-3.9345-0.5512-6.24530.4242QC'd by SIGMAInactive0-7.93964.95490.4551
Inactive0004-5.3318-1.94410.4522-8.3321.0107-0.1156-10.7826-10.8532-4.24710.20287.2076-6.6671-8.3789-5.3318QC'd by SIGMAInactive0
Inactive00040.6118-3.3835-2.5203-9.6183-0.5168-7.3565-1.9351-3.59144.7435-5.2628-2.1247-4.3417-14.53680.6118QC'd by SIGMAInactive0
Inactive0004-5.3821-1.5125-3.5484-1.106-5.2777-3.6383-5.511-10.9006-6.9604-1.92230.6192-4.5677-4.7296-8.0223QC'd by SIGMAInactive0-8.2680.30.4015
Inactive00040.87320.4702-0.8794-0.6340.6861-1.04133.7723-12.8167-6.05652.7542-1.535-7.9041-5.49780.8732QC'd by SIGMAInactive0
Inactive0-6.83964.95490.55124-4.470340 0 0 0 0 0 0 0 0 0 0 0 0 0 01.0676-1.3224-9.1419-1.1865-3.6159-5.2485-8.195310.19175.79951.09081.49983.96712.02971.0676QC'd by SIGMAInactive0-6.78964.95490.3599
Inactive0004-1.0220.210.2513-2.37471.3717-0.50383.9894-1.7888-6.79872.53691.01664.19945.5844-1.022QC'd by SIGMAInactive0-6.38964.95490.3471
Inactive0004-1.4059-3.132-7.66070.7238-4.33320.32411.33020.24797.5234-14.4771-13.01446.36361.2275-1.4059QC'd by RocheInactive0
Inactive0-4.33964.95490.3429-10.88620.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.07183.4287-0.5118-4.4669-2.302-2.17713.30782.8439-1.01244.2267-6.21353.9872-0.6916-9.0718QC'd by TCIInactive0
Inactive0004-0.68310.0297-0.9593-0.7386-2.2052-1.3291-4.3626-5.62091.9907011.30340.7086-3.1047-0.6831QC'd by SIGMAInactive0-5.48964.95490.3751
Inactive0-5.93961.78850.35820-3.229640 0 0 0 0 0 0 0 0 0 0 0 0 0 00.3463-2.7679-2.538-3.6541-2.975-8.1080.403-4.8358-1.7099-1.45512.2456-0.5792-0.4960.3463QC'd by SIGMAInactive0
Inactive0004-11.95511.4361-7.8259-8.6263-1.52171.5909-12.8729-11.017-6.8916-3.5531-4.5898-4.7446-6.1302-11.9551QC'd by LightBiologicalsInactive0
Inactive0004-9.9242-1.6531-3.70011.0424-7.9893.6152-5.8328-1.3701-2.0464-3.8438-5.7091-2.1285-5.1644-9.9242QC'd by SIGMAInactive0-4.33963.67720.3682
Cytotoxic40.77972.441840Partial curve; high efficacy-4.38963.92950.8982-74.5596-2.1178-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-64.8179-2.60644.2761-5.9881-1.3877-6.5057-2.59266.3601-8.70221.2883-0.5997-1.9403-18.4593-64.8179QC'd by TCICytotoxic51.337734.492820Single point of activity-4.28964.95490.8014
Inactive0004-14.5026-3.1743.642-4.3769-9.3023-7.6508-8.2832-19.8532-7.861711.7122-6.9451-14.94643.8797-14.5026QC'd by SIGMAInactive0
Inactive0004-2.2222-0.98421.4931-1.41171.1017-10.6336-4.34-12.0027-8.0387-2.805-8.872512.3039-3.6772-2.2222QC'd by SIGMAInactive0
Inactive0-7.33964.95490.52824.5-2.771840 0 0 0 0 0 0 0 0 0 0 0 0 0 01.0674-3.5855-4.2141.2009-4.39320.913.422214.0382.72535.26962.21886.31271.41211.0674QC'd by RocheInactive0-4.73964.0950.6096
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478MB
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (MEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.1115-0.1251-0.0765-0.06640.0949-0.1115QC'd by "SIGMA"0
Inactive04-0.0069-0.10850.02610.0208-0.0462-0.0069QC'd by "SigmaAldrich"0
Inactive04-0.172-0.0309-0.0124-0.0718-0.0262-0.172QC'd by "SIGMA"0
Inactive040.0130.0073-0.01730.01340.00240.013QC'd by "SigmaAldrich"0
Inactive04-0.052-0.0612-0.0736-0.0496-0.0413-0.052QC'd by "SigmaAldrich"0
Inactive04-0.0569-0.01650.10050.1139-0.0959-0.0569QC'd by "SigmaAldrich"0
Inactive04-0.0353-0.0623-0.04670.00960.0134-0.0353QC'd by "SIGMA"0
Inactive040.22820.00980.01520.0163-0.02330.2282QC'd by "Alfa Aesar"0
Inactive04-0.1287-0.0353-0.0866-0.012-0.0014-0.1287QC'd by "SIGMA"0
Inactive04-0.0565-0.1141-0.0255-0.009-0.0415-0.0565QC'd by "SIGMA"Inactive04
Inactive04-0.1244-0.1158-0.0769-0.0272-0.0887-0.1244QC'd by "SIGMA"0
Inactive04-0.1459-0.077-0.0696-0.0992-0.1072-0.1459QC'd by "SIGMA"0
Inactive04-0.0112-0.12120.0729-0.0657-0.1082-0.0112QC'd by "SIGMA"0
Inactive04-0.0758-0.1319-0.0931-0.0564-0.0431-0.0758QC'd by "SIGMA"0
Inactive04-0.0061-0.0301-0.0049-0.0052-0.0205-0.0061QC'd by "SigmaAldrich"0
Inactive040.06630.0020.1992-0.0417-0.05850.0663QC'd by "SigmaAldrich"0
Inactive040.1620.0128-0.0595-0.0493-0.05030.162QC'd by "Interchem"0
Inactive04-0.0217-0.0781-0.08430.00810.004-0.0217QC'd by "SigmaAldrich"0
Inactive040-0.0307-1.0E-4-0.0089-0.03580QC'd by "SigmaAldrich"0
Inactive04-0.02990.0039-0.03650.0192-0.0786-0.0299QC'd by "SigmaAldrich"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:tumor suppressor p53 [Homo sapiens]
External ID: P53MS898
Protocol: Tox21 Assay Protocol Summary:

The p53RE-bla cells were dispensed at 4,000cells/3ul/well in 1536-well black-clear bottom plates. After the assay plates were incubated at 37 C, 5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate. Following compound addition, 3 uL of rat liver microsomes (Molecular Toxicology, Boone, NC) at final concentration of 0.5 mg/mL and 1uL of Beta-Nicotinamide adenine dinucleotide 2-phosphate (NADPH) at final concentration of 0.5 mg/mL were transferred to the assay plate. The plates were incubated at 37 C for 16 hours. 1 uL of LiveBLAzer detection mixture was added to each well and the plates were incubated at room temperature in the dark for 2 h. Fluorescence intensity at 460 and 530 nm emission and 405 nm excitation were measured by an Envision plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (https://www.epa.gov/comptox-tools/comptox-chemicals-dashboard) and NTP (https://cebs.niehs.nih.gov/cebs/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000043397 uM-Replicate_1W530-Activity at 0.0000099416 uM-Replicate_1W530-Activity at 0.0000388206 uM-Replicate_1W530-Activity at 0.0000933245 uM-Replicate_1W530-Activity at 0.0002146562 uM-Replicate_1W530-Activity at 0.0004427766 uM-Replicate_1W530-Activity at 0.00122 uM-Replicate_1W530-Activity at 0.00372 uM-Replicate_1W530-Activity at 0.00957 uM-Replicate_1W530-Activity at 0.022 uM-Replicate_1W530-Activity at 0.049 uM-Replicate_1W530-Activity at 0.109 uM-Replicate_1W530-Activity at 0.249 uM-Replicate_1W530-Activity at 0.768 uM-Replicate_1W530-Activity at 2.332 uM-Replicate_1W530-Activity at 5.987 uM-Replicate_1W530-Activity at 13.55 uM-Replicate_1W530-Activity at 30.33 uM-Replicate_1W530-Activity at 65.98 uM-Replicate_1W530-Activity at 172.8 uM-Replicate_1W530-Activity at 616.1 uM-Replicate_1W530-Activity at 1320.0 uM-Replicate_1W530-Activity at 2952.0 uM-Replicate_1W530-Activity at 6600.0 uM-Replicate_1W530-Activity at 14760.0 uM-Replicate_1W530-Activity at 33000.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10004-0.0766-0.0658-2.15293.9062-0.3999-1.37385.63961.2637-2.85641.76041.55167.3112-1.1534-0.076610004.0000-0.5396
Inactive10004-9.26574.0277-6.0118-0.0071-1.8112.0788-0.1063-9.81183.02231.6158-3.4131-0.3905-0.1348-9.265710004.0000-0.7395
Inconclusive17.752636.150110Partial curve; partial efficacy-4.75072.40640.95137.51.34992.20 0 0 0 0 0 0 0 0 0 0 0 0 0 030.754-1.3751.59181.76342.18881.4238-0.72522.56751.81642.88342.28283.111216.001330.75410-4.70072.40640.9040-16.0184-1.00004.00000 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.5153
Inactive10004-0.8668-1.48543.1589-1.5267-0.3498-0.9828-1.6965-4.30540.34461.0195-3.8892-0.0431-3.4971-0.866810004.00002.1550
Inactive100040.4687-0.3692-2.2383-2.0699-1.1088-1.1038-1.892-3.7217-0.3761-2.9675-7.199-1.25980.5490.468710004.0000-4.3810
Inactive100040.4126-1.2865-0.5387-2.298-1.8546-1.5264-1.5856-1.7954-2.1107-10.0252-3.0851-2.8249-1.38430.412610004.00000.0966
Inactive10-8.75291.53860.542-3.90151040 0 0 0 0 0 0 0 0 0 0 0 0 0 10.10826.8455-0.6219-1.9403-3.2657-2.4784-1.636-6.3641-2.7947-6.0758-3.8759-3.1216-2.63750.108210004.0000-1.7240
Inactive10004-2.64841.2797-2.7761-6.4353-4.779-1.4021-0.3446-1.6237-1.1309-5.3966-0.90140-0.5502-2.648410004.00004.8834
Inactive10004-0.1792-0.474-1.4694-0.8953-0.4709-0.74150.1743-4.2804-1.4515-8.5725-1.40966.8573-0.4899-0.179210004.00000.3507
Inactive10-5.2314.95490.63782.5-6.309340 0 0 0 0 0 0 0 0 0 0 0 0 0 03.5172-6.7601-8.0367-0.7524-8.9539-6.7515-6.0875-9.8411-8.2478-4.204-0.20621.74341.04493.517210004.00007.8280
Inactive10-5.25464.95490.73888-2.536240 0 0 0 0 0 0 0 0 0 0 0 0 0 011.2916-1.1337-0.9738-3.7502-3.5438-3.92812.0571-0.3539-3.0856-2.45181.10275.54624.50711.291610004.00000.2257
Inactive10-4.71910.80.3767-22.1814-240 0 0 0 0 0 0 0 0 0 0 0 0 0 1-7.9565-2.4609-4.7653-0.7909-4.3968-2.1758-2.0522-3.5012-2.3448-13.94742.318-16.8178-12.5058-7.956510004.0000-0.5576
Inactive10-5.38594.95490.609313-3.112140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.9382-2.1013-5.1202-0.9168-6.4291-0.2473-7.5114-1.6150.7413-1.600515.74921.42750.7564-0.938210004.00003.5229
Inactive10004-2.5193-0.5943-0.7208-2.3194-2.31182.0984-4.0928-2.1388-3.1827-4.05230.0794-0.2907-0.4065-2.519310004.00002.1690
Inactive10-4.97912.72020.55856-4.095340 0 0 0 0 0 0 0 0 0 0 0 0 0 08.8855-0.6587-4.6588-0.4651-5.4882-3.2508-2.652-4.0762-6.6845-6.0914-4.67266.54320.29268.885510004.00008.4566
Inactive100040.3919-1.19260.06151.2782-3.2151-0.8299-0.6638-3.5934-2.2676-3.964912.1718-12.289-2.3960.391910-4.28643.13200.766711.50000.55584.00000 0 0 0 0 0 0 0 0 0 0 0 0 0 08.8922
Inactive100041.3115-1.013-0.5151-0.4031-1.1603-0.0285-0.1807-1.90091.5472-3.20528.574-14.1104-2.36981.311510004.00000.7374
Inactive100041.2453-0.1374-0.3605-3.4935-1.2563-2.4487-0.2616-0.72990.0304-4.47-0.75345.7775-0.09731.245310004.00001.2743
Inactive100040.0274-0.9052-3.7849-3.6459-0.6677-0.01462.1795-6.8978-0.8919-5.2845-0.8362-13.15210.1420.027410004.0000-2.5213
Inactive10004-2.4878-3.5001-2.6738-5.3379-5.5521-3.88740.4423-5.0105-3.9092-8.9672-0.5005-7.892-0.4544-2.487810004.00000.0360
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478CR
Protocol: Tox21 Assay Protocol Summary:

2,000 HepG2 cells in 5 uL of culture medium (MEM containing 10% FBS) per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). The assay plates were incubated overnight at 37 C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys , San Diego, CA). After the assay plates were incubated for 1 hr at 37 C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590 nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.77120.05930.0635-0.0984-0.218-0.7712QC'd by "Prestwick Chemical; Inc."0
Inactive040.28480.45950.13770.23990.45920.2848QC'd by "Prestwick Chemical; Inc."0
Inactive040.10910.08720.002-0.128-0.01040.1091QC'd by "Prestwick Chemical; Inc."0
Inactive040.35690.44360.30790.14920.38140.3569QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.4718-0.21590.1141-0.2538-0.4782-0.4718QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.7519-0.0052-0.0382-0.3499-0.5531-0.7519QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.3026-0.176-0.2919-0.2217-0.1667-0.3026QC'd by "Prestwick Chemical; Inc."0
Inactive040.00260.10340.01420.20370.21520.0026QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.309-0.54610.3903-0.3625-0.0293-0.309QC'd by "Prestwick Chemical; Inc."0
Inactive040.1015-0.23980.08980.41030.37930.1015QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.02650.19180.1501-0.07350.0724-0.0265QC'd by "Prestwick Chemical; Inc."0
Inactive040.3519-0.54170.1370.20740.37870.3519QC'd by "Prestwick Chemical; Inc."0
Inactive040.11140.07490.32080.3560.48040.1114QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.45320.0227-0.0204-0.4367-0.3391-0.4532QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.4937-0.7632-0.0181-0.4913-0.1598-0.4937QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.2868-0.3361-0.3349-0.465-0.3474-0.2868QC'd by "Prestwick Chemical; Inc."0
Inactive040.33880.03910.14580.56180.08170.3388QC'd by "Prestwick Chemical; Inc."0
Inactive040.5747-0.55850.02420.36260.57350.5747QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.3048-0.2054-0.3202-0.3697-0.1434-0.3048QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.27210.25420.1392-0.3556-0.4304-0.2721QC'd by "Prestwick Chemical; Inc."0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: TRHR611
Protocol: Tox21 Assay Protocol Summary:

The TRHR-Hek293 cells were dispensed at 1500cells/4uL/well in 1536-well black-clear bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 18 hours, 4 uL of Dye-Loading Solution was added to each well. The plates were incubated at 37 C for 2 hours. For agonist mode, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool. The fluorescence intensity in the plates was measured using FDSS 7000EX kinetic plate reader for 3 min at 1 sec intervals. For antagonist mode, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool. After 5 min incubation at room temperature, 1 uL of TRH was added on the top of the cell/compound mixtures to achieve a final agonist concentration of 1 nM. The fluorescence intensity in the plates was measured using FDSS 7000EX kinetic plate reader for 3 min at 1 sec intervals. Each test compound was measured at 15 concentrations and in triplicates.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000033322 uM-Replicate_1Activity at 0.0000076425 uM-Replicate_1Activity at 0.0000302545 uM-Replicate_1Activity at 0.0000719386 uM-Replicate_1Activity at 0.0001666559 uM-Replicate_1Activity at 0.0003439494 uM-Replicate_1Activity at 0.0009432137 uM-Replicate_1Activity at 0.00290 uM-Replicate_1Activity at 0.00744 uM-Replicate_1Activity at 0.017 uM-Replicate_1Activity at 0.038 uM-Replicate_1Activity at 0.085 uM-Replicate_1Activity at 0.194 uM-Replicate_1Activity at 0.597 uM-Replicate_1Activity at 1.813 uM-Replicate_1Activity at 4.654 uM-Replicate_1Activity at 10.52 uM-Replicate_1Activity at 23.57 uM-Replicate_1Activity at 51.28 uM-Replicate_1Activity at 133.3 uM-Replicate_1Activity at 484.2 uM-Replicate_1Activity at 1026.0 uM-Replicate_1Activity at 2295.0 uM-Replicate_1Activity at 5131.0 uM-Replicate_1Activity at 11470.0 uM-Replicate_1Activity at 25660.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-0.7744-2.9676-3.5336-2.0879-1.19781.1881.14731.4749-2.1654-0.5693-0.3565-2.7155-2.1355-0.7744QC'd by SIGMAInactive0
Inactive0004-3.8248-3.8007-4.0065-1.0553-3.3562-0.39150.1642.0983-2.5376-0.4451-4.23-3.1441-0.0179-3.8248QC'd by SIGMAInactive0
Inactive0004-2.816-0.58230.961-4.2135-2.8784-1.3211-0.4465-1.7796-0.60655.8623-0.4085-2.09140.44-2.816QC'd by EnamineInactive0
Inactive0-4.82071.17050.5128-9.36493.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-7.80412.31667.02673.7969-3.38579.2767-0.27464.97642.59914.28-0.6299-1.2303-3.5953-7.8041QC'd by Astellas PharmaInactive0-4.42074.95490.8279
Inactive0004-0.52874.09797.20243.2011-0.81582.48942.94894.2283-1.09431.6134-0.62470.379-2.51710.0409-0.5287QC'd by SIGMAInactive0
Inactive0-4.92071.53860.8342-27.6782040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-23.89855.1868-1.0467-0.352-7.51551.63921.1963-3.0718-1.9286-1.6973-5.6079-9.8676-22.5753-23.8985QC'd by LightBiologicalsInhibitor15.109550.817921Partial curve; partial efficacy-4.82071.50950.9098
Inactive00042.98924.72094.31383.7992-3.1974.55073.17640.49431.0409-0.69416.4130.69623.67912.9892QC'd by SIGMAInactive0
Inactive0004-3.6304-0.80541.76713.27213.2046-2.9585-0.9728-2.38430.2278-4.6072-0.0977-1.82750.2011-3.6304QC'd by SIGMAInactive0
Inactive0004-4.23550.00631.01451.17612.8799-0.22811.3028-1.0820.2702-0.3033-1.016-0.2938-0.1436-4.2355QC'd by SIGMAInactive0
Inactive0-4.65471.3310.6709-16.0615-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.71790.9207-1.56980.4890.1513-1.0708-0.16710.5122-1.9389-0.5306-1.1892-4.1206-2.1676-11.7179QC'd by SIGMAInactive0
Inactive0004-5.0893-0.6163-0.4494-3.01832.2944-2.1401-2.1537-3.8439-1.0556-0.789-8.1267-2.9119-2.3372-5.0893QC'd by FLUKAInactive0-7.92074.95490.4397
Inactive0004-0.6018-4.4247-2.5009-1.17-5.8691-0.6116-3.8612-3.0508-2.99750.0497-1.1142-1.4293-2.3401-0.6018QC'd by SIGMAInactive0-4.62070.40.3945
Inactive0004-3.4471-7.1239-3.8104-9.2894-6.7658-6.2027-4.0978-6.4890.1913-2.5663-4.1436-7.4351-5.2613-3.4471QC'd by SIGMAInactive0-4.47073.62720.6482
Inactive0004-4.0530.4267-0.6302-4.11610.9771.3099-3.8626-4.4544-2.4911-2.6511.1843-2.3234-8.7644-4.053QC'd by SIGMAInactive0
Inactive0004-9.1702-1.0714-3.8813-3.6742-2.9292-2.42871.7722-6.9647-0.875-6.1442-0.004-2.08110.9883-9.1702QC'd by SIGMAInactive0
Inactive0004-2.38590.93520.66930.78463.2569-0.3728-4.5542-3.6-0.27051.5551-1.0698-4.444-3.1433-2.3859QC'd by Sigma DiscoveryCPRInactive0
Inactive00042.2162.06790.73634.7092.69724.29754.33757.8846-1.82772.28743.6777-0.67839.62350.45812.216QC'd by SIGMAInactive0-4.9334.0950.4028
Inactive0004-0.1149-2.2956-0.2967-0.6614-0.7834-1.0672-1.86790.16950.2001-0.1104-0.75150.022-2.3663-0.1149QC'd by SIGMAInactive0
Inactive0004-7.8583-4.0761-1.69240.16735.0127-1.50412.3766-5.3461.0702-3.8043-2.525-0.383-3.9348-7.8583QC'd by SIGMAInactive0
Inactive00040.99981.2942-0.02581.57658.44621.6462.6384-0.5997-0.64140.57591.40520.37520.76210.9998QC'd by SIGMAInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478CG
Protocol: Tox21 Assay Protocol Summary:

2,000 HepG2 cells in 5 uL of culture medium (MEM containing 10% FBS) per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). The assay plates were incubated overnight at 37 C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys , San Diego, CA). After the assay plates were incubated for 1 hr at 37 C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590 nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.0029-0.0082-0.00260.13990.0699-0.0029QC'd by "SIGMA"0
Inactive04-0.10090.004-0.1385-0.05520.0167-0.1009QC'd by "ChromaDex"0
Inactive04-0.00270.04690.0106-0.0323-0.0264-0.0027QC'd by "SIGMA"0
Inactive040.0680.04520.00930.1349-0.05650.068QC'd by "SigmaAldrich"0
Inactive04-0.01020.00830.0497-0.0368-0.1188-0.0102QC'd by "Sensient"0
Inactive040.16110.01260.0217-0.06560.10580.1611QC'd by "Pfaltz-Bauer"0
Inactive040.01860.00820.0242-0.11250.1760.0186QC'd by "SigmaAldrich"0
Inactive040.0141-0.0188-0.03030.00210.09840.0141QC'd by "SigmaAldrich"0
Inactive04-0.06960.0137-0.0094-0.0575-0.0122-0.0696QC'd by "SigmaAldrich"0
Inactive04-0.0879-0.00670.1326-0.0156-0.0041-0.0879QC'd by "SigmaAldrich"0
Inactive040.0162-0.0159-0.0079-0.01810.08710.0162QC'd by "SigmaAldrich"0
Inactive040.02930.0807-0.0391-0.1788-0.09160.0293QC'd by "SIGMA"0
Inactive04-0.0528-0.0224-0.08430.0049-0.0082-0.0528QC'd by "SIGMA"0
Inactive040.11520.05240.1778-0.0592-0.05560.1152QC'd by "SIGMA"0
Inactive04-0.03240.04210.01430.01780.0302-0.0324QC'd by "SIGMA"0
Inactive04-0.1527-0.0095-0.1287-0.0855-0.0912-0.1527QC'd by "SIGMA"0
Inactive040.1560.0209-0.00190.010.00660.156QC'd by "SIGMA"0
Inactive040.0052-0.00170.0141-0.07196.0E-40.0052QC'd by "SIGMA"0
Inactive04-0.0288-0.0779-0.0066-0.0587-0.0039-0.0288QC'd by "SIGMA"0
Inactive04-0.0014-0.08470.0444-0.017-0.0041-0.0014QC'd by "SigmaAldrich"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167CB
Protocol: Tox21 Assay Protocol Summary:

2,000 HEK293 cells in 5 uL of culture medium containing 10% dialyzed FBS per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (Thermo Scientific). The assay plates were incubated for 4-5 hr at 37C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys, San Diego, CA). After the assay plates were incubated overnight at 37C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.0993-0.0315-0.0456-0.0314-0.0445-0.0993QC'd by "SIGMA"0
Inactive04-0.0413-0.330.9732-0.1408-0.2626-0.0413QC'd by "SIGMA"0
Inactive043.0E-4-0.0951-0.0908-0.0608-0.01023.0E-4QC'd by "SIGMA"0
Inactive040.00362.0E-4-0.1154-0.1852-0.02580.0036QC'd by "SIGMA"0
Inactive04-0.08410.02920.0072-0.0606-0.0747-0.0841QC'd by "SIGMA"0
Inactive04-0.0562-0.02190.0027-0.0792-0.1435-0.0562QC'd by "SIGMA"0
Inactive04-0.0228-0.2225-0.17238.0E-4-0.2899-0.0228QC'd by "SIGMA"0
Inactive04-0.10910.0012-0.0968-0.007-0.2223-0.1091QC'd by "SIGMA"0
Inactive04-0.03890.07040.0162-0.0035-0.0387-0.0389QC'd by "SIGMA"0
Inactive040.0777-0.1888-0.0421-0.0179-0.13070.0777QC'd by "SIGMA"0
Inactive04-0.1076-0.1771-0.0039-0.04160.0041-0.1076QC'd by "SIGMA"0
Inactive04-0.0441-0.05340.0039-0.0433-0.1015-0.0441QC'd by "TCI"0
Inactive04-0.42250.18470.0082-0.0822-0.0703-0.4225QC'd by "SIGMA"0
Inactive040.0630.0914-0.00420.0899-0.04430.063QC'd by "SIGMA"0
Inactive040.21370.17290.0260.23310.10530.2137QC'd by "SIGMA"0
Inactive04-0.0274-0.01920.12090.04090.0156-0.0274QC'd by "SIGMA"0
Inactive040.0634-0.01480.0720.08030.08560.0634QC'd by "SIGMA"0
Inactive040.0335-0.04990.1012-0.00170.26310.0335QC'd by "SIGMA"0
Inactive04-0.0334-0.0211-0.0049-0.03310.19-0.0334QC'd by "SIGMA"0
Inactive040.15920.01470.11910.10190.12680.1592QC'd by "SIGMA"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167CR
Protocol: Tox21 Assay Protocol Summary:

2,000 HEK293 cells in 5 uL of culture medium containing 10% dialyzed FBS per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (Thermo Scientific). The assay plates were incubated for 4-5 hr at 37C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys, San Diego, CA). After the assay plates were incubated overnight at 37C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.1742-0.0105-0.0707-0.708-0.8608-0.1742QC'd by "NCI"0
Inactive04-0.15950.087-0.0389-0.0424-0.0089-0.1595QC'd by "NCI"0
Inactive040.17150.56230.2590.06620.03240.1715QC'd by "NCI"0
Inactive040.04060.1038-4.0E-40.08940.12640.0406QC'd by "SigmaAldrich"0
Inactive040.439-0.1165-0.2370.53740.0650.439QC'd by "NCI"0
Inactive04-0.1787-0.0681-0.0763-0.05880.0674-0.1787QC'd by "NCI"0
Inactive04-0.26880.03020.2349-0.1201-0.1287-0.2688QC'd by "NCI"0
Inactive04-0.1086-0.2195-0.0573-0.14660.1358-0.1086QC'd by "NCI"0
Inactive04-0.1833-0.03-0.0379-0.4701-0.1431-0.1833QC'd by "NCI"0
Inactive04-0.9523-1.1611-0.9118-1.0013-1.0781-0.9523QC'd by "Labotest"0
Inactive04-0.2307-0.10680.4032-0.0433-0.0679-0.2307QC'd by "NCI"0
Inactive040.06170.30390.1775-0.00510.08570.0617QC'd by "NCI"0
Inactive04-0.1350.1614-0.083-0.1721-0.0432-0.135QC'd by "NCI"0
Inactive040.2214-0.6929-0.11650.0685-0.05560.2214QC'd by "NCI"0
Inactive04-0.2027-0.05290.0564-0.9701-0.3154-0.2027QC'd by "NCI"0
Inactive040.06990.0444-0.03810.03760.19960.0699QC'd by "NCI"0
Inactive040.0459-0.04550.12930.11980.02850.0459QC'd by "NCI"0
Inactive04-0.0306-0.0309-0.01430.02940.0175-0.0306QC'd by "Chembridge"0
Inactive04-0.02680.23620.2368-0.0791-0.0097-0.0268QC'd by "NCI"0
Inactive040.0114-0.9843-0.7454-0.13590.21030.0114QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:muscarinic acetylcholine receptor M1 [Homo sapiens]
External ID: CHRM1326
Protocol: Please refer to other AIDs, 1963589, 720680, 720682, 720675, 720686, for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the CHRM1 agonist mode assay (AID 1963589) and auto fluorescence counter screens (AID 720680, AID 720682, AID 720675, AID 720686). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.
Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Activity SummaryAgonist ActivityAgonist Potency (uM)Agonist Efficacy (%)Green auto fluorescence outcomeSample Source
inactiveinactive0inactiveLightBiologicals
inactiveinactive0inactiveSIGMA
inactiveinactive0inactiveLightBiologicals
inactiveinactive0inactiveAcros
inactiveinactive0inactiveLightBiologicals
inactiveinactive0inactiveLightBiologicals
inactiveinactive0inactiveAcros
inactiveinactive0inactiveSIGMA
inactiveinactive0inactiveAcros
inactiveinactive0inactiveLightBiologicals
inactiveinactive0inactivePfaltz-Bauer
inactiveinactive0inactiveSIGMA
inactiveinactive0inactiveSIGMA
inactiveinactive0inactiveSIGMA
inactiveinactive0inactiveEQ Laboratories
inactiveinactive0inactiveAK Scientific
inactiveinactive0inactiveSigma DiscoveryCPR
inactiveinactive0inactiveLightBiologicals
inactiveinactive0inactiveSigma DiscoveryCPR
inactiveinactive0inactiveLightBiologicals
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: VDRV271
Protocol: Tox21 Assay Protocol Summary:

VDR-bla cells were dispensed at 2,000 cells/5 uL of assay medium per well into black wall/clear-bottom 1536-well plates using a Multidrop Combi (Thermo Fisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37C and 5% CO2 for 4 h, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of 1-alpha, 25-Dihydroxy Vitamin D3 (3 nM, final concentration in the wells) using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN). The plates were incubated at 37C and 5% CO2 for 16 h, and then 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Bioraptr FRD. The plates were incubated at room temperature for 2 h and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT). For cell viability readout that measures cytotoxicity, 3 ul/well of CellTiter-Glo reagent was added into the assay plates using a Bioraptr FRD. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader (PerkinElmer).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000047774 uM-Replicate_1Activity at 0.0000106865 uM-Replicate_1Activity at 0.0000238870 uM-Replicate_1Activity at 0.0000515884 uM-Replicate_1Activity at 0.0001141219 uM-Replicate_1Activity at 0.0002523297 uM-Replicate_1Activity at 0.0004987423 uM-Replicate_1Activity at 0.00102 uM-Replicate_1Activity at 0.00227 uM-Replicate_1Activity at 0.00507 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.056 uM-Replicate_1Activity at 0.126 uM-Replicate_1Activity at 0.281 uM-Replicate_1Activity at 0.628 uM-Replicate_1Activity at 1.401 uM-Replicate_1Activity at 3.112 uM-Replicate_1Activity at 6.948 uM-Replicate_1Activity at 15.07 uM-Replicate_1Activity at 28.54 uM-Replicate_1Activity at 60.96 uM-Replicate_1Activity at 78.83 uM-Replicate_1Activity at 216.1 uM-Replicate_1Activity at 765.1 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive042.346610.2132.6172-4.0074-1.831-1.25842.985514.270713.2881-2.6689-2.5632-2.66182.8861-0.68860.69192.3466QC'd by ACCInactive0
Inactive0-6.32134.95490.48055.5-5.912840 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.2243-7.0875-7.8855-3.947-1.13833.5123-6.2515-5.9973-12.4274-9.65516.9770.64852.087917.3413-0.1755-0.2243QC'd by ACCInconclusive10Single point of activity
Inactive044.1825-7.16486.8101-13.797614.039611.5997-2.4203-4.04890.67041.95310.012212.48492.333816.91-22.53944.1825QC'd by ACCInactive0-4.72134.44950.5713-26.8202
Inactive042.18860.48937.00722.89341.573913.288710.722413.66249.00162.926-2.228823.35168.65991.27976.70022.1886QC'd by ACCInactive0
Inactive046.676812.62685.5568-4.81073.57761.180818.0134.1707-0.8259-1.7076-4.73347.40895.92741.865512.27726.6768QC'd by RTIInactive0
Inactive0-6.21951.22210.4584-2.89041040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-5.28387.6635-0.47769.751710.601427.31729.28824.56435.26995.17970.9633-6.384.69330.9658-7.8253-5.2838QC'd by RTIInactive0-4.36951.22210.4733-38.4053
Inactive0412.1296-0.70230.88315.669910.7293-2.4084-1.4746-1.4072-2.5547-1.04830.7657-1.98978.9985-1.1576-1.005912.1296QC'd by RTIInactive0
Inactive040.2136-1.0456-1.534320.631323.05124.996321.652612.4885-1.19994.2855-2.043519.469713.841-0.55129.33420.2136QC'd by RTIInactive0
Inactive0-5.53094.95490.3969-0.25791140 0 0 0 0 0 0 0 0 0 0 0 0 0 00.068612.387912.570226.3486-0.96252.05985.5788.035319.089414.06352.9066-6.46492.16920.59562.6140.0686QC'd by RTIInactive0
Inactive0-4.25132.09370.3952-22.6651340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.55430.3938-0.6006-1.16551.174512.8664-2.0945-2.85329.240518.3836-0.5284-1.90221.4256-1.3499-3.7208-15.5543QC'd by RTIInconclusive0.002231.396310Complete curve; partial efficacy-8.65132.47290.68384
Inactive04-0.6972-0.78551.311719.4646-3.7292-10.502711.1262-14.1035-3.5791-4.2561-0.0347-2.0909-0.4590.2905-7.465-0.6972QC'd by RTIInactive0
Inactive0-4.23973.62720.4888-29.60621.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-22.17181.0422-0.45371.963315.1591-1.3347-2.314413.9484-1.57763.5586-9.4248-4.36251.0069-0.8936-2.8913-22.1718QC'd by RTICytotoxic28.861639.442820Complete curve; partial efficacy; poor fit-4.53972.33320.4553-44.6424
Cytotoxic44.002381.840241Partial curve; partial efficacy-4.35651.86170.9211-77.45274.3876-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-59.3565-0.242312.89231.3797-1.65121.22198.644611.71258.8941-2.430612.1896-2.72071.2057-7.358-30.2263-59.3565QC'd by RTICytotoxic62.154987.354320Partial curve; high efficacy; poor fit-4.20654.0950.6815-89.9964
Inactive0-5.68824.95490.4946-4.90392.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-7.72194.072-2.5394-0.1074-2.51691.50223.816910.54894.03222.51842.1844-7.8366-4.57960.6353-5.7045-7.7219QC'd by RTIInactive0
Inactive0-4.49990.70.4494-18.4815440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.4012-2.49820.07910.17579.14891.02498.4978-2.173-0.185714.6083-2.1844-1.5623-4.5287-4.5637-1.7687-15.4012QC'd by RTIInactive0-4.89992.33320.328-10.6657
Inactive043.14454.71635.3992-1.76277.9853-3.37313.4851-3.4804-4.0637-0.40273.0273-16.2281-0.4805-2.2628-1.99513.1445QC'd by RTIInactive0
Inactive045.2697-1.76248.5923-3.825716.155919.5624-1.94473.449718.98025.55781.02226.016120.53039.3432-3.65715.2697QC'd by RTIInactive0-5.04893.06540.3818-16.9042
Cytotoxic57.296846.159620Single point of activity-4.24192.35310.6136-42.28993.8696-30 0 0 0 0 0 1 0 0 0 0 0 0 0 0-30.8577-0.8301-1.17816.8922-0.207-1.121321.7494-21.769118.4810.05966.4188-4.1994-1.4913-1.7602-8.1236-30.8577QC'd by RTIInactive0
Inactive04-0.78738.6165-1.9056.6526-0.0567-0.6090.08434.80480.5054-0.3911.5095-0.10890.9939-17.77695.3204-0.7873QC'd by RTIInactive0
Inactive044.57181.191510.95070.08227.67165.31214.73488.902912.70251.138915.6906-6.17016.251305.8024.5718QC'd by RTIInactive0-6.11043.51170.3814-8.4608
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: VDRV930
Protocol: Tox21 Assay Protocol Summary:

VDR-bla cells were dispensed at 2,000 cells/6 uL/well into black wall/clear-bottom 1536-well plates using a Multidrop Combi (Thermo Fisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37C and 5% CO2 for 4 h, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA). The plates were incubated at 37C and 5% CO2 for 16 h. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA), the plates were incubated at room temperature for 2 h, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT). For cell viability readout that measures cytotoxicity, 3 ul/well of CellTiter-Glo reagent was added into the assay plates using a FRD. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux (PerkinElmer) plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000056507 uM-Replicate_1Activity at 0.0000126354 uM-Replicate_1Activity at 0.0000282534 uM-Replicate_1Activity at 0.0000545573 uM-Replicate_1Activity at 0.0001216490 uM-Replicate_1Activity at 0.0002748434 uM-Replicate_1Activity at 0.0005839002 uM-Replicate_1Activity at 0.00107 uM-Replicate_1Activity at 0.00238 uM-Replicate_1Activity at 0.00531 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.026 uM-Replicate_1Activity at 0.059 uM-Replicate_1Activity at 0.132 uM-Replicate_1Activity at 0.275 uM-Replicate_1Activity at 0.550 uM-Replicate_1Activity at 1.225 uM-Replicate_1Activity at 2.701 uM-Replicate_1Activity at 5.947 uM-Replicate_1Activity at 13.22 uM-Replicate_1Activity at 29.14 uM-Replicate_1Activity at 62.57 uM-Replicate_1Activity at 81.11 uM-Replicate_1Activity at 231.6 uM-Replicate_1Activity at 765.1 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive046.93951.53443.84360.26481.3462.1647-12.19961.834-2.61415.7431-11.80059.32336.69177.1913-0.44326.9395QC'd by ACCInactive0
Inactive0-4.725110.5012241.738340 0 0 0 0 0 0 0 0 0 0 0 0 0 016.97988.473-0.16712.4805-4.623-0.04323.50270.218412.03270.9469-6.46813.243110.33343.486117.109916.9798QC'd by ACCInactive0
Inactive0-8.52514.95490.47120.215721.436140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.420612.382630.58089.8478-2.1314-3.1811-15.5095-0.30488.0421-1.614-1.643319.4011-2.07024.2201-0.797-1.4206QC'd by ACCInactive0
Inactive0-5.37514.95490.3803-0.7077640 0 0 0 0 0 0 0 0 0 0 0 0 0 110.24894.53053.63390.32555.35677.533710.87512.99917.18118.98823.506710.50142.5849-3.08971.84510.2489QC'd by ACCInactive0
Inactive0-5.38994.95490.5221-2.3911441 0 0 0 0 0 0 0 0 0 0 0 0 0 112.386427.02220.28463.85660.29918.96943.39586.60456.26830.92195.3466-0.1824-2.1365-5.74260.180712.3864QC'd by RTIInactive0-8.13994.95490.38192
Inactive047.77691.18711.65440.06298.599329.1737-2.01711.39431.62599.9095-3.1003-3.0624-1.02083.87178.70287.7769QC'd by RTIInactive0-5.97332.72020.39841
Inactive04-0.54436.40182.35631.03588.232410.0867-12.599125.743619.00150.71134.6078-1.21959.11488.331717.4624-0.5443QC'd by RTIInactive0
Inactive04-1.393-5.04459.120412.67046.1710.82233.95854.81042.147113.41773.68172.92292.77665.484214.2863-1.393QC'd by RTIInactive0-4.42981.39870.566617.5
Inactive0-3.68464.95490.3295-21.04733.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.206112.71783.97392.53410.7503-3.08980.4913-11.419811.2761-1.72712.09816.146110.74513.21118.6332-14.2061QC'd by RTIInactive0
Inactive04-12.1459-8.490814.71670.0559-1.7378.1302-0.3571-0.1963-1.48525.0092-2.5099-0.20170.5627-4.5037-0.5621-12.1459QC'd by RTIInactive0-4.10534.50450.4215-24.1493
Inactive04-6.216613.042-0.1449-2.96398.27591.08770.1563-1.9128-0.97239.5859-0.2936-0.26660.7853-11.27092.1086-6.2166QC'd by RTIInactive0
Inactive0-4.54340.90.6398-28.5156040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-23.763-0.3535-3.2004-8.63280.12410.23117.5837-1.8333-5.77970.3207-0.4891-6.2173-12.579-4.4698-16.265-23.763QC'd by RTIInactive0
Cytotoxic19.490342.363720Complete curve; partial efficacy-4.71023.06540.7807-39.75772.6059-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-42.2098-16.51534.47094.3929-0.63315.6712-2.80484.8733-3.136912.1034-0.519812.903-0.7863-22.2412-32.4618-42.2098QC'd by RTICytotoxic61.633893.318541Partial curve; high efficacy-4.21022.30310.9696-89.2289
Inactive041.4868-0.227114.0116-2.783315.14241.468-2.2315-2.19188.5163-0.2049-0.3148-1.734110.881713.387414.18621.4868QC'd by RTIInactive0-4.34171.10.494314
Inactive0-8.75344.95490.5632-0.159321.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.592417.3509-0.95591.1918-2.61137.38390.8192-2.56138.704-0.5636-0.67380.0444-2.0281-7.21611.0418-1.5924QC'd by RTIInactive0-4.85342.25260.4954-14.488
Cytotoxic61.567143.073521Partial curve; partial efficacy-4.21071.71370.771-43.7918-0.7184-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-32.9779-0.5080.4256-1.63870.9654-13.21132.99990.60249.2056-3.2213-0.68920.7967-1.0638-11.0126-13.4517-32.9779QC'd by RTICytotoxic43.586222.590920Partial curve; partial efficacy; poor fit-4.36071.88510.9208-24.0909
Inactive0416.89058.69830.09827.1276-3.90660.99756.706714.745711.088610.0596-5.21315.3636.6771-3.241718.095716.8905QC'd by RTIInactive0
Inactive0-4.94583.92950.6015-12.9616-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.8803-1.7264-2.1923-1.05571.83041.44-2.531-1.5846-2.3313.83250.1513-1.4821-2.9549-20.8014-2.6667-15.8803QC'd by RTIInactive0
Inactive046.9134-1.9690.9481.057811.68887.6039-0.42711.33437.4977-0.07090.5707-1.27261.2167-3.03640.08996.9134QC'd by RTIInactive0
Inactive0-6.41424.95490.4621-2.4623740 0 0 0 0 0 0 0 0 0 0 0 0 0 17.30560.42736.66010.275113.105212.07437.48979.81953.191-9.5519-5.3319-2.29628.2379-5.7421-0.80147.3056QC'd by RTIInactive0-8.16420.20.4494-11.7655
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:nuclear factor erythroid 2-related factor 2 isoform 1 [Homo sapiens]
External ID: ARE591
Protocol: Please refer to other AIDs 743202, 743203, 720687, 720685, 720678 and 720681, for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the ARE agonist mode assay (AID 743202), cell viability counter screen ( 743203), and auto fluorescence counter screens (AIDs 720687, 720685, 720678 and 720681). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Blue (460 nm) auto fluorescence outcomeSample Source
inconclusive agonistinconclusive agonist12.586451.8374inactive0active agonist9.997782.3994inactive0inactiveACC
inactiveinactive0inactive0inactive0inactive0inactiveACC
inactiveinactive0inactive0inactive0inactive0inactiveACC
inactiveinactive0inactive0inactive0inactive0inactiveACC
inactiveinactive0inactive0inactive0inactive0inactiveACC
inactiveinactive0inactive0inactive0inactive0inactiveRTI
inactiveinactive0inactive0inactive0inactive0inactiveRTI
inactiveinactive0inactive0inactive0inactive0inactiveRTI
inactiveinactive0inactive0inactive0inactive0inactiveRTI
inactiveinactive0inactive0inactive0inactive0inactiveRTI
inactiveinactive0inactive0inconclusiveinactive0inactiveRTI
inactiveinactive0inactive0inactive0inactive0inactiveRTI
inactiveinactive0inactive0inactive0inactive0inactiveRTI
inconclusive antagonistinconclusive antagonist15.4817-38.4103inactive0active antagonist65.2859-147.056active antagonist65.2859-111.903inactiveRTI
inactiveinactive0inactive0inactive0inactive0inactiveRTI
inactiveinactive0inactive0inactive0inactive0inactiveRTI
inconclusive agonistinconclusive agonist33.318246.7001inactive0inconclusive agonist54.871756.5212inactive0inactiveRTI
inactiveinactive0inactive0inactive0inactive0inactiveRTI
inconclusive antagonistinconclusive antagonist37.9484-24.8694inactive0inconclusive antagonistinactive0inactiveRTI
inactiveinactive0inactive0inactive0inactive0inactiveRTI
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: GRA481
Protocol: Tox21 Assay Protocol Summary:

The GR-bla HeLa cells were dispensed at 1500 cells/6 ul/well in 1536-well black wall/clear bottom plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 4 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pintool station (Kalypsys, San Diego, CA). The plates were incubated at 37 C for 18 hours. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA), the plates were incubated at room temperature for 2 hours, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W460-Activity_Score-Replicate_1W460-Curve_Description-Replicate_1W460-Fit_LogAC50-Replicate_1W460-Fit_HillSlope-Replicate_1W460-Fit_R2-Replicate_1W460-Fit_InfiniteActivity-Replicate_1W460-Fit_ZeroActivity-Replicate_1W460-Fit_CurveClass-Replicate_1W460-Excluded_Points-Replicate_1W460-Max_Response-Replicate_1W460-Activity at 0.0000036780 uM-Replicate_1W460-Activity at 0.0000082250 uM-Replicate_1W460-Activity at 0.0000183900 uM-Replicate_1W460-Activity at 0.0000514703 uM-Replicate_1W460-Activity at 0.0001157795 uM-Replicate_1W460-Activity at 0.0002347639 uM-Replicate_1W460-Activity at 0.0005064679 uM-Replicate_1W460-Activity at 0.00101 uM-Replicate_1W460-Activity at 0.00226 uM-Replicate_1W460-Activity at 0.00505 uM-Replicate_1W460-Activity at 0.011 uM-Replicate_1W460-Activity at 0.025 uM-Replicate_1W460-Activity at 0.056 uM-Replicate_1W460-Activity at 0.125 uM-Replicate_1W460-Activity at 0.280 uM-Replicate_1W460-Activity at 0.624 uM-Replicate_1W460-Activity at 1.391 uM-Replicate_1W460-Activity at 3.095 uM-Replicate_1W460-Activity at 6.900 uM-Replicate_1W460-Activity at 15.01 uM-Replicate_1W460-Activity at 29.18 uM-Replicate_1W460-Activity at 62.39 uM-Replicate_1W460-Activity at 79.15 uM-Replicate_1W460-Activity at 213.3 uM-Replicate_1W460-Activity at 765.1 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1Ratio-Activity at 0.0000036780 uM-Replicate_1
Inactive040.7562-2.0191-2.8763-0.9026-3.551-0.7809-0.2770.3016-2.05597.6695-0.4571-0.4785-0.3067-3.19312.29950.7562102.72020.5091-13.21010.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.8015
Inconclusive2.683243.355504.95490.33697-1.259840 0 0 0 0 0 0 0 0 0 0 0 0 0 05.13651.0101-0.5652-4.3951-0.2458-3.9615-0.72250.0703-5.2165-4.71332.5855-0.82580.39810.8412-1.08125.1365103.06540.430911-0.15540 0 0 0 0 0 0 0 0 0 0 0 0 0 010.4779
Inactive00.9310.515-2.2498140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.19170.0432-0.94582.66191.9187-0.00912.6540.7197-0.8071-0.0436-0.1456-2.86940.2333-3.1248-1.627-2.19171040.5349
Cytotoxic23.914564.59580Partial curve; partial efficacy-4.72133.1320.9596-43.45790.2745-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-39.3622.89331.82591.0907-0.1463-0.10590.92180.09150.19131.3078-6.7647-0.7119-0.62320.4675-17.992-39.362100.30.5041-9.1529140 0 0 0 0 0 0 0 0 0 0 0 0 0 13.6116
Inactive00.50.455-21.31571.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.42971.0157-1.7522.7232.69846.869-3.71430.19816.1321-2.0281-8.9254-4.3551-0.3757-5.1288-2.2826-14.4297100.20.470911.5-5.046140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.922
Inconclusive15.08948.866903.51170.44866.5-1.011940 0 0 0 0 0 0 0 0 0 0 0 0 0 05.50351.07060.905-0.25830.69930.4392-0.1511-3.58922.2605-4.5752-0.49010.3402-2.2626-5.42666.35045.5035103.1320.5006-12.72791.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.019
Activator0.095244.78110Single point of activity-7.02134.95490.971588.6934-1.347630 0 0 0 0 0 0 0 1 1 1 1 1 1 1-0.2744-4.73250.61890.21280.81980.5686-0.35281.205386.9543-3.9984-3.1116-0.3361-4.4875-4.0498-7.4011-0.27440Single point of activity-7.02134.95490.969543.878-0.903130 0 0 0 0 0 0 0 1 1 1 1 1 1 1-0.1232
Inactive043.93180.3895-0.21130.182-0.9258-0.4412-3.95122.1721-0.1688-5.0997-0.15442.3995-4.165-0.19191.89093.9318104-1.6204
Inactive04.95490.4549-2.1971140 0 0 0 0 0 0 0 0 0 0 0 0 0 10.39480.2258-0.38513.3271.6718-0.0652.57751.6671-0.09210.011-0.24882.0368-2.0108-3.4976-0.2290.3948103.51170.49812-0.310640 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.5444
Inactive04.95490.49990.779540 0 0 0 0 0 0 0 0 0 0 0 0 0 07.19890.56481.7838-0.99043.56074.2105-1.85041.559-0.7889-0.57311.13450.3821.1458-0.6344-0.05567.19891043.2539
Inconclusive26.832542.156903.1320.6237-18.228140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.8509-0.43261.3737-0.723-1.5954-0.98793.3248-0.25092.6333-1.3551-3.191.65445.081210.7255-16.44-14.85090Complete curve; partial efficacy; poor fit-5.32134.95490.903616-1.39761.40 0 0 0 0 0 0 0 0 0 0 0 0 1 014.2731
Inactive01.3310.44069-1.315540 0 0 0 0 0 0 0 0 0 0 0 0 0 07.7682-8.1796-1.2864-0.92690.0489-1.1023.6629-5.3855-2.0892-3.4173.63520.2376-0.11450.36824.02527.7682104.0950.645512.50.056140 0 0 0 0 0 0 0 0 0 0 0 0 0 013.4789
Inactive04-1.77665.9446-8.071110.9483-0.66150.7628-0.19420.81740.424-0.04970.3107-1.4675-4.3278-0.9634-3.4067-1.77661040.3915
Cytotoxic30.106580.09980Single point of activity-4.57134.95490.9233-34.1878-1-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-30.15651.4442-1.42590.5602-0.5727-1.5149-1.1531-1.7711-0.5991-1.6507-0.5856-0.7334-2.4262-6.8854-0.1814-30.15650Single point of activity-4.57134.95490.964133.76670.413730 0 0 0 0 0 0 0 0 0 0 0 0 0 0123.858
Inactive04.0950.6978-0.5-7.11540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.8355-7.1792-4.2685-1.14751.1488-2.8672-0.65330.9563-0.5809-0.63290.28570.6351.0765-3.2022-0.934-0.8355104.95490.8946-0.469515.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.4115
Inactive047.6683-0.213812.7411-0.95732.68175.82062.76031.9502-1.1272.6603-0.154-4.84897.2899-0.02820.21517.6683100.70.4452-6.3234340 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.9779
Inactive04.95490.38580-3.382540 0 0 0 0 0 0 0 0 0 0 0 0 0 00.3426-2.7245-4.1769-2.5201-5.3186-0.55251.2952-5.152-6.9854-0.68020.87571.22690.5227-3.0321.11160.3426104-1.3858
Inactive043.5373-0.4222-4.6002-0.5607-0.0671-0.45211.69491.7648-0.6170.1086-4.2139-4.41190.48912.0611-0.44833.5373104-0.2942
Activator10.682283.89470Single point of activity-4.97133.92950.884675.0549-2.701730 0 0 0 0 0 0 0 0 0 0 0 0 0 10.7587-0.7027-0.0356-2.9874-6.5873-2.95230.4426-0.8132-2.168-2.9385-0.9678-1.866-0.243-1.378889.35110.75870Single point of activity-4.97133.990.888280.6868-3.207930 0 0 0 0 0 0 0 0 0 0 0 0 0 10.0157
Inactive043.2274-0.4217-5.36674.2879-0.76117.993-0.6172-2.95230.12040.2389-2.49690.367-2.94147.0059-0.88663.2274103.06540.600216-1.455840 0 0 0 0 0 0 0 0 0 0 0 0 0 15.6692
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: FXRV164
Protocol: Tox21 Assay Protocol Summary:

FXR-bla cells were dispensed at 5000 cells/5uL/well in 1536-well black wall/clear bottom plates using a Multidrop Combi (Thermo Fisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C and 5% CO2 for 5 h, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA). The assay plates were incubated at 37C for 16 h. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN), the plates were incubated at room temperature for 2 h, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT). For cell viability readout that measures cytotoxicity, 4uL/well of CellTiter-Glo reagent was added into the assay plates using a Bioraptr FRD. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader (PerkinElmer).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000056507 uM-Replicate_1Activity at 0.0000126354 uM-Replicate_1Activity at 0.0000282534 uM-Replicate_1Activity at 0.0000545573 uM-Replicate_1Activity at 0.0001216490 uM-Replicate_1Activity at 0.0002748434 uM-Replicate_1Activity at 0.0005839002 uM-Replicate_1Activity at 0.00107 uM-Replicate_1Activity at 0.00238 uM-Replicate_1Activity at 0.00531 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.026 uM-Replicate_1Activity at 0.059 uM-Replicate_1Activity at 0.132 uM-Replicate_1Activity at 0.275 uM-Replicate_1Activity at 0.550 uM-Replicate_1Activity at 1.225 uM-Replicate_1Activity at 2.701 uM-Replicate_1Activity at 5.947 uM-Replicate_1Activity at 13.22 uM-Replicate_1Activity at 29.14 uM-Replicate_1Activity at 62.57 uM-Replicate_1Activity at 81.11 uM-Replicate_1Activity at 231.6 uM-Replicate_1Activity at 765.1 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive042.88213.6284-9.3198-12.04284.26050.451-0.52510.622-2.569-19.58746.8043-10.68779.6489-0.97651.95332.8821QC'd by ACCInactive0
Inactive04.95490.85070-26.924540 0 0 0 0 0 0 0 0 0 0 0 0 0 05.8663-28.7081-21.5346-29.5204-18.39840.7363-8.58422.9693-11.185-0.2638-0.159-1.02392.01563.34242.98385.8663QC'd by ACCInactive04.95490.3816-4.5547
Inactive04-9.8431-11.97062.33752.3593-0.7609-10.30924.7943-3.17735.2596-2.58266.79418.23-3.0208-9.05512.8275-9.8431QC'd by ACCInconclusive0.094442.53510Partial curve; partial efficacy-7.02512.09370.907342.0111
Inactive045.984413.52733.03677.334716.0905-6.48426.616510.192325.109624.98736.90589.610210.375813.34778.66565.9844QC'd by ACCInactive0
Inactive04-3.1652-4.31328.987-4.8567-21.09195.3757-2.363-4.0819-0.661-10.0729-17.6429-4.9567-1.383-15.4953-12.9019-3.1652QC'd by RTIInconclusive3.236624.136910Complete curve; partial efficacy; poor fit-5.48994.95490.334722.3974
Inactive04.95490.4021-8.1966740 0 0 0 0 0 0 0 0 0 0 0 0 0 18.447316.24820.0199-9.242514.2063-1.87969.503-4.606312.6633-0.5537-4.9402-19.3305-9.7838-3.0372-2.05168.4473QC'd by RTIInactive0
Inactive04.0950.369222-1.904441 0 0 0 0 0 0 0 0 0 0 0 0 0 1-5.285737.03493.4912-6.898218.2421-8.8646-4.7955-1.87642.9305-0.8984-3.9707-14.9203-2.0913.211519.3262-5.2857QC'd by RTIInactive04.95490.6055-1.5
Inactive0417.559611.820824.03041.0776-20.781416.90520.59126.786812.2023-1.32267.59759.120817.003510.36950.144617.5596QC'd by RTIInactive0
Inactive04-29.243413.605427.3521-2.96912.0493-2.1744-5.867233.376113.886813.30830.915422.4197-3.626-1.88128.9345-29.2434QC'd by RTIInactive03.1320.588317
Inactive04-10.6679-4.2487-0.610316.4918-13.006611.7791-4.145121.3922-3.3439-22.2644-14.728714.085211.6556-1.7269-19.7785-10.6679QC'd by RTIInactive04.0950.4597.5916
Inactive04-16.7396-8.5959-1.6452-8.9075-20.6137-3.9182-8.6858-12.945-10.81350.6276-23.6421-2.6595-12.296-6.2621-18.7076-16.7396QC'd by RTIInactive0
Inactive04.95490.35087-4.686641 0 0 0 1 0 0 0 0 0 0 0 0 0 1-22.638626.8398-0.7833-20.1555-0.0073-48.6695-1.52211.30511.5731-13.2338-4.711811.568916.73681.6304-1.399-22.6386QC'd by RTIInactive04.0950.3943-1
Cytotoxic61.633892.882841Partial curve; high efficacy-4.21021.88510.8005-100.7268-7.844-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-76.3082-8.6228-16.7346-20.05771.9282-9.6626-8.0269-19.9091-16.7769-3.7216-7.7635-14.7531-17.87682.1315-51.3777-76.3082QC'd by RTICytotoxic1.09651.087520Complete curve; partial efficacy; poor fit-5.96020.30.4031-54.9507
Inactive04-1.4525-2.3038-6.4691-0.2054-15.202721.3177-7.719821.3653-9.2632-11.4342-19.7465-11.82652.96043.2843-7.0608-1.4525QC'd by RTIInactive04.95490.4032
Inactive04-14.5503-12.45210.0721.8436-21.903511.8261-9.4007-2.566-11.1301-11.287117.8736-17.087713.468615.0757-1.3414-14.5503QC'd by RTIInactive0
Inactive04-0.5867-8.61059.87255.682718.9179-12.3997-8.1976-16.2292-12.5678-0.2429.03950.7892-9.79568.325-19.7928-0.5867QC'd by RTIInactive04.50450.402314
Inactive04.95490.31012-8.283440 0 0 0 0 0 0 0 0 0 0 0 0 0 03.3235-5.3234-16.2445-3.6289-4.0284-13.6836-6.3506-6.9801-7.29510.412516.2309-17.7362-0.38431.276310.69483.3235QC'd by RTIInactive02.25260.3984-2
Inactive04.0950.6389-27.8026740 0 0 0 0 0 0 0 0 0 0 0 0 0 0-28.07058.914716.6131-1.70080.05048.1826-5.17111.785611.3518-0.36862.154329.568710.3336-1.3344-22.7723-28.0705QC'd by RTIInactive04.95490.3887-21.9542
Inactive047.7693-0.06144.410711.3872-19.35653.3079-21.89960.2098-13.087-2.055.60741.223416.814622.5859-17.05957.7693QC'd by RTIInactive0
Inconclusive0.768830.07610Partial curve; partial efficacy; poor fit-6.11423.92950.5867332.9242.40 0 0 0 0 0 0 0 0 0 1 1 1 1 1-0.814719.053211.68292.4782-0.210112.2417-0.89660.22932.203519.861132.1714-3.4178-5.947-0.536915.5923-0.8147QC'd by RTIInactive00.20.3964
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: VDRN244
Protocol: Tox21 Assay Protocol Summary:

VDR-bla cells were dispensed at 2,000 cells/5 uL of assay medium per well into black wall/clear-bottom 1536-well plates using a Multidrop Combi (Thermo Fisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37C and 5% CO2 for 4 h, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of 1alpha, 25-Dihydroxy Vitamin D3 (3 nM, final concentration in the wells) using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN). The plates were incubated at 37C and 5% CO2 for 16 h, and then 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Bioraptr FRD. The plates were incubated at room temperature for 2 h and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W460-Activity_Score-Replicate_1W460-Curve_Description-Replicate_1W460-Fit_LogAC50-Replicate_1W460-Fit_HillSlope-Replicate_1W460-Fit_R2-Replicate_1W460-Fit_InfiniteActivity-Replicate_1W460-Fit_ZeroActivity-Replicate_1W460-Fit_CurveClass-Replicate_1W460-Excluded_Points-Replicate_1W460-Max_Response-Replicate_1W460-Activity at 0.0000047774 uM-Replicate_1W460-Activity at 0.0000106865 uM-Replicate_1W460-Activity at 0.0000238870 uM-Replicate_1W460-Activity at 0.0000515884 uM-Replicate_1W460-Activity at 0.0001141219 uM-Replicate_1W460-Activity at 0.0002523297 uM-Replicate_1W460-Activity at 0.0004987423 uM-Replicate_1W460-Activity at 0.00102 uM-Replicate_1W460-Activity at 0.00227 uM-Replicate_1W460-Activity at 0.00507 uM-Replicate_1W460-Activity at 0.011 uM-Replicate_1W460-Activity at 0.025 uM-Replicate_1W460-Activity at 0.056 uM-Replicate_1W460-Activity at 0.126 uM-Replicate_1W460-Activity at 0.281 uM-Replicate_1W460-Activity at 0.628 uM-Replicate_1W460-Activity at 1.401 uM-Replicate_1W460-Activity at 3.112 uM-Replicate_1W460-Activity at 6.948 uM-Replicate_1W460-Activity at 15.07 uM-Replicate_1W460-Activity at 28.54 uM-Replicate_1W460-Activity at 60.96 uM-Replicate_1W460-Activity at 78.83 uM-Replicate_1W460-Activity at 216.1 uM-Replicate_1W460-Activity at 765.1 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1Ratio-Activity at 0.0000047774 uM-Replicate_1
Inconclusive0Single point of activity-3-58.9097-40.186126.761827.0795-44.2985-31.2171-30.3618-8.24710.59983.5796-15.9344-40.4731034.1149-4.2368-58.9097104-23.2513
Inconclusive0Single point of activity-4.57134.95490.899262.2747-3.366430 0 0 0 1 0 0 0 0 0 0 0 0 0 055.6496-14.0285-2.31312.9681-6.289540.01224.317-0.4162-5.9358-2.4575-0.4264-10.1075-0.34221.0887-1.665255.6496104-4.2105
Inactive0412.140511.67010.846822.252219.5997-4.850242.101617.93627.647416.23658.29810010.51-3.792612.1405104-1.8859
Inactive04-3.006-16.29-11.17450-16.803503.1058-0.16310-19.09260-1.574-1.5375-10.01410-3.00610-9.17134.95490.4227-12.029213.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.3721
Inactive0-5.47131.88510.6275-33.5111-2.751940 0 0 0 0 0 0 0 0 0 0 0 0 0 1-5.69772.0819-9.0589-1.80110.46698.458-10.6425-9.929-1.54021.1381-8.9874-9.8748-7.8486-44.0608-23.1863-5.6977104-0.9699
Inactive0-7.93264.95490.3632-12.4149-1.540 0 1 0 0 0 0 0 0 0 0 0 0 0 12.56511.4578-0.5148-40.5447-7.28810.0364-9.1734-18.7791-10.7483-8.6236-16.6289-9.23-10.5939-26.59581.98022.5651104-5.8247
Inactive0-5.78261.47870.3632-18.9916-2.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.1842-23.7430-7.9249-4.42837.34815.7655.5698-5.882-0.9418-2.379-13.4782-5.0801-16.0702-23.6907-14.1842104-6.3295
Inactive04-8.3549.6728-12.4902-6.04729.288712.8052-8.080416.83752.731400-3.4138-0.31223.39783.7955-8.3541040.9913
Inactive04-2.39595.2698-5.8799-5.1917-4.842837.6494-11.57630-5.8052-6.068142.1913-9.25255.8095-22.32344.0636-2.3959104-4.9413
Inconclusive0Complete curve; partial efficacy-4.97134.44950.837269.1739-0.43061.20 0 0 0 0 0 0 0 0 0 0 0 0 0 064.7945-12.95063.953113.59250.0256-19.97842.5473-2.55232.14872.464419.03340-16.06613.879766.978164.794510-6.07131.22210.664823-1.194540 0 0 0 0 0 0 0 0 0 0 1 0 0 10.0445
Inactive0-5.37134.95490.65527.51.965240 0 0 0 0 0 0 0 0 0 0 0 0 1 024.1962-10.02915.80275.3828-0.075-1.94714.86177.22785.69820.5899-8.08223.62127.351929.6274-8.631424.19621042.3192
Inconclusive26.832519.01210-8.02134.44950.5869-9.106426.202540 0 1 0 0 0 0 0 0 0 1 0 0 0 0-33.966118.6435.0422-10.418622.04670.692-24.47942.5126-8.2179-0.716-15.619523.4257-9.1426-8.251315.8158-33.96610Single point of activity-4.57134.95490.5658-46.4647-2.1401-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-41.0706
Inactive0-5.32134.95490.6173-22.2086240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.84057.56744.94617.5912-19.307514.5698-2.30427.1181-3.12467.8414-1.155-1.1983-0.3483-21.7476-21.0306-21.840510-4.97133.06540.5079-17.83110.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.5181
Inactive04013.352125.32111.049918.296116.90243.897554.099912.553414.70699.310248.8231.688452.406421.773501041.0402
Inconclusive0Single point of activity-5.02132.33320.792252.8946-6.37330 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.8632-1.88883.4577-2.8684-10.1078-8.8992-14.748-12.4509-12.5297-8.7875-0.01-1.8468.48262.72851.743-0.863210-4.97131.3310.426131.3082-0.77340 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.0826
Inactive0-5.92132.33320.6885-21.1207-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-9.5112-2.3521-7.4271-7.00121.09911.5864.9108-1.4841-4.84130.4347-7.878-8.7623-31.7672-12.6622-21.475-9.511210-6.42132.18760.8204-18.44630.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.3112
Inconclusive0Partial curve; partial efficacy; poor fit-5.37130.40.707465.4179-7.55152.40 0 0 0 0 0 0 0 0 0 0 1 0 0 049.416-15.0742-7.02337.9812-16.10644.0559.45210.789430.55645.3346-3.311223.6052-8.787424.721248.574649.41610-7.72134.95490.4018.5-2.916940 0 0 0 0 0 0 0 0 0 0 0 0 0 08.8758
Inactive0-4.97134.44950.50834.77090.689840 0 0 0 0 0 0 0 0 0 0 0 0 0 025.7053-2.7987-6.103221.12882.1098-11.5623-16.280300.28164.906324.66911.1932-5.8546-1.282147.350725.70531047.0697
Inconclusive0Single point of activity3-2.218819.8878-1.383235.2167-1.463538.040218.518424.44691.2827-2.638718.9237-1.827143.067528.888158.3197-2.2188104-1.2725
Inconclusive0446.219219.851934.206964.9896-2.637167.219410.363135.1545008.5022035.06168.039997.519446.21921041.57
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: VDRA122
Protocol: Tox21 Assay Protocol Summary:

VDR-bla cells were dispensed at 2,000 cells/6 uL/well into black wall/clear-bottom 1536-well plates using a Multidrop Combi (Thermo Fisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37C and 5% CO2 for 4 h, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA). The plates were incubated at 37C and 5% CO2 for 16 h. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA), the plates were incubated at room temperature for 2 h, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W460-Activity_Score-Replicate_1W460-Curve_Description-Replicate_1W460-Fit_LogAC50-Replicate_1W460-Fit_HillSlope-Replicate_1W460-Fit_R2-Replicate_1W460-Fit_InfiniteActivity-Replicate_1W460-Fit_ZeroActivity-Replicate_1W460-Fit_CurveClass-Replicate_1W460-Excluded_Points-Replicate_1W460-Max_Response-Replicate_1W460-Activity at 0.0000056507 uM-Replicate_1W460-Activity at 0.0000126354 uM-Replicate_1W460-Activity at 0.0000282534 uM-Replicate_1W460-Activity at 0.0000545573 uM-Replicate_1W460-Activity at 0.0001220400 uM-Replicate_1W460-Activity at 0.0002755047 uM-Replicate_1W460-Activity at 0.0005838754 uM-Replicate_1W460-Activity at 0.00106 uM-Replicate_1W460-Activity at 0.00236 uM-Replicate_1W460-Activity at 0.00528 uM-Replicate_1W460-Activity at 0.012 uM-Replicate_1W460-Activity at 0.026 uM-Replicate_1W460-Activity at 0.059 uM-Replicate_1W460-Activity at 0.131 uM-Replicate_1W460-Activity at 0.275 uM-Replicate_1W460-Activity at 0.554 uM-Replicate_1W460-Activity at 1.234 uM-Replicate_1W460-Activity at 2.714 uM-Replicate_1W460-Activity at 6.009 uM-Replicate_1W460-Activity at 13.37 uM-Replicate_1W460-Activity at 29.47 uM-Replicate_1W460-Activity at 63.53 uM-Replicate_1W460-Activity at 81.11 uM-Replicate_1W460-Activity at 236.0 uM-Replicate_1W460-Activity at 765.1 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1Ratio-Activity at 0.0000056507 uM-Replicate_1
Inconclusive61.644825.60-4.71014.44950.4757-20.61042.306940 0 0 0 0 0 0 0 0 0 0 0 0 0-17.7487-13.2106-1.8139-1.1899-1.851209.017412.989021.9431-1.1787-2.0778-2.989-21.9196-17.748710-4.21014.95490.7845-25.23542.540 0 0 0 1 0 0 0 0 0 0 0 0 0 0-19.3629
Inconclusive10.963544.19430-8.76013.1320.65371.04272840 0 0 0 0 0 0 0 0 0 0 0 0 0 00.869424.5019.54750.04483.5091.0069-1.154-0.88292.9721-2.7422-8.714411.45814.456-1.91426.3530.869410-4.96012.72020.7603-7.7269140 0 0 0 0 0 0 0 0 0 0 0 0 11.4673
Inactive047.221-0.28459.99470.6047-1.7264-2.6265-1.72537.8887-1.599-0.303-7.90085.78334.63345.8886-2.89067.22110-8.310110.4214-3.121911.540 0 0 0 0 0 0 0 0 0 0 0 0 15.7997
Inconclusive15.486442.14880Complete curve; partial efficacy-4.66014.95490.80628.318-3.16341.20 0 0 0 0 0 0 0 0 0 0 0 0 0 024.0204-2.3454-2.6605-8.01382.43230.4795-11.4745-2.11631.6748-5.6392-7.37930.00524.2067-6.52732.565424.02040Complete curve; high efficacy-4.66014.95490.925463.06190.61391.10 0 0 0 0 0 0 0 0 0 0 0 0 0 053.2518
Inactive04-5.37830.44420.00928.0925-0.90989.9353-0.3638-17.83850.89667.52590.2941-0.5831-0.995-0.932-5.378310-5.21063.1320.5189-5.8761.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-5.4591
Inconclusive24.541230.9970-7.31014.95490.4626-3.625410.540 0 0 0 0 0 0 0 0 0 0 0 0 0-5.518512.512112.51725.47514.33425.65223.2099-16.3545-14.8421-2.538310.0322.1959-6.46644.8915-5.51850Complete curve; partial efficacy-4.66013.51170.852332.8639-0.54971.20 0 0 0 0 0 0 0 0 0 0 0 0 031.0196
Inactive0-4.81014.95490.43123.5-6.489340 0 0 0 0 0 0 0 0 0 0 0 0 0 1-5.8361-8.1769-11.6578-6.5969-1.5159-8.0577-1.317-7.2091-0.9766-8.516-8.1184-7.9697-10.4262-0.97532.8945-5.836110-4.66012.40640.5778160.94740 0 0 0 0 0 0 0 0 0 0 0 0 0 1-7.4151
Inactive04-11.7958-5.3934-4.1655-5.7882-7.1273-9.6729-13.0839-2.83276.136-9.6265-0.2829-0.2804-8.972-6.7574-8.9806-11.795810-4.83063.990.8548-13.1524240 0 0 0 0 0 0 0 0 0 0 0 0 0-11.9361
Inactive0-5.41012.40640.4699.5-3.561840 0 0 0 0 0 0 0 0 0 0 0 0 010.0916.0873-0.123-2.209-4.9596-3.4448-8.49951.089-2.4815-17.9682-1.74159.3330.671114.705410.09110-8.66010.40.3449-1.211140 0 0 0 0 0 0 0 0 0 0 0 0 14.9617
Inactive04-13.2074-1.4275-4.83512.6172-7.47473.1337-1.7134-5.1559-0.417326.8250.3098-3.17283.1436.10951.457-13.20741041.9672
Inactive043.05040.7728-12.64670.0577.256915.90553.4118-2.5921-17.65482.6492-3.2386-5.6182-3.12955.03773.050410-5.61014.95490.39295-2.643140 0 0 0 0 0 0 0 0 0 0 0 0 0 07.8742
Inconclusive48.972249.18570422.89922.786317.817511.53454.34622.229615.043904.46773.068-3.337813.4271-2.9419-1.42523.609522.899210-4.36012.63840.4067-16.6566140 0 0 0 0 0 0 0 0 0 0 0 0 0-13.4638
Inconclusive61.644845.11560Single point of activity-6.71014.95490.940876.87850.064330 0 0 0 0 0 0 0 1 1 1 1 1 1-20.39811.0827-6.61312.37032.66271.94456.7998-3.89671.28417.076-3.99681.7022-0.9349-11.7244-20.39810Single point of activity-6.76014.95490.882944.1096-1.06230 0 0 0 0 0 0 0 1 1 1 1 1 124.1081
Inactive0-4.21014.95490.451222-1.056240 0 0 0 0 0 0 0 0 0 0 0 0 0 016.4366-6.58986.49251.46452.9269-5.9502-0.394-4.3642-0.7283.1043-11.29691.1934-4.2836.5098-1.258116.43661048.0761
Inactive0-7.210110.3595-1.6461540 0 0 0 0 0 0 0 0 0 0 0 0 0 00.62412.109410.4825-0.14786.55131.43780.25483.58790.4122-0.9784-6.7884-1.6865-3.5521-4.29764.81460.62411042.2206
Inactive042.2848-0.27360.11396.31992.24278.596711.419217.96699.31627.7080.1490.144613.9623.542.284810411.1317
Inactive0-7.66014.95490.38623.5-7.207640 0 0 0 0 0 0 0 0 0 0 0 0 01.1898-14.8382.09450.7114-17.6731.48351.8839-0.204510.344812.825-0.32192.47120.78342.03231.189810-4.21014.95490.5199-17.1744-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-13.4787
Activator47.448630.2160Single point of activity-4.32384.95490.693142.9691-4.919430 0 0 0 0 0 0 0 0 0 0 0 0 0 036.3111-3.4802-2.08062.6639-14.4162-3.356304.0144-1.9931-17.7214-19.4707-5.3604-0.1415-0.9383-2.671836.31110Partial curve; partial efficacy; poor fit-4.32384.95490.774429-1.2162.40 0 0 0 0 0 0 0 0 0 0 0 0 0 024.675
Inconclusive3.089915.51270-4.21014.95490.7091-19.2585-240 0 0 0 0 0 0 0 0 0 0 0 1 0 0-16.0488-4.5643-2.1358-3.42971.997-4.15380-5.40141.1188-2.3685-3.6568-4.4267-2.562541.0133-0.7315-16.048810-5.51010.30.6547-10.1617.540 0 0 0 0 0 0 0 0 0 0 0 0 0-8.8841
Inactive0-8.46514.95490.567-0.8833840 0 0 0 0 0 0 0 0 0 0 0 0 0-0.55390.148110.910113.8912-0.709-3.3049-3.6528-0.8491-1.2901-0.0714-1.1921.4839-0.10821.5033-0.553910-5.26511.86170.6106-13.5992540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.5827
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: GRN257
Protocol: Tox21 Assay Protocol Summary:

The GR-bla HeLa cells were dispensed at 1500 cells/5 ul/well in 1536-well black wall/clear bottom plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 4 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of dexamethasone (5 nM, final concentration in the well). The plates were incubated at 37 C for 18 hours. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA), the plates were incubated at room temperature for 2 hours, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W460-Activity_Score-Replicate_1W460-Curve_Description-Replicate_1W460-Fit_LogAC50-Replicate_1W460-Fit_HillSlope-Replicate_1W460-Fit_R2-Replicate_1W460-Fit_InfiniteActivity-Replicate_1W460-Fit_ZeroActivity-Replicate_1W460-Fit_CurveClass-Replicate_1W460-Excluded_Points-Replicate_1W460-Max_Response-Replicate_1W460-Activity at 0.0000036780 uM-Replicate_1W460-Activity at 0.0000082250 uM-Replicate_1W460-Activity at 0.0000183900 uM-Replicate_1W460-Activity at 0.0000514202 uM-Replicate_1W460-Activity at 0.0001158387 uM-Replicate_1W460-Activity at 0.0002261535 uM-Replicate_1W460-Activity at 0.0004949824 uM-Replicate_1W460-Activity at 0.00102 uM-Replicate_1W460-Activity at 0.00229 uM-Replicate_1W460-Activity at 0.00510 uM-Replicate_1W460-Activity at 0.011 uM-Replicate_1W460-Activity at 0.025 uM-Replicate_1W460-Activity at 0.057 uM-Replicate_1W460-Activity at 0.127 uM-Replicate_1W460-Activity at 0.284 uM-Replicate_1W460-Activity at 0.634 uM-Replicate_1W460-Activity at 1.415 uM-Replicate_1W460-Activity at 3.154 uM-Replicate_1W460-Activity at 7.040 uM-Replicate_1W460-Activity at 15.11 uM-Replicate_1W460-Activity at 27.01 uM-Replicate_1W460-Activity at 58.48 uM-Replicate_1W460-Activity at 78.95 uM-Replicate_1W460-Activity at 216.1 uM-Replicate_1W460-Activity at 765.1 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1Ratio-Activity at 0.0000036780 uM-Replicate_1
Inactive04-12.097-15.4211.22518.50446.32020.846114.98991.67820.3453-2.12172.5147-17.8498-9.32760.28162.6709-12.097104-12.0519
Inconclusive0Single point of activity-4.52134.95490.372839.41940.385430 0 0 0 0 0 0 0 0 0 0 0 0 0 032.79711.95395.33912.21820.80081.884415.32420.02920.8207-21.1398-1.4369-24.04185.752217.14520.630832.79711040.9716
Inactive04-5.25290.17872.973832.766221.31856.600616.055125.63979.842634.3918-9.8497-0.1044-5.717114.7663-0.7047-5.25291046.6113
Cytotoxic23.914544.75320Partial curve; high efficacy-4.77133.06540.9397-151.36460.7993-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-140.15255.712-11.72013.174311.80043.9627-11.745919.69894.1037-4.89243.0574-21.16290.0911-4.4585-74.4823-140.15250Complete curve; high efficacy-4.97133.51170.8761-65.1981-0.3709-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-64.7954
Inhibitor26.8325102.2380Single point of activity-4.57134.95490.7068-122.91268.4508-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-103.83561.9814-8.2905-0.6801-2.507810.7911-7.456524.81948.5806-7.33822.7627-1.146220.661865.1802-2.288-103.83560Single point of activity-4.57134.95490.8259-97.04015.198-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-85.6797
Inactive043.352-18.3617-0.7198-1.82120.7254-2.3887-0.71138.1346-18.636610.8874-1.88711.636-16.58518.3351-18.83343.3521042.0179
Inconclusive0Complete curve; partial efficacy; poor fit-7.52131.46410.680236.20112.51.41 0 0 0 0 0 0 0 0 0 1 1 1 1 122.057130.60393.688701.975524.92820.940436.70837.549926.490437.73945.076219.601119.7132-3.264822.0571104-2.2828
Inactive043.5852-0.9953.1779-2.90782.9481-0.79636.8681-22.0598-14.2108-2.2977-16.3346-2.03172.00522.18690.90223.5852104-2.9287
Inactive04-2.74024.46784.162900.150523.553338.24690.453-5.2560.55339.8796-0.6274-4.2999023.1032-2.7402104-6.1592
Inactive0417.07540.24292.78673.44132.792-1.4151.419821.8245-2.16183.6162-18.04260.0956-1.3056-2.398512.358417.0754104-11.8022
Cytotoxic26.832542.81820Single point of activity-4.57134.95490.9428-140.4676.5416-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-123.21672.731110.1203-0.9412-0.006715.33822.152318.6872.49431.3665-0.576414.2545-2.3685-1.0992-1.3076-123.21670Partial curve; partial efficacy; poor fit-4.52130.60.588-65.2178-6.1658-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-51.7601
Inconclusive0Partial curve; partial efficacy-4.92131.10.711641.11172.152.20 0 0 0 0 0 0 0 0 0 0 0 0 0 040.5279-2.658815.3997-1.32051.54133.8511.1616-0.54452.66480.16530.4079-0.475322.922612.925317.4440.5279104-1.1211
Inactive045.3983-14.35172.32162.82171.398410.6583-13.337-1.73434.042716.340518.8055-0.856912.351214.0297-4.28015.3983104-15.3874
Cytotoxic26.832560.9510Single point of activity-4.57134.95490.8965-166.924610.764-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-155.4129-4.74481.248714.33939.9359-5.64392.083840.29660.993714.79787.97237.785523.56762.329620.0585-155.41290Single point of activity-4.57134.95490.72-34.1482.3048-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-30.286
Inactive04-17.9221-5.6935-9.7378-15.0242-13.45874.1955-20.9421.6642.78496.2808-1.65063.6358-21.3152-1.5804-17.7116-17.9221104-3.4006
Inactive04-16.0736-0.16670.063414.39452.22271.76036.0139-16.78778.30026.13620.2785-23.70580.041617.93561.9071-16.0736104-0.4858
Inactive00.70.515419.5726-16.145540 0 0 0 0 0 1 0 0 0 0 0 0 0 1-18.9267-14.0001-14.1391-15.825-18.1982-31.1347-5.992124.7447-16.7843-1.0696-18.5346-4.5707-4.9181-7.002213.1558-18.9267104-7.4051
Inactive04-15.437230.19180.87326.82955.19737.68435.82839.8057-1.3433-0.6271-0.7496-16.36081.435420.67980.2025-15.43721040.541
Inactive04-8.09546.20142.679-3.15441.45620.91-3.2719-6.17514.4834-9.2058-3.6067-5.2067-7.29356.5535-11.4671-8.0954104-19.5741
Inconclusive04-6.5078-13.7847-11.6608-0.2953-62.2272-22.8473-5.7475-4.5773-29.0585-18.6043-33.5711-11.69590-23.5243-23.2348-6.50780Single point of activity-4.57134.95490.701639.7004-8.651930 0 0 0 0 0 0 0 0 0 0 0 0 0 036.4575
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: FXRV189
Protocol: Tox21 Assay Protocol Summary:

FXR-bla cells were dispensed at 5000 cells/5uL/well in 1536-well black wall/clear bottom plates using a Multidrop Combi (Thermo Fisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C and 5% CO2 for 5 h, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL Chenodeoxycholic acid (50 uM, final concentration in the wells). The assay plates were incubated at 37C for 16 h. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN), the plates were incubated at room temperature for 2 h, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT). For cell viability readout that measures cytotoxicity, 4uL/well of CellTiter-Glo reagent was added into the assay plates using a Bioraptr FRD. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader (PerkinElmer).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000056507 uM-Replicate_1Activity at 0.0000126354 uM-Replicate_1Activity at 0.0000282534 uM-Replicate_1Activity at 0.0000545573 uM-Replicate_1Activity at 0.0001216490 uM-Replicate_1Activity at 0.0002748434 uM-Replicate_1Activity at 0.0005839002 uM-Replicate_1Activity at 0.00107 uM-Replicate_1Activity at 0.00238 uM-Replicate_1Activity at 0.00531 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.026 uM-Replicate_1Activity at 0.059 uM-Replicate_1Activity at 0.132 uM-Replicate_1Activity at 0.275 uM-Replicate_1Activity at 0.550 uM-Replicate_1Activity at 1.224 uM-Replicate_1Activity at 2.686 uM-Replicate_1Activity at 5.948 uM-Replicate_1Activity at 13.22 uM-Replicate_1Activity at 29.14 uM-Replicate_1Activity at 62.57 uM-Replicate_1Activity at 81.11 uM-Replicate_1Activity at 231.6 uM-Replicate_1Activity at 765.1 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive044.10321.25260.19657.1055-0.29514.1773-0.49540.02330.84861.3599-1.13061.32917.12090.302911.91914.1032QC'd by ACCInactive0
Inactive0411.6822.10439.4292-14.59168.4884-4.4439-0.435911.29654.13062.6408-0.1663-1.47244.6246.27582.002711.682QC'd by ACCInactive0
Inactive04.95490.5114-0.4735940 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.0923.21078.00372.37356.45373.584715.97812.557415.914514.14175.1351-1.22793.0773-1.1991-0.4988-1.092QC'd by ACCInactive0
Inactive043.1509-1.2804-2.21285.3811-1.6126-6.8811.390711.71778.67323.1956-8.42117.6847-1.52447.48471.773.1509QC'd by ACCInactive0
Inactive00.60.440216-5.239840 0 0 0 0 0 0 0 0 0 0 0 0 0 010.6842-5.19990.041-13.11650.1799-7.2442-4.7303-7.9217-0.2795-7.31311.92474.5068-7.91245.54061.675710.6842QC'd by RTICytotoxic8.129965.228620Single point of activity-5.08994.95490.8985-66.2838
Inactive00.20.5378-21.21531240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.012812.60991.14017.1263.4799-0.78887.8719-0.7962-2.7948-9.63363.3091-2.96960.579-0.4089-9.8355-16.0128QC'd by RTIInactive0
Inactive040.8454-5.1068-9.98953.5679-0.266-13.767-4.5435-2.5667-2.9888-4.632-2.952-13.8702-2.5479-7.179-7.87940.8454QC'd by RTIInactive0
Inactive042.36-0.35996.16864.92165.052-0.4332-5.40131.55511.0949-2.46260.71323.36191.67187.0937-2.13282.36QC'd by RTIInactive0
Inactive04-0.7865-0.13830.4844.9047.9311-15.67732.156-0.5688-1.08358.3029-14.00971.74430.463712.86960.995-0.7865QC'd by RTIInactive0
Cytotoxic15.657961.45521Complete curve; partial efficacy-4.80532.72020.8281-64.5224-3.0675-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 1-16.70299.2181-2.27732.6997-3.9853-10.8292-1.1214-0.6174-9.4571-14.2664-12.2002-2.73820.578-56.4564-56.3264-16.7029QC'd by RTIInactive04.95490.4844-6.9351
Inactive00.80.5379-29.8897-440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.57486.4013-7.3705-0.5714-7.7046-2.7104-9.8185-7.2561-8.658-9.5185-0.4995-1.7558-7.4332-11.4028-14.3295-21.5748QC'd by RTIInactive04.95490.4263-24.9159
Cytotoxic71.874760.574120Partial curve; partial efficacy; poor fit-4.14341.46410.5808-66.5837-6.0096-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-50.4422-12.29-21.7687-10.4368-0.8776-4.2264-0.9486-3.5474-11.8587-5.1545-19.0547-7.6223-1.1792-22.0345-11.0461-50.4422QC'd by RTIInactive0
Cytotoxic69.154384.46842Partial curve; high efficacy-4.16022.40640.9302-88.859-4.3909-2.10 0 0 0 1 0 0 0 0 0 0 0 0 0 0-67.3174-0.3544-2.6214-7.1052-0.5847-34.0081-2.32386.5918-3.921-9.5564-7.3291-11.9498-8.2707-12.0974-25.0902-67.3174QC'd by RTIInactive03.92950.5665-13.7208
Inactive03.990.4598-3.88542.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.37316.816-0.02120.6121.9256-2.7963-6.7121-5.7809-8.65453.8563-2.9828-5.1056-5.4722-1.9986-4.2795-2.3731QC'd by RTIInactive0
Inactive00.50.6196-12.0074040 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.68232.7616-0.8312-0.67-2.2504-1.35413.0282-4.1398-0.0316-3.4056-2.8502-4.239-2.16-6.9407-8.3395-3.6823QC'd by RTIInactive00.50.6092-12.3811
Inactive04-2.2853.75040.86615.54553.9147-0.59010.82042.40051.8382-4.01082.686613.68140.06253.30653.1875-2.285QC'd by RTIInactive0
Inactive045.2012-0.22483.51993.52232.31563.17227.5191-24.4796-1.3984-3.8312-18.38289.24265.2452-0.52146.46965.2012QC'd by RTIInactive04.95490.35-3.7683
Cytotoxic31.929628.940120Partial curve; partial efficacy; poor fit-4.49584.95490.8915-29.9401-1-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 1-14.0922-3.4119-4.79642.08121.41643.0187-2.204-4.2809-0.7236-0.3355-0.5739-3.48970.4851-2.0964-29.9501-14.0922QC'd by RTIInactive0
Inactive040.1103-5.499-4.9943-5.85630.37431.5325-0.01340.04110.12860.5455-8.28661.3606-2.714-5.7626-6.97910.1103QC'd by RTIInactive0
Inactive04.95490.51092.5-9.212440 0 0 0 0 0 0 0 0 0 0 0 0 0 1-12.7587-2.0115-7.8851-10.2434-10.4324-16.84376.56232.18522.9355.03122.6384-0.8222-8.3235-0.844311.3743-12.7587QC'd by RTIInactive02.72020.3382-14.6103
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: TGF255
Protocol: Tox21 Assay Protocol Summary:

SBE-bla HEK 293T cells were dispensed at 4,000/well in 6 uL of assay medium into black wall/clear-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C and 5% CO2 for an overnight, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA). The assay plates were incubated at 37 C and 5% CO2 for 5 hr. One uL of LiveBLAzer B/G FRET substrate (Life Technologies) was added using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA) and the plates were incubated at room temperature for 2 hr. Fluorescence intensity (405 nm excitation, 460 nm and 530 nm emissions) was measured using an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000049913 uM-Replicate_1W530-Activity at 0.0000115944 uM-Replicate_1W530-Activity at 0.0000453222 uM-Replicate_1W530-Activity at 0.0001076943 uM-Replicate_1W530-Activity at 0.0002499208 uM-Replicate_1W530-Activity at 0.0005150359 uM-Replicate_1W530-Activity at 0.00142 uM-Replicate_1W530-Activity at 0.00434 uM-Replicate_1W530-Activity at 0.011 uM-Replicate_1W530-Activity at 0.025 uM-Replicate_1W530-Activity at 0.057 uM-Replicate_1W530-Activity at 0.127 uM-Replicate_1W530-Activity at 0.290 uM-Replicate_1W530-Activity at 0.887 uM-Replicate_1W530-Activity at 2.716 uM-Replicate_1W530-Activity at 6.973 uM-Replicate_1W530-Activity at 15.76 uM-Replicate_1W530-Activity at 35.30 uM-Replicate_1W530-Activity at 76.83 uM-Replicate_1W530-Activity at 199.8 uM-Replicate_1W530-Activity at 725.3 uM-Replicate_1W530-Activity at 1537.0 uM-Replicate_1W530-Activity at 3438.0 uM-Replicate_1W530-Activity at 7687.0 uM-Replicate_1W530-Activity at 17190.0 uM-Replicate_1W530-Activity at 38440.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive100047.5075-0.85036.5859-1.0635-1.6023-0.3086-3.4622-1.35334.67687.26923.31746.2497-5.65217.507510004-2.7438
Inactive10004-1.28870.8753-6.2501-1.3857-1.4798-0.8404-0.236-3.1797-0.9103-4.2604-1.36420.6331-5.8425-1.2887100040.0676
Inconclusive18.9959145.361410Partial curve; high efficacy-4.72130.90.9188144.5041-0.85732.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0109.9727-2.0766-1.7253-4.6916-7.58760.08260.32240.573611.295315.955920.996444.907445.1038109.97270Partial curve; partial efficacy; poor fit-4.92130.50.8862-28.4592-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-22.0491
Inactive10004-6.4338-1.0341-8.39771.934-1.7661-1.5079-2.4935-3.7532-1.6719-7.2189-0.7574-3.1297-0.0318-6.4338100041.3315
Inactive100049.85963.01998.2155-6.8884-0.0179.05278.537710.12172.00917.64318.4564.97095.20899.859610004-3.1319
Inactive1000410.31864.02425.8987-3.27783.691512.55185.52654.79640.45891.70539.28419.67945.384710.318610004-7.9666
Inactive10004-5.82564.01543.328411.3993-2.8532-3.14291.66583.1389-3.5164-3.7932-0.7781-6.034915.8059-5.825610004-0.1547
Inactive100041.42223.33975.3037-13.82891.017510.80678.90837.21042.06962.23865.87032.68043.06021.422210004-0.8644
Inactive10-7.33094.95490.4101-0.5861940 0 0 0 0 0 0 0 0 0 0 0 0 0 00.01295.189310.898714.8076-2.4549-2.4984-5.0717-3.433-1.947.7856-2.8644-0.75919.85430.0129100040.6149
Inactive100047.0581-1.63851.7037-6.0631.19361.22060.71740.3153.12120.55781.34552.40110.05917.058110004-2.0669
Inactive10-7.1254.95490.47383.5-2.978840 0 0 0 0 0 0 0 0 0 0 0 0 0 06.67130.5898-0.0173-3.0625-8.73240.64983.42651.3135.39496.05361.7549-0.26116.32586.671310004-2.6844
Inconclusive8.134342.018910Partial curve; partial efficacy-5.08971.41630.969941.9989-0.022.20 0 0 0 0 0 0 0 0 0 0 0 0 0 122.566-2.476-2.27040.35060.05390.00634.6469-2.24293.14719.858418.493328.64841.665322.56610-5.43971.10.9656-9.5994140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.2495
Inactive10-4.75651.46410.84927.51.750840 0 0 0 0 0 0 0 0 0 0 0 0 0 16.2621-3.95772.84074.3063-0.21850.22192.68385.07820.7383.75254.360116.576320.72476.262110004-2.4015
Inactive100044.46320.9961.0612-4.481815.44753.86030.6225.61672.13720.7845.34077.8319-0.49114.463210004-2.3472
Inactive10-5.04990.40.788724-5.628940 0 0 0 0 0 0 0 0 0 0 0 0 0 017.0836-11.7741-5.90074.36231.3645-3.50143.00160.3886-0.53832.88298.639210.751315.58817.083610-6.34990.20.7235-8.2096640 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.008
Inactive10-4.8570.80.620325.50.594740 0 0 0 0 0 0 0 0 0 0 0 0 0 022.8122.17973.2852-14.92112.35344.13817.72352.69921.40883.245214.992713.588414.224322.81210-5.1070.70.5375-7.786-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-7.7384
Inconclusive31.702366.609710Partial curve; partial efficacy; poor fit-4.49890.30.571271.73475.12512.40 0 0 0 0 0 0 0 0 0 0 0 0 0 054.84716.429520.56591.097517.76932.581224.098517.437722.220723.724628.199738.441926.932154.84710-4.49890.40.4983-11.38140.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-8.6511
Inactive10-8.84194.95490.62224-10.992540 0 0 0 0 0 0 0 0 0 0 0 0 0 03.6297-8.32713.39360.54518.87982.38882.5354.72694.08194.9942.97562.09288.90943.629710004-0.0914
Inactive10-8.84144.95490.3999-0.5-12.181740 0 0 0 0 0 0 0 0 0 0 0 0 0 04.9391-10.15140.5543-6.67930.5862-0.22940.56961.5006-0.1114-3.71070.4490.51320.35334.939110004-1.894
Inactive100042.2454-0.16621.56738.952-13.1994-0.1453-0.0030.4507-10.37920.5678-0.496-4.590817.04082.245410004-0.4072
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: GRV193
Protocol: Tox21 Assay Protocol Summary:

The GR-bla HeLa cells were dispensed at 1500 cells/5 ul/well in 1536-well black wall/clear bottom plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 4 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of dexamethasone (5 nM, final concentration in the well). The plates were incubated at 37 C for 18 hours. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA), the plates were incubated at room temperature (RT) for 2 hours, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT). After measurement of bla assay, 3 ul CellTiter-Glo (Promega, Madison, WI) was added to measure the cytotoxicity and the plates were then incubated at RT for 30 min. The luminescence was measured using a ViewLux (Perkin Elmer) plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000036780 uM-Replicate_1Activity at 0.0000082250 uM-Replicate_1Activity at 0.0000183900 uM-Replicate_1Activity at 0.0000514202 uM-Replicate_1Activity at 0.0001156673 uM-Replicate_1Activity at 0.0002261535 uM-Replicate_1Activity at 0.0004949824 uM-Replicate_1Activity at 0.00102 uM-Replicate_1Activity at 0.00229 uM-Replicate_1Activity at 0.00510 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.284 uM-Replicate_1Activity at 0.634 uM-Replicate_1Activity at 1.415 uM-Replicate_1Activity at 3.154 uM-Replicate_1Activity at 7.040 uM-Replicate_1Activity at 15.11 uM-Replicate_1Activity at 27.01 uM-Replicate_1Activity at 58.48 uM-Replicate_1Activity at 78.95 uM-Replicate_1Activity at 216.1 uM-Replicate_1Activity at 765.1 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive04-8.9896-7.3975-6.7113-14.8241-4.5178-1.517512.264-8.1607-13.49270.92690.0472-1.09210.2383-2.6378-1.9489-8.9896QC'd by SequoiaCytotoxic0.006727.901520Complete curve; partial efficacy; poor fit-8.17134.95490.4115-26.6818
Inactive04-12.8644-12.4335-6.4744-20.0821-10.89713.6433-6.8703-5.7214-9.84543.7236-7.371-2.7049-10.4097-16.8792-5.8495-12.8644QC'd by FLUKAInactive0
Inactive00.60.6935-5.705513.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.93149.184113.869-0.63448.33090.23784.4977-4.6175-6.73290.5376-2.5323-8.0879-5.8972-4.0555-7.5668-2.9314QC'd by FLUKACytotoxic47.715650.274420Partial curve; partial efficacy; poor fit-4.32130.30.4501-54.3952
Inactive0412.0884-2.3949-3.4828-3.133815.632524.520517.03-4.6009-4.4756-1.6879.12462.7279-2.11843.193-0.18912.0884QC'd by BIOMOLInconclusive1.068269.039710Partial curve; partial efficacy; poor fit-5.97130.20.438955.7277
Cytotoxic26.832573.745320Single point of activity-4.57134.95490.8323-69.69384.0515-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-61.368517.6007-1.759413.0949-3.274312.563612.30281.95770.648-6.95350.28381.5448-0.0522-1.42575.7042-61.3685QC'd by BIOMOLCytotoxic21.313893.273741Partial curve; high efficacy-4.67132.90230.9235-86.9043
Inactive046.7909-1.31027.7383-4.547-2.65212.1059-2.4181-1.10118.09747.2420.3477-5.05879.40029.3931-0.87996.7909QC'd by BIOMOLInactive0
Inactive041.4423-3.99322.77927.1221-0.8837-8.95352.295-0.51041.37322.285720.59571.5207-5.3744.2397-11.91461.4423QC'd by BIOMOLInactive0
Inactive00.60.3367-9.79324.540 0 0 0 0 0 0 0 0 0 0 0 0 0 12.02261.3465-0.45472.410510.291411.99868.0638-8.1616.00951.6819-2.0122-2.01511.6093-6.3684-6.20422.0226QC'd by BIOMOLInactive02.47290.378538.7776
Inactive0415.2343-1.80842.058715.92577.90848.0244-2.30815.36692.48331.03819.9575-3.366-5.2227-2.2446-0.160715.2343QC'd by BIOMOLInactive0
Inactive047.9538-1.872810.9648-1.09872.6071-1.078614.35211.0497-1.76951.8577-2.7126-2.4267-0.2948-1.380911.52387.9538QC'd by BIOMOLInconclusive18.995953.670810Partial curve; partial efficacy; poor fit-4.72132.40640.570554.7236
Inactive04.95490.518517.50.289140 0 0 0 0 0 0 0 0 0 0 0 0 0 013.283514.4715-2.8018-2.2504-1.854-1.0751.91726.8822-1.1544-5.5924-0.0354-3.34427.78934.034525.595213.2835QC'd by BIOMOLInactive0
Inactive049.45185.1439-10.9187-3.6004-4.60710.015617.848513.801-6.53560.5436-3.981315.85290.99558.7778-0.51489.4518QC'd by BIOMOLInconclusive0.169342.502710Single point of activity-6.77133.92950.653739.4606
Inactive041.8471-10.88334.52062.79765.23563.9098-5.1881-2.0961-0.0954-3.919-3.2093-1.8064-33.7228-4.1242-0.88821.8471QC'd by BIOMOLInactive04.95490.31142.5
Inactive044.8349-4.63776.5338-3.86720.3182-6.07670.8186-2.79026.0128-0.779714.731111.52557.4133-0.9249-2.93594.8349QC'd by BIOMOLInactive04.95490.371213.3777
Inactive04-4.067912.1355-8.423722.677520.0333.0761-4.23854.78041.17568.42751.9834-7.49172.3009-2.1910.399-4.0679QC'd by BIOMOLInconclusive0.016923.312910Complete curve; partial efficacy; poor fit-7.77134.95490.334218.2886
Inactive042.05745.26574.3417-5.6188-2.5518-0.73413.2906-1.1924-0.81874.4295-6.552710.0188-0.8658-4.17642.45482.0574QC'd by BIOMOLInactive0
Inactive048.5616-2.0682-0.46498.21222.20687.6990.2449-0.087712.19887.0464-0.3008-1.4858-2.93310.76220.39078.5616QC'd by BIOMOLInactive0
Cytotoxic6.00796.604783Complete curve; high efficacy-5.22134.95490.9827-93.96262.6422-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.07621.3064-6.14065.13090.1256-0.83290.3014-0.60629.61044.55867.1299-0.84948.1454-69.6407-92.7982-96.0762QC'd by BIOMOLCytotoxic5.353889.607684Complete curve; high efficacy-5.27134.95490.9148-95.5166
Inactive04-3.2987-4.8177-8.49767.47813.7599.2959-2.2766-1.27941.7611-5.167216.38672.699710.28948.2038-9.5775-3.2987QC'd by BIOMOLInconclusive0.030119.213610Complete curve; partial efficacy; poor fit-7.52134.95490.332612.8869
Inactive048.7339-1.21470.07750.0749-2.3291-0.54618.96933.3015-2.1752-15.4981-13.43471.2297-0.91132.62215.99288.7339QC'd by BIOMOLInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: FXRA481
Protocol: Tox21 Assay Protocol Summary:

FXR-bla cells were dispensed at 5000 cells/5uL/well in 1536-well black wall/clear bottom plates using a Multidrop Combi (Thermo Fisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37C and 5% CO2 for 5 h, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA). The assay plates were incubated at 37C for 16 h. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN), the plates were incubated at room temperature for 2 h, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W460-Activity_Score-Replicate_1W460-Curve_Description-Replicate_1W460-Fit_LogAC50-Replicate_1W460-Fit_HillSlope-Replicate_1W460-Fit_R2-Replicate_1W460-Fit_InfiniteActivity-Replicate_1W460-Fit_ZeroActivity-Replicate_1W460-Fit_CurveClass-Replicate_1W460-Excluded_Points-Replicate_1W460-Max_Response-Replicate_1W460-Activity at 0.0000056507 uM-Replicate_1W460-Activity at 0.0000126354 uM-Replicate_1W460-Activity at 0.0000282534 uM-Replicate_1W460-Activity at 0.0000545573 uM-Replicate_1W460-Activity at 0.0001216490 uM-Replicate_1W460-Activity at 0.0002748434 uM-Replicate_1W460-Activity at 0.0005839002 uM-Replicate_1W460-Activity at 0.00107 uM-Replicate_1W460-Activity at 0.00238 uM-Replicate_1W460-Activity at 0.00531 uM-Replicate_1W460-Activity at 0.012 uM-Replicate_1W460-Activity at 0.026 uM-Replicate_1W460-Activity at 0.059 uM-Replicate_1W460-Activity at 0.132 uM-Replicate_1W460-Activity at 0.275 uM-Replicate_1W460-Activity at 0.550 uM-Replicate_1W460-Activity at 1.225 uM-Replicate_1W460-Activity at 2.701 uM-Replicate_1W460-Activity at 5.947 uM-Replicate_1W460-Activity at 13.22 uM-Replicate_1W460-Activity at 29.14 uM-Replicate_1W460-Activity at 62.57 uM-Replicate_1W460-Activity at 81.11 uM-Replicate_1W460-Activity at 231.6 uM-Replicate_1W460-Activity at 765.1 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1Ratio-Activity at 0.0000056507 uM-Replicate_1
Inactive04-2.57180.98020.33340.113-0.34891.66330.5384-1.28830.37030.56371.00092.3938-1.0839-1.03180.1621-2.5718104-0.2891
Inactive00.20.4114-2.0655440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.84392.94330.790.64291.12950.14980.6177-2.55460.59861.743-0.8395-0.63430.6932-0.7305-1.4331-1.84391040.0371
Inconclusive23.708351.4077042.19060.7168-0.2279-1.2192-0.14841.0112-0.6188-0.3852-1.0064-0.3745-0.3394-0.2426-0.07791.58892.1442.1906104.0950.3908-6.32980.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-4.8582
Inactive042.7189-0.1950.6872-1.63360.88331.01420.3547-0.3021-0.3177-0.7101-1.7531-0.5091-1.059-0.0318-1.69682.7189100.20.35085.5-3.092140 0 0 0 0 0 0 0 0 0 0 0 0 0 00.4356
Inactive04-0.79041.3245-0.32432.9021.42320.7760.85640.60773.48341.29680.1761-0.00760.2684.3467-4.1484-0.7904104-3.4321
Inactive04-1.98313.0402-0.20892.36663.4105-2.91341.98530.24890.9752-1.1540.72550.2561.69421.2263-1.9306-1.9831104-4.2144
Inactive04-1.874-0.2797-0.4478-0.11060.0196-0.3681-0.2842-0.0801-0.1231-0.414-0.2738-1.237-1.5347-1.2956-3.671-1.8741040.6536
Inactive04.95490.5172-5.4710.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.9533-0.42351.13520.08322.0854-0.67540.5186-0.26643.64210.58660.2001-0.38270.97550.5733-3.7258-0.9533104-1.9261
Inactive04-0.5502-0.77020.0578-0.3584-0.2534-2.3599-0.40930.5046-0.03810.10580.915-0.1554-3.45420.0747-2.8652-0.5502104.95490.5659-7.7260.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-4.7716
Inactive01.06410.5114-6.94450.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-4.1204-1.219-0.1624.36991.1803-0.1152-0.53410.0936-0.69330.94870.6683-0.852-0.725-0.1811-2.7386-4.1204102.40640.4025-4.4652040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.721
Inactive043.55510.8473-0.51673.62083.7221-1.26510.80582.42383.22781.02351.7084-0.82120.13391.35821.36883.5551104-1.7988
Inactive040.58641.7410.61753.87642.52580.0612-0.8879-1.0658-0.6910.6962-0.98790.9341-1.3479-1.09863.92640.5864104-2.7731
Inactive04.95490.6811-8.03010.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-5.4418-0.08951.67220.8968-0.05530.28610.10812.74242.0357-0.6849-1.2466-0.42550.68460.02180.7106-5.4418104.95490.553-8.6041-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-5.5034
Inactive04-1.0699-0.15550.1220.13423.9079-1.3566-0.04140.41690.55563.03281.14423.0678-0.0239-0.7809-1.1254-1.0699104-2.7435
Inactive01.27160.7536-9.23680.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.0306-0.0448-0.00540.33521.6111-0.1205-0.2846-1.318-0.33552.81540.72860.229-1.2273-1.0794-2.65-6.0306104-1.7251
Inactive04-0.46410.07120.31061.24232.463-0.52982.4943.74033.00582.04640.091.16351.27483.00322.3365-0.4641101.47810.50161.5-1.400140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.3843
Inactive04.50450.8216-6.6183140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-5.51520.94940.16121.06891.2421.07640.82391.35751.38422.9546-0.1705-0.48241.24741.5533-0.0628-5.5152102.72020.7492-9.6375-1.089340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.3645
Inactive00.90.3847-5.19340.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.66122.5541-0.00910.63460.6376-0.58542.5922-0.01190.03320.5360.566-1.78590.85780.2753-0.6216-2.6612104.95490.4271-4.85020.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.772
Inactive04-3.1207-0.0789-0.10761.23980.92010.5687-0.1273-0.25290.6047-0.2627-0.03110.3651-0.404-0.1813-0.111-3.1207104-0.3555
Inconclusive86.259627.9936041.58550.3002-0.32391.8510.47771.19330.3852-0.08870.6167-0.36810.7528-3.60090.0278-0.19980.19731.5855104-1.1059
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:vitamin D (1,25- dihydroxyvitamin D3) receptor [Homo sapiens]
External ID: VDRN803
Protocol: Please refer to other AIDs, 743223 and 743225, for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the VDR antagonist mode assay (AID 743223) and cell viability counter screen (AID 743225). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Sample Source
inactiveinactive0inactive0inactive0inactive0Specs
inactiveinactive0inactive0inactive0inconclusive antagonist13.44808836-45.65325464ACC
inactiveinactive0inactive0inconclusive antagonistinactive0ACC
inconclusiveinconclusive antagonist18.99592971-79.65537907active agonist19.73909424103.9743345inconclusive agonist8.48517011947.11906569inactive0ACC
inactiveinactive0inactive0inactive0inactive0ACC
inactiveinactive0inactive0inactive0inactive0ACC
inactiveinactive0inactive0inactive0inactive0RTI
inactiveinactive0inactive0inactive0inactive0RTI
inactiveinactive0inactive0inactive0inactive0RTI
inactiveinactive0inactive0inactive0inactive0RTI
inactiveinactive0inactive0inactive0inactive0RTI
inactiveinactive0inactive0inactive0inconclusive agonistRTI
inactiveinactive0inactive0active agonist18.835391981.58279101inactive0RTI
inactiveinactive0inactive0inactive0inconclusive antagonist-37.210722RTI
inconclusive antagonist (cytotoxic)active antagonist55.39562326-83.86566927inconclusive agonist49.371401256.90317268inconclusive antagonist62.15491158-77.79590493active antagonist49.3714012-87.9114088RTI
inactiveinactive0inactive0inactive0inactive0RTI
inactiveinactive0inactive0inactive0inactive0RTI
inactiveinactive0inactive0inactive0inactive0RTI
inactiveinactive0inactive0inactive0inactive0RTI
inactiveinactive0inactive0inactive0inactive0RTI
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:vitamin D (1,25- dihydroxyvitamin D3) receptor [Homo sapiens]
External ID: VDRA806
Protocol: Please refer to other AIDs 743222, 743224, 720687, 720685, 720678 and 720681, for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the VDR agonist mode assay (AID 743222), cell viability counter screen (AID 743224), and auto fluorescence counter screens (AIDs 720687, 720685, 720678 and 720681). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Blue (460 nm) auto fluorescence outcomeSample Source
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inconclusiveinconclusive antagonistinconclusive agonistinactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inconclusive agonist51.2590329435.69791807inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inconclusive antagonistinconclusive antagonistinconclusive antagonist35.56651116-44.23282371active antagonist4.74287049-28.02320569active antagonist8.273855514-104.21648inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0active antagonist2.55200741-57.4287968inactiveSIGMA
inactiveinactive0inactive0inactive0active antagonist14.18427047-61.81556827inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:farnesoid X nuclear receptor [Homo sapiens]
External ID: FXRN519
Protocol: Please refer to other AIDs, 743217 and 743221, for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the FXR antagonist mode assay (AID 743217) and cell viability counter screen (AID 743221). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Sample Source
inconclusiveinconclusive antagonistinactive0inactive0inactive0LightBiologicals
inconclusive antagonist (cytotoxic)inconclusive antagonist38.87469986-124.1224182inconclusive agonist43.6181306579.87254751active antagonist38.87469986-126.3307013active antagonist38.87469986-127.2859123LightBiologicals
inactiveinactive0inactive0inactive0inactive0LightBiologicals
inactiveinactive0inactive0inactive0inactive0LightBiologicals
inactiveinactive0inactive0inactive0inactive0LightBiologicals
inactiveinactive0inactive0inactive0inactive0LightBiologicals
inactiveinactive0inactive0inactive0inconclusive agonistLightBiologicals
inactiveinactive0inactive0inactive0inconclusive agonistLightBiologicals
inconclusiveinconclusive antagonist-29.93634007inactive0inactive0inactive0LightBiologicals
inactiveinactive0inactive0inactive0inactive0LightBiologicals
inactiveinactive0inactive0inactive0inactive0LightBiologicals
inactiveinactive0inactive0inactive0inactive0LightBiologicals
inactiveinactive0inactive0inactive0inactive0LightBiologicals
inactiveinactive0inactive0inactive0inactive0LightBiologicals
inactiveinactive0inactive0inactive0inactive0LightBiologicals
inconclusive antagonist (cytotoxic)active antagonist14.90149639-102.6716503inconclusiveactive antagonist30.89559395-167.1364103active antagonist33.36029497-114.8429818LightBiologicals
inconclusiveinconclusive antagonist38.89524834-64.53531705inconclusive agonistinconclusiveinconclusive antagonist24.5412426-65.33795352LightBiologicals
inactiveinactive0inactive0inactive0inactive0LightBiologicals
inactiveinactive0inactive0inactive0inactive0LightBiologicals
inconclusive antagonistinconclusive antagonist7.760622324-33.80631207inconclusive agonistinconclusive antagonist-20.21410535inactive0LightBiologicals
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: NFKB358
Protocol: Tox21 Assay Protocol Summary:

NFkB-bla ME-180 cells were dispensed at 2,000 cells/6 uL of assay medium per well into black wall/clear-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C and 5% CO2 for an overnight, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA). The assay plates were incubated at 37 C and 5% CO2 for 5 hr. One uL of LiveBLAzer B/G FRET substrate (Life Technologies) was added using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA) and the plates were incubated at room temperature for 1.5 hr. Fluorescence intensity (405 nm excitation, 460 nm and 530 nm emissions) was measured using an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000047774 uM-Replicate_1W530-Activity at 0.0000106865 uM-Replicate_1W530-Activity at 0.0000238870 uM-Replicate_1W530-Activity at 0.0000515884 uM-Replicate_1W530-Activity at 0.0001141219 uM-Replicate_1W530-Activity at 0.0002523297 uM-Replicate_1W530-Activity at 0.0004987423 uM-Replicate_1W530-Activity at 0.00102 uM-Replicate_1W530-Activity at 0.00227 uM-Replicate_1W530-Activity at 0.00507 uM-Replicate_1W530-Activity at 0.011 uM-Replicate_1W530-Activity at 0.025 uM-Replicate_1W530-Activity at 0.057 uM-Replicate_1W530-Activity at 0.126 uM-Replicate_1W530-Activity at 0.281 uM-Replicate_1W530-Activity at 0.628 uM-Replicate_1W530-Activity at 1.401 uM-Replicate_1W530-Activity at 3.112 uM-Replicate_1W530-Activity at 6.948 uM-Replicate_1W530-Activity at 15.07 uM-Replicate_1W530-Activity at 28.54 uM-Replicate_1W530-Activity at 60.96 uM-Replicate_1W530-Activity at 78.83 uM-Replicate_1W530-Activity at 216.1 uM-Replicate_1W530-Activity at 765.1 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1Ratio-Activity at 0.0000047774 uM-Replicate_1
Inactive104-1.8583-2.194-3.40923.5331-0.892-0.61820.9865-0.36573.4970.4744-1.4296-0.62348.3783-0.7566-1.1611-1.85831040.1664
Inactive10-8.10711.17050.48612.5-4.840940 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.1162-4.8674-3.0229-0.3889-2.1283-0.29443.17083.63895.10465.0396-1.9578-0.4397.48812.706-0.0303-0.1162104-0.2177
Inactive10-8.39121.39870.38070.5-5.565840 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.6623-4.4436-4.6382-0.3896-1.2519-3.10553.0035.6264-0.6660.6908-0.2751-1.609-1.2579-0.1596-0.1279-2.66231040
Inactive10-4.870310.5824-14.3897-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-6.6433-1.8536-2.1008-1.47460.078-4.8483-1.84544.7631-0.6623-1.9958-7.893-3.9303-3.1059-8.4272-11.9914-6.64331040.5067
Inactive10-4.20844.95490.47610.5-0.067840 0 0 0 0 0 0 0 0 0 0 0 0 0 07.8661-1.71580.1072-4.6399-0.0642-0.67053.02442.513-0.7946-2.7483-0.52140.42263.8319-0.5685-1.05887.8661104-0.5076
Inactive10-8.90634.95490.33770.5-7.120340 0 0 0 0 0 0 0 0 0 0 0 0 0 1-4.9335-5.51691.7805-0.4698-1.4031-1.06450.63554.77064.44740.03832.476-1.42182.5218-1.5645-2.3525-4.9335104-0.0803
Inactive104-2.9269-2.9812-2.93210.4185-1.7705-0.16963.1288-1.93330.16620.0619-4.27135.6119-2.53012.6398-0.302-2.92691040.1106
Inconclusive54.840258.05110Single point of activity-4.26094.95490.9157-61.0187-2.9677-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-52.0989-3.3067-6.2666-5.1441-3.04612.57790.4953-2.72611.6206-7.4429-8.3541-8.5881-1.1865-2.6605-1.9568-52.09890Partial curve; partial efficacy; poor fit-4.41092.40640.978112.5-0.04552.40 0 0 0 0 0 0 0 0 0 0 0 0 0 010.3149
Inactive104-1.466-4.99932.3785-1.183-0.06553.26271.73535.10831.8386-0.0138-6.6083-3.4253-0.0532-0.1580.9167-1.4661040.0158
Inactive1041.3997-6.2450.0762-0.766-1.9443-9.8341-0.2667-0.60446.9406-5.2308-8.7015-1.9232-0.924-1.29320.57451.39971040.1002
Inactive1040.3399-6.46171.3209-3.0101-2.05964.12320.2450.94761.4047-11.1564-4.4033-1.33123.0713.3214-2.060.3399104-0.0044
Inactive104-0.5904-0.73351.2617-6.3242.9035-0.0991.16083.2066-3.8776-0.86390.0951-0.8166-1.2342-6.5356-4.1121-0.5904104-0.0276
Inactive104-4.7435-0.6989-2.479-0.0554-2.1660.08760.6952-2.51077.528-5.1886-0.4905-0.468-0.3173-5.5279-2.3727-4.7435104-0.0782
Inactive1041.7404-0.2186-3.66451.32844.614-1.89295.10486.82161.0980.513-10.4068-2.30831.4323-2.105-3.37981.7404104-0.2106
Inactive104-2.0965-1.1578-1.49545.90620.2399-2.0418-1.94961.50990.833-10.07570.1889-0.8237-0.63871.3648-4.3408-2.0965104-0.3672
Inactive104-4.6931-4.6603-2.8144-1.1981-0.5868-0.6535-0.53010.28380.9037-1.7863-5.01120.6013-2.0323-0.9628-1.0329-4.69311040.7433
Inactive1041.1038-1.0592-1.9274-0.68770.6871.23720.75487.22591.430.5824-1.88352.5517-0.91460-0.79221.1038104-0.0792
Inactive1040.8977-4.2973-0.3684-3.7243-7.5405-3.4063.9373-0.16973.4417-0.83460.4612-2.61238.72640.3873-4.10320.89771040.0503
Inconclusive24.598330.200110Partial curve; partial efficacy-4.60911.78850.8031-31.7001-1.5-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.7501-3.4536-6.4097-0.2598-6.6318-0.0849-2.6676-0.43321.45628.8246-2.3648-7.1683-0.8076-12.852-17.7209-29.75011043.7583
Inactive104-3.9318-1.10342.2788-2.07661.7494-2.32610.2809-1.88892.20562.31512.9713-0.2863-0.6475-1.4356-0.0898-3.93181040.6523
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:glucocorticoid receptor [Homo sapiens]
External ID: GRA646
Protocol: Please refer to other AIDs 720691, 720687, 720685, 720678 and 720681, for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the GR agonist mode assay (AID 720691) and auto fluorescence counter screens (AIDs 720687, 720685, 720678 and 720681). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Blue (460 nm) auto fluorescence outcomeSample Source
inconclusiveinconclusive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inconclusiveactive agonist26.2133798280.63773882active antagonist23.36269936-80.71273442active antagonist26.21337982-33.67998135inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inconclusive agonist0inconclusive agonist0inactiveSigmaAldrich
inconclusiveinconclusive agonist25.01773299170.756549active antagonist26.21337982-71.55109769inconclusive antagonist26.83246391-39.31724907inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inconclusiveactive agonist14.2449376949.76333982active antagonist13.44808836-78.84104162inconclusive antagonist13.44808836-40.31184202inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: NFKB729
Protocol: Tox21 Assay Protocol Summary:

NFkB-bla ME-180 cells were dispensed at 2,000 cells/6 uL of assay medium per well into black wall/clear-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C and 5% CO2 for an overnight, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA). The assay plates were incubated at 37 C and 5% CO2 for 5 hr. One uL of LiveBLAzer B/G FRET substrate (Life Technologies) was added using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA) and the plates were incubated at room temperature for 1.5 hr. Fluorescence intensity (405 nm excitation, 460 nm and 530 nm emissions) was measured using an Envision plate reader (PerkinElmer, Shelton, CT). For cytotoxicity, 3 ul/well of CellTiter-Glo reagent was added into the assay plates using an FRD. After 30 min incubation at room temperature, the luminescence intensity was measured using a ViewLux plate reader (PerkinElmer).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000047774 uM-Replicate_1Activity at 0.0000106865 uM-Replicate_1Activity at 0.0000238870 uM-Replicate_1Activity at 0.0000515884 uM-Replicate_1Activity at 0.0001141219 uM-Replicate_1Activity at 0.0002523297 uM-Replicate_1Activity at 0.0004987423 uM-Replicate_1Activity at 0.00102 uM-Replicate_1Activity at 0.00227 uM-Replicate_1Activity at 0.00507 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.056 uM-Replicate_1Activity at 0.126 uM-Replicate_1Activity at 0.281 uM-Replicate_1Activity at 0.628 uM-Replicate_1Activity at 1.403 uM-Replicate_1Activity at 3.118 uM-Replicate_1Activity at 6.950 uM-Replicate_1Activity at 15.07 uM-Replicate_1Activity at 28.54 uM-Replicate_1Activity at 60.96 uM-Replicate_1Activity at 78.83 uM-Replicate_1Activity at 216.1 uM-Replicate_1Activity at 765.1 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive04-26.57950.0319-2.2395-20.9732-26.52123.48793.787-12.25470.9846-4.0751-5.3886-21.4913-24.896116.4645-11.4599-26.5795QC'd by GVKInactive0-5.22131.46410.934319
Inactive0-6.32131.210.51335-5.416240 0 0 0 0 0 0 0 0 0 0 0 0 0 08.2466-2.4915-10.9981-2.89952.9981-11.1964-3.7965-12.01350.2715-1.03041.22921.48382.4517.06890.90468.2466QC'd by SpecsInactive0
Inactive04-5.5889-0.6489-4.58647.81770.5085-1.0682-1.31267.0916.06955.27784.063-1.77327.00123.3422-2.1031-5.5889QC'd by SIGMAInactive0-4.52134.95490.5833-11.0203
Inactive04-0.539-1.0098-0.4217-1.0435-0.2693-1.82410.3049-1.0563-1.34251.6146-1.9765-2.1989-2.5617-3.6481-2.7521-0.539QC'd by GVKInactive0
Inactive04-6.14670.811-6.2646-1.0013-11.03996.19121.04120.5509-5.58941.24230.166-2.7864-4.2126-3.6922-1.701-6.1467QC'd by VitasInactive0-5.23262.72020.5924-29.2456
Inactive0-4.57134.95490.7064-13.82952.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-13.1912-1.24124.67712.94924.5616-0.33781.4392-0.4731.8230.2423.31493.3643.86364.9336.3509-13.1912QC'd by LabotestInactive0-4.52134.50450.41768
Inactive041.1486-2.2662-4.6681-2.7013-5.4895-2.8375-4.5830.9438-2.7065-0.5785-11.8845-3.0286-4.7567-5.1332-4.491.1486QC'd by TocrisInactive0
Inactive0411.9827-2.83953.28416.35311.34642.32495.13140.02692.48242.55572.80715.31165.6476-0.04293.444111.9827QC'd by TocrisInactive0
Inactive04-6.3534-3.3574-10.3617-1.0219-2.6828-28.4527-1.2207-6.48210.1882-0.5395-3.5868-2.8121-1.7053-1.165-6.758-6.3534QC'd by MicrosourceInactive0
Inactive04-12.5932-1.7845-1.6263-0.4269-30.2763-4.01591.0188-0.3707-3.2966-1.1175-0.562-6.1605-5.4441-0.7659-0.8895-12.5932QC'd by VitasInactive0
Inactive045.0969-0.584-1.7444-3.11223.4854-0.22510.57210.19090.7853.9335.07474.8259-2.88076.36931.38645.0969QC'd by VitasInactive0
Inactive0-4.67134.0950.70688.5-1.050140 0 0 0 0 0 0 0 0 0 0 0 0 0 07.582-2.40850.0658-1.3516-1.95260.20290.0351-0.38620.06970.8961-4.6251-0.6703-2.29920.67451.42137.582QC'd by MicrosourceInactive0
Inactive0-6.87134.95490.4952-6.9762-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-5.91420.08551.8962-4.4486-6.39251.881.59681.2053-4.2111-9.8077-0.8338-11.2302-7.902-6.4937-5.6231-5.9142QC'd by TocrisInactive0-4.77130.80.8839-21.6175
Cytotoxic23.914569.697440Partial curve; high efficacy-4.62134.95490.9058-75.2666-5.5691-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-69.5321-10.3764-6.8596-6.5497-0.4266-4.8-8.1145-0.1311-0.5864-6.2619-0.1054-10.2354-0.2294-19.8092-14.5842-69.5321QC'd by Prestwick Chemical; Inc.Inactive0-4.62132.84730.9487-23.9527
Inactive0-4.82133.06540.570514.50.599740 0 0 0 0 0 0 0 0 0 0 0 0 0 012.7255-1.05656.2388-0.49150.04154.11325.96870.7731-0.62093.9149-3.2502-1.1906-2.3142-3.106311.171912.7255QC'd by GVKInconclusive11.985619.615310Partial curve; partial efficacy; poor fit-4.92134.44950.698922
Inactive045.41972.19265.6750.21063.37696.67362.54111.1909-0.72881.83693.7165-1.2747-5.0771-1.76033.75585.4197QC'd by GVKCytotoxic10.682222.50920Partial curve; partial efficacy; poor fit-4.97133.92950.8061-22.509
Inactive04-3.1537-9.5794-2.6405-2.1205-2.9173-0.3221-6.3257-2.2577-3.2512-8.3905-0.4509-3.6169-1.634-5.77960.2818-3.1537QC'd by TocrisInactive0
Inactive046.78773.4475-0.80391.84744.96331.0083-0.16324.86413.43720.29156.59173.38420.14622.86772.76066.7877QC'd by VitasInactive0
Inactive0-5.37130.60.464812-7.341840 0 0 0 0 0 0 0 0 0 0 0 0 0 1-26.03520-15.2848-3.7668-11.2044-11.6891-3.243-3.6388-2.98163.8598-10.3043-2.43151.9395.43496.9989-26.0352QC'd by SpecsInactive0-8.07130.60.65416.5
Inactive04-12.1227-1.5763-14.30661.2944-0.88630.9044-2.1455-2.2263-0.5864-13.9507-1.40740.8684-0.6483-6.7158-7.6719-12.1227QC'd by TocrisCytotoxic0.37918.494220Complete curve; partial efficacy; poor fit-6.42134.50450.6047-16.7975
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: ESRE694
Protocol: Tox21 Assay Protocol Summary:

ESRE-bla HeLa cells were dispensed at 1,500 cells/6 uL of assay medium per well into black wall/clear-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C and 5% CO2 for an overnight, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA). The assay plates were incubated at 37 C and 5% CO2 for 5 hr. One uL of LiveBLAzer B/G FRET substrate (Life Technologies) was added using a FRD (Flying Reagent Dispenser, Aurora Discovery, San Diego, CA) and the plates were incubated at room temperature for 2 hr. Fluorescence intensity (405 nm excitation, 460 nm and 530 nm emissions) was measured using an Envision plate reader (PerkinElmer, Shelton, CT). For cytotoxicity, 4 ul/well of CellTiter-Glo reagent was added into the assay plates using an FRD. After 30 min incubation at room temperature, the luminescence intensity was measured using a ViewLux plate reader (PerkinElmer).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000047774 uM-Replicate_1Activity at 0.0000106865 uM-Replicate_1Activity at 0.0000238870 uM-Replicate_1Activity at 0.0000515884 uM-Replicate_1Activity at 0.0001141219 uM-Replicate_1Activity at 0.0002523297 uM-Replicate_1Activity at 0.0004987423 uM-Replicate_1Activity at 0.00102 uM-Replicate_1Activity at 0.00227 uM-Replicate_1Activity at 0.00507 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.056 uM-Replicate_1Activity at 0.126 uM-Replicate_1Activity at 0.281 uM-Replicate_1Activity at 0.628 uM-Replicate_1Activity at 1.401 uM-Replicate_1Activity at 3.112 uM-Replicate_1Activity at 6.950 uM-Replicate_1Activity at 15.07 uM-Replicate_1Activity at 28.54 uM-Replicate_1Activity at 60.96 uM-Replicate_1Activity at 78.83 uM-Replicate_1Activity at 216.1 uM-Replicate_1Activity at 765.1 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive042.55841.03043.74775.03540.0130.19121.99344.4682-1.118-0.92650.40597.3742-0.29430.148912.16252.5584QC'd by ACCInactive0-8.92134.95490.58521.7114
Inactive041.04449.38030.74763.12786.69211.1460.6932.1717-2.62790.9131-0.21058.3459-0.39582.1025-2.99771.0444QC'd by ACCInactive0
Cytotoxic16.930131.200620Partial curve; partial efficacy; poor fit-4.77132.40640.9303-29.70061.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-25.58396.44840.62985.4169-0.4558-0.5744-0.07771.25670.2130.7041.3743-0.26441.10850.1243-15.2939-25.5839QC'd by ACCInactive0
Inactive04-0.02421.69930.6704-1.17845.11071.72274.56411.87884.1671-17.44842.42443.59520.40153.59042.9209-0.0242QC'd by ACCInactive0
Inactive04-0.291814.46025.117312.83713.75061.0339-20.34848.58755.54497.91138.0385-4.34499.26670.4529-3.0258-0.2918QC'd by RTICytotoxic29.092754.022620Partial curve; partial efficacy; poor fit-4.53624.95490.6086-54.3077
Inactive04-9.564-1.37929.524312.21587.69061.0726-0.196111.93439.92037.5776-5.21577.5016-1.86575.235611.9122-9.564QC'd by RTIInactive0
Inactive0-7.77354.95490.3601-14.529-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.1321-4.10392.2036-4.4477-0.6391-20.4583-13.1672-20.3521-4.5893-29.1908-2.469-10.2273-4.2183-26.0356-15.5929-16.1321QC'd by RTIInactive0
Inactive04-10.57479.6583-18.8266-15.9381-18.8298-22.5498-11.4525-11.258-19.3715-1.261611.6996-7.8792-15.9308-24.0597-4.8818-10.5747QC'd by RTIInactive0-4.82630.40.5505-9.7277
Inactive040 0 0 0 0 0 0 0 0 0 0 0 0 0 04.01340.424-2.9139-16.1733-6.9968-23.9446-16.20085.92260.98-20.2493-13.92747.9486-35.7003-9.99484.29044.0134QC'd by RTIInactive0
Inactive04-10.2656-14.8903-15.3655-2.7845-28.2021-20.9296-30.9304-24.9765-16.31760-2.46261.1777-26.2927-7.96083.661-10.2656QC'd by RTIInactive0
Inactive0-8.7754.95490.3424-6.180224.131440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.05819.133-9.61582.59212.1272-10.0621-19.0183-3.175-6.056203.8277-6.9417-8.1697-29.63821.9231-6.058QC'd by RTIInactive0
Inactive04-2.862-2.41431.3999-12.3192-0.5489-27.7245-0.9532-5.0434-6.70340.76034.3515-26.8359-5.00540.0419-9.5532-2.862QC'd by RTICytotoxic2.043244.502520Complete curve; partial efficacy; poor fit-5.68970.20.347-49.0165
Inactive0-8.65650.90.3817-4.1413-41.081440 0 0 0 0 0 0 0 0 0 0 0 0 0 1-9.7717-32.5089-30.9537-4.1171-5.4822-3.9972-5.3055-21.487-12.2295-0.2654-25.22736.0876-0.02868.9044-9.836-9.7717QC'd by RTIInactive0
Inactive0-4.68822.30310.498121.5906-13.101740 0 0 0 0 0 1 0 0 0 0 0 0 0 13.7326-14.422-10.9017-12.1335-7.4022-23.6361-9.3772-46.3098-0.8702-3.697-32.8039-19.7954-4.12590.431715.55843.7326QC'd by RTIInactive0-4.83824.95490.50086.5
Inactive0-6.44994.95490.59060.6936-20.956540 0 0 0 0 0 0 0 0 0 0 0 0 0 010.5461-15.8465-28.4952-15.7447-30.7297-13.9437-22.4089-18.7042-15.42371.831210.094912.3343-12.1314-18.169-1.419510.5461QC'd by RTIInactive0
Inactive04-11.695710.72272.44510.82060.51511.94345.47812.92324.14064.93384.82110.57272.1279-14.043217.6455-11.6957QC'd by RTIInactive0-8.8574.95490.60374
Inactive0-8.74894.0950.3141-3.421916.540 0 0 0 0 0 0 0 0 0 0 0 0 0 00.432314.17440.7676-2.1997-8.221-5.6454-16.1217-1.1755-3.59195.6415-0.28148.858-1.1034-3.3158-17.01820.4323QC'd by RTIInactive0
Inactive04-0.009612.5115-6.85851.1252-9.1791-10.4868-21.59850.4491-5.7144-10.416817.2452-11.9951.0883-7.0749-4.2644-0.0096QC'd by RTIInactive0
Inactive04-12.2476-9.7064-5.7734-0.3846-25.9418-36.8141-3.35579.4431-6.96929.6933-36.122508.4922-7.0737-36.9038-12.2476QC'd by RTIInactive0
Inactive0-4.31044.95490.4712.5-4.066640 0 0 0 0 0 0 0 0 0 0 0 0 0 011.4789-1.6142.1526-9.6333-3.0751-1.05270.2688-0.9689-9.0025-10.5739-2.6465-3.1882-0.6735-11.7222-0.633811.4789QC'd by RTIInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:farnesoid X nuclear receptor [Homo sapiens]
External ID: FXRA272
Protocol: Please refer to other AIDs 743220, 743218, 720687, 720685, 720678 and 720681, for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the FXR agonist mode assay (AID 743220), cell viability counter screen (AID 743218), and auto fluorescence counter screens (AIDs 720687, 720685, 720678 and 720681). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Blue (460 nm) auto fluorescence outcomeSample Source
inconclusiveactive agonist59.1570255634.88054886active antagonist59.15702556-59.30826733inactive0active antagonist48.82845648-96.1476759inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inconclusiveinactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveChromaDex
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveChemService
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inconclusive antagonist9.785586343-32.52481865inactiveSIGMA
inactiveinactive0active agonist26.0199156936.83924472inactive0active antagonist14.3539871-48.56059954inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ESRE160
Protocol: Tox21 Assay Protocol Summary:

ESRE-bla HeLa cells were dispensed at 1,500 cells/6 uL of assay medium per well into black wall/clear-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37 C and 5% CO2 for an overnight, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA). The assay plates were incubated at 37 C and 5% CO2 for 5 hr. One uL of LiveBLAzer B/G FRET substrate (Life Technologies) was added using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA) and the plates were incubated at room temperature for 2 hr. Fluorescence intensity (405 nm excitation, 460 nm and 530 nm emissions) was measured using an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000047774 uM-Replicate_1W530-Activity at 0.0000106865 uM-Replicate_1W530-Activity at 0.0000238870 uM-Replicate_1W530-Activity at 0.0000515884 uM-Replicate_1W530-Activity at 0.0001141219 uM-Replicate_1W530-Activity at 0.0002523297 uM-Replicate_1W530-Activity at 0.0004987423 uM-Replicate_1W530-Activity at 0.00102 uM-Replicate_1W530-Activity at 0.00227 uM-Replicate_1W530-Activity at 0.00507 uM-Replicate_1W530-Activity at 0.011 uM-Replicate_1W530-Activity at 0.025 uM-Replicate_1W530-Activity at 0.056 uM-Replicate_1W530-Activity at 0.126 uM-Replicate_1W530-Activity at 0.281 uM-Replicate_1W530-Activity at 0.628 uM-Replicate_1W530-Activity at 1.401 uM-Replicate_1W530-Activity at 3.112 uM-Replicate_1W530-Activity at 6.948 uM-Replicate_1W530-Activity at 15.07 uM-Replicate_1W530-Activity at 28.54 uM-Replicate_1W530-Activity at 60.96 uM-Replicate_1W530-Activity at 78.83 uM-Replicate_1W530-Activity at 216.1 uM-Replicate_1W530-Activity at 765.1 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1Ratio-Activity at 0.0000047774 uM-Replicate_1
Inactive10-8.22134.95490.36050.5-2.543140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.0222-2.2852-1.1657-4.6192-1.35181.3405-0.03092.36874.908-1.5411-0.7314-0.00271.1240.6529-2.503-0.02221041.1641
Inactive104-0.47222.1485-2.15464.6966-2.86183.72276.2452-2.47760.2385-3.3646-0.0133-0.8681-0.4271-4.21-3.3222-0.47221040.0844
Inconclusive11.985657.950610Partial curve; high efficacy-4.92131.50950.948459.37121.42062.10 0 0 0 0 0 0 0 0 0 0 0 0 0 055.20382.1002-0.6722.45033.9322-3.4554-3.093-0.23811.40672.65413.70653.645317.72414.45139.413355.20380Partial curve; partial efficacy-4.62131.3310.9399-26.5671-1-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-18.8059
Inactive10-4.52134.95490.6333-10.4205040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-8.6838-0.3079-0.05671.77552.6829-1.04082.3519-3.23321.1682-0.266-1.68540.0814-1.65932.6006-0.0013-8.68381040.0273
Inactive104-6.44350.32330.01231.52611.3287-1.3352-11.0077-7.4145-1.82011.92910.60791.5121-0.08460.94830.8459-6.44351040.4969
Inactive10-5.31954.95490.3785-5.3874040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.7326-1.32515.71060.28840.7987-5.2671-5.1751-1.0185-0.27590.22494.02092.8758-8.2395-2.5244-4.8806-6.732610-5.36954.95490.66313-0.601240 0 0 0 0 0 0 0 0 0 0 0 0 0 02.6337
Inactive104-5.2596-3.6793-7.4608-2.70071.8404-8.2627-4.12187.33773.98314.4958-5.9058-2.0259-6.86832.352-5.5842-5.25961041.1368
Inactive1043.6898-6.291-4.79640.5074-2.7037-10.2613-4.9133-4.7545-0.4239-1.0686-0.7316-4.0413-4.8163-10.9343-6.02013.68981041.1325
Inactive104-6.3821.5235-1.8362-8.5234-0.71562.5718-11.54022.2493-0.07210.11172.2126-1.41322.8530.2261.6551-6.3821042.0056
Inactive1042.81624.212811.3964-1.80631.198816.301818.58716.490824.439610.8718-1.59492.684111.76911.731613.6882.81621040.3465
Inactive1043.1734-6.0893-0.0097-0.08816.76812.13268.27070.8781-1.8635-1.910112.75374.5432-2.08351.91744.41623.1734104-0.4367
Inactive1044.79223.3762-5.4463-0.80986.339811.56292.5886-0.1578-0.5814-1.0404-1.677616.11281.43372.34274.4774.7922104-2.2294
Inactive104-0.08034.15438.07365.0450.78891.40111.11710.23342.86250.2701-4.3831-1.29883.53955.83121.5052-0.0803104-0.4464
Inactive1043.04374.6967-0.0225-3.4924-4.51612.96729.1388.4633-3.23146.27078.28164.0983-3.67080.7275-0.46083.04371040.1223
Inconclusive0.014116.231610Complete curve; partial efficacy-7.84991.10.71731.768418-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 03.130512.982519.314417.22339.28112.62587.66536.6323-1.2325-0.33990.25690.64079.04712.0112-2.6933.130510-7.79994.95490.7405-1-6.743140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.079
Inactive104-1.8097-1.2027-6.0213-1.3404-0.9317-1.8804-2.6877-1.2692-2.8966-2.3896-0.81090.6062-4.1572-1.71510.9477-1.8097104-3.1464
Inactive104-2.33390.5072-0.40980.2711-2.7738-3.809-0.12930.2296-2.0807-0.936-2.7281-0.22380.66492.9535-3.3422-2.3339104-3.1191
Inactive104-13.5794-0.65133.02166.9338-9.75152.56081.5806-9.59962.7879-1.2733-1.58431.0439-11.39921.0295.8878-13.57941042.9551
Inconclusive2.283534.840810Partial curve; high efficacy; poor fit-5.64140.40.3297372.15922.30 0 0 0 0 0 0 0 0 0 0 1 1 0 1-2.02721.86891.475-3.200719.138225.0145-2.89835.514123.5276-2.323718.673230.5553-0.36653.00926.6829-2.0272104-0.0263
Inactive10-8.31043.92950.6167-0.5-9.500840 0 0 0 0 0 0 0 0 0 0 0 0 0 02.0328-9.584-9.22-3.8216-0.74610.0324-1.85742.0871-1.1373-4.493.6207-3.8899-4.56962.19851.78042.0328104-1.9849
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:activating transcription factor 6 [Homo sapiens]
External ID: ESRE918
Protocol: Please refer to other AIDs 1159516, 1159517, 720687, 720685, 720678 and 720681, for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the ESRE agonist mode assay (AID 1159516), cell viability counter screen (AID 1159517), and auto fluorescence counter screens (AIDs 720687, 720685, 720678 and 720681). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Blue (460 nm) auto fluorescence outcomeSample Source
inactiveinactive0inactive0inactive0inconclusive agonistinactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactive0inactiveAlfa Aesar
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0active antagonist48.9722075-57.42188559inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveAcros
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0active antagonist-17.83479565active antagonist54.69909614-48.70342914inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inconclusive agonistinactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSigmaAldrich